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What Is a TIp?
 
Treatment Improvement Protocols (TIPs) are developed by the Center for Substance Abuse 
Treatment (CSAT), part of the Substance Abuse and Mental Health Services Administration 
(SAMHSA) within the U.S. Department of Health and Human Services (HHS). Each TIP 
involves the development of topic-specific best-practice guidelines for the prevention and treat­
ment of substance use and mental disorders. TIPs draw on the experience and knowledge of 
clinical, research, and administrative experts of various forms of treatment and prevention. TIPs 
are distributed to facilities and individuals across the country. Published TIPs can be accessed 
via the Internet at http://www.kap.samhsa.gov. 
Although each consensus-based TIP strives to include an evidence base for the practices it 
recommends, SAMHSA recognizes that behavioral health is continually evolving, and research 
frequently lags behind the innovations pioneered in the field. A major goal of each TIP is 
to convey “front-line” information quickly but responsibly. If research supports a particular 
approach, citations are provided. 
TIp Format 
This TIP is organized into two parts: 
•	 Part 1 is for counselors and administrators of behavioral health programs providing substance
abuse treatment. It comprises seven chapters and emphasizes steps substance abuse treatment
counselors and administrators can take to educate clients, prevent new hepatitis infections,
and help clients who have viral hepatitis recover from their substance use disorders (SUDs).
Information is provided at a basic level so that it can be understood by readers without 
medical training. Chapter 1 presents an overview of the most common types of viral hepati­
tis. Chapters 2 and 3 provide detailed information on screening for hepatitis and evaluation,
respectively. Factors to consider when helping a client decide whether to undergo hepatitis 
treatment are addressed in Chapter 4; the treatment process is explained in Chapter 5.
Chapter 6 describes counseling approaches for treating clients who have SUDs and viral 
hepatitis. Chapter 7 offers recommendations for administrators on how to add or improve 
hepatitis services, showcasing programs with proven track records. Note: Many people 
in treatment for SUDs are affected by mental disorders prior to the start of hepatitis 
treatment; mental disorders also may arise through the course of hepatitis treatment.
Guidance for addressing co-occurring mental disorders is included throughout the TIP.
Hepatitis-related issues specific to the treatment of mental disorders, not in the context of 
co-occurring SUDs, are covered in Appendix F.
viii 
 
 
 
 
 
 
 
 
•	 Part 2 is an online literature review for clinical supervisors, program administrators, and 
counselors interested in reviewing the medical literature on which this TIP is based. The 
literature review, available at http://www.kap.samhsa.gov, will be updated every 6 months 
for 5 years following publication of this TIP.
TIp Development process 
TIP topics are based on the current needs of behavioral health professionals and other healthcare
providers for information and guidance. After selecting a topic, SAMHSA invites staff members 
from Federal agencies and national organizations to be members of a resource panel that reviews 
an initial draft prospectus and outline and recommends specific areas of focus, as well as resources
that should be considered in developing the content for the TIP. These recommendations are 
communicated to a consensus panel composed of experts on the topic who have been nominated
by their peers. In partnership with Knowledge Application Program writers, consensus panel 
members participate in creating a draft document and then meet to review and discuss the draft.
The information and recommendations on which they reach consensus form the foundation of 
the TIP. A panel chair ensures that the guidelines mirror the results of the group’s collaboration. 
A diverse group of experts closely reviews the draft document. Once the changes recommended 
by these field reviewers have been incorporated, the TIP is prepared for publication, in print and 
online. TIPs can be accessed via the Internet at http://www.kap.samhsa.gov. 
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You come in here to stop drinking and using drugs; I don’t 
want to die no more. I don’t want to go, to live in a box.
I don’t want to eat out of the garbage. I don’t want to go 
to jail. I want to change. And 2 weeks, 3 weeks into this 
thing, I’m just starting to feel right, and I get news that I 
got hepatitis C. 
— A Client’s Perspective (Strauss, Astone, Munoz-
Plaza, Hagan, & Des Jarlais, 2005, pp. 1821–1822) 
Introduction 
An estimated 3.5–5.3 million people in the United States live with
chronic viral hepatitis (Institute of Medicine [IOM], 2010). Viral
hepatitis is often a silent disease whose symptoms and signs become
evident only after the disease has caused severe liver damage. The
symptoms of hepatitis can take decades to manifest, so many people
who are infected with hepatitis are unaware that they have the dis­
ease and therefore do not seek treatment. As a result, between 2010
and 2020, an estimated 150,000 people in the United States could
die of liver cancer or other hepatitis-related liver disease (IOM,
2010). For many of these people, substance use will be a major factor
that contributes to or worsens their hepatitis-related outcomes.
All people who use or have used illicit substances are at risk of 
contracting viral hepatitis. Injection drug use (IDU) is the primary
way of contracting hepatitis C, and people who use substances are at
risk for contracting other forms of viral hepatitis. Substance use dis­
orders (SUDs) do not cause viral hepatitis, but people can contract
or spread some types of viral hepatitis by sharing needles and other
drug paraphernalia. In people who have chronic hepatitis, continued
use of alcohol contributes to and frequently accelerates liver damage
(Bhattacharya & Shuhart, 2003), increasing the likelihood that the
individuals will develop cirrhosis or liver cancer.
In 2010, the U.S. Department of Health and Human Services (HHS)
convened an interagency working group on viral hepatitis, comprised
1 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
  
 
 
  
 
 
  
  
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
  
 
of experts throughout HHS to develop a
comprehensive strategy for addressing the
prevention, screening, and treatment of viral
hepatitis, and for improving the coordination
of care and treatment of individuals infected
with viral hepatitis. The working group broad­
ened the scope of expertise even further by
soliciting information from other government
agencies, professional organizations, commu­
nity organizations, and members of the general
public. As a result of many months of work by
this diverse group of experts, HHS recently
released Combating the Silent Epidemic of
Viral Hepatitis: U.S. Department of Health and
Human Services Action Plan for the Prevention,
Care and Treatment of Viral Hepatitis (also
called the Viral Hepatitis Action Plan) (HHS,
2011). This TIP supports the goals and objec­
tives of the Viral Hepatitis Action Plan by
providing information on the prevention and
treatment of viral hepatitis and by encouraging
behavioral health professionals to recommend
hepatitis screening for their clients who might
be at risk for hepatitis infection.
Viral hepatitis can be prevented and treated.
Counselors, health professionals, and admin­
istrators in SUD treatment settings play an
important role in promoting the prevention
and treatment of viral hepatitis among their
clients.
purpose of and Audience 
for the TIp 
The main objective of this Treatment
Improvement Protocol (TIP) is to improve
care for clients with SUDs by increasing
knowledge of viral hepatitis among staff in
behavioral health programs that provide sub­
stance abuse treatment. Some surveys have
shown that substance abuse treatment provid­
ers are not well informed about viral hepatitis
(Strauss et al., 2006). Clients often perceive
that counselors do not have the information
they need (Munoz-Plaza, Strauss, Astone,
Des Jarlais, & Hagan, 2004). With up-to-date
information, counselors, health professionals,
and administrators in SUD treatment settings
can encourage clients to understand the seri­
ous nature of hepatitis, risk factors, the impor­
tance of liver wellness, screening, treatment
options, and ways to avoid spreading—
or contracting—hepatitis.
Other behavioral health treatment providers
(e.g., counselors in mental health treatment
settings, nurses, mid-level providers) will
also find useful information in this TIP.
Information is provided in lay terms so that
it can be understood by readers who do not
have medical training. 
Terminology 
Terminology in the medical field may differ
from that used in the substance abuse treat­
ment field. This TIP uses terms from both
disciplines. Appendix B contains a glossary
of terms used in this TIP.
Because the TIP is primarily focused on care
for clients with SUDs, counselor refers to
substance abuse treatment counselor. Client refers
to people seeking services at behavioral health
programs providing substance abuse treatment.
Occasionally, the TIP refers to people seeking
services at a medical facility; in these instances,
the term patient is used. People refers to adults,
unless otherwise indicated. 
Treatment program refers to a behavioral
health program providing treatment for
SUDs. Medical care refers to care for the body
(e.g., treatment for hepatitis) as distinct from
behavioral health care, which is the subset of
medical care that addresses mental, emotional,
and behavioral issues. Co-occurring is used to
refer to health conditions (e.g., SUDs, mental
3 
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disorders, hepatitis) that appear together in
sequence or simultaneously; wherever this term
is used, the pertaining conditions are indicated.
Hepatitis refers to viral hepatitis infection. 
Relapse, when used alone, refers to relapse
to substance use. Virologists sometimes use
relapse to refer to the return of hepatitis after
antiviral treatment, which here is referred to
as virologic relapse. 
The liver 
To appreciate the impact of hepatitis, it is
essential to understand the liver—the organ
predominantly affected in people with hepa­
titis. The liver, located on the upper right side
of the abdomen just beneath the rib cage
(Exhibit 1-1), performs numerous functions
essential to human life. 
Blood passes from the intestines to the liver.
Blood from the intestines contains nearly 
everything absorbed by the intestines, includ­
ing nutrients and harmful or toxic substances 
(toxins). The liver breaks down toxins found 
in the blood and excretes them as harmless 
byproducts into the bile (a greenish yellow,
thick, sticky fluid that aids in digestion) or 
back into the blood. Bile enters the intestine 
and leaves the body in stool. Byproducts 
excreted by the liver into blood are filtered out
by the kidneys, then leave the body in urine.
The liver also metabolizes drugs, alcohol, and 
prescription and over-the-counter medica­
tions, often making them inactive or easier 
to excrete from the body. If a person has a 
severely damaged liver, these substances build 
up in the body.
The liver manufactures several physiological 
products necessary for the body to function:
cholesterol, bile, and other substances (e.g.,
clotting factors that are needed to stop 
exhibit 1-1 The liver 
bleeding). The liver also stores sugar, fats, and 
vitamins for later use. Sugar is stored in the 
liver as glycogen, transformed into glucose,
and released into the bloodstream when 
needed.
What Is viral hepatitis? 
Hepatitis is inflammation of the liver. It can 
be caused by viruses, alcohol or substance use,
exposure to toxins, and certain diseases. Viral 
hepatitis refers to liver inflammation caused by 
one of several types of viruses that attack the 
liver. In the United States, these are primar­
ily hepatitis A virus (HAV), hepatitis B virus 
(HBV), and hepatitis C virus (HCV) (Exhibit 
1-2), but other types of hepatitis viruses do 
exist. The body can rid itself of infection in 
some cases. In others, the body cannot get 
rid of the infection by itself and the infection 
becomes chronic (continues indefinitely).
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exhibit 1-2 overview of the most common Types of viral hepatitis 
category hepatitis A hepatitis B hepatitis c 
Transmission route Fecal–oral route Blood and body 
fluids 
Blood 
Percentage of adults 
infected who develop 
chronic infection 
0% 6%–10% 75%–85% 
Immunity after infection Yes Yes No 
Vaccine available Yes Yes No 
Hepatitis can be acute, which means that the 
infection does not last longer than 6 months.
If the body’s immune system cannot fight off 
the virus within 6 months, the disease is con­
sidered chronic. In the United States, three to 
five times more people are living with chronic 
hepatitis B or C than with human immuno­
deficiency virus (HIV). Chronic hepatitis can 
lead to very serious health consequences—
even death—because of liver failure or related 
medical conditions.
Most people who have chronic hepatitis do 
not know it (IOM, 2010). In most cases,
people with infection have no symptoms of 
the disease, or their symptoms are so mild they 
do not see a medical care provider about them.
Symptoms of hepatitis include the following:
•	 Fatigue (tiredness) 
•	 General feeling of being unwell (malaise) 
•	 Flu-like symptoms (e.g., headaches,

muscle aches, low-grade fever)
 
•	 Lack of appetite, weight loss 
•	 Nausea and vomiting, abdominal pain 
•	 Jaundice (new or uncharacteristic yellow 
tinge to skin and mucus membranes) 
•	 Diarrhea 
•	 Itching of the skin 
•	 Tea- or dark-colored urine 
•	 Pale bowel movements 
A person with chronic hepatitis can remain 
symptom free for decades while the liver is 
silently damaged. As hepatitis progresses 
and causes more liver damage, the liver 
may become scarred, referred to as f ibrosis. 
Fibrosis sometimes leads to cirrhosis, which 
is profuse scarring of liver tissue. When cir­
rhosis develops, changes in the liver’s structure 
compromise its ability to function. The spleen
(an organ that fights infections and regulates 
the flow of blood in the body) may also be 
affected. Muscle wasting can occur, resulting 
from lack of appetite and the liver’s inability 
to produce crucial proteins that build muscles.
Sometimes the abdomen and ankles swell 
because of the body’s increased difficulty with 
sodium handling and removing fluids and tox­
ins. The person may develop jaundice. When 
liver damage is this extensive, serious compli­
cations are likely, including bleeding from the 
esophagus (varices) or stomach, abdominal 
swelling (ascites), and difficulty thinking and 
making decisions (encephalopathy). By the 
time these symptoms occur, liver damage is 
extensive, and the individual is at risk of liver 
failure or liver cancer—a condition that almost 
always has a poor prognosis.
hepatitis A 
Hepatitis A never becomes chronic, and most 
individuals recover within 6 months. Once 
recovered, a person is no longer contagious 
and is immune to reinfection with HAV.
5 
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Modes of Transmission 
HAV is spread by the oral transmission of 
fecal matter (stool) of a person who is infected 
with HAV and it is extremely contagious.
Minute amounts of fecal matter containing 
the virus left on a person’s hands can contami­
nate water, food, or utensils, and a person who 
ingests this material can develop hepatitis A.
HAV can survive outside the body for several 
days and in water for several months. People 
are most infectious during the 2 weeks before 
the onset of symptoms. HAV is not spread 
through casual contact. The virus is not pres­
ent in semen.
Disease Burden 
An estimated one-third of U.S. residents have 
had HAV infection (Bell et al., 2005). The 
number of new HAV cases has declined by 
92 percent since a vaccine became available 
in 1995. Nevertheless, approximately 3,000 
new infections were investigated and reported 
in 2007, representing an estimated 25,000 
infections during that year (Daniels, Grytdal,
& Wasley, 2009). The primary risk factor in 
the United States for contracting hepatitis A 
is traveling to areas where HAV is endemic,
followed by contact with someone who is 
infected with HAV, or having anal intercourse 
with an infected person. However, many 
people who contract hepatitis A do not report 
any risk factors (Klevens et al., 2010; Daniels 
et al., 2009).
Disease Course 
HAV infection is rarely life threatening,
although severity and mortality may increase 
with age and underlying chronic liver disease.
Signs and symptoms include fatigue, fever, loss 
of appetite, dark urine, and jaundice. When 
symptoms occur, they usually appear sud­
denly and generally disappear within a month.
Hepatitis A can be serious when coupled with 
other forms of hepatitis or HIV.
Hepatitis A and Substance Use 
People who use drugs are at risk for acquiring 
hepatitis A. Outbreaks occur among people 
who inject drugs (Daniels et al., 2009; Wells,
Fenaughty, Cagle, & Jaffe, 2006) and are 
associated with poor hygiene and low socio­
economic status (Crowcroft, 2003; Quaglio,
Lugoboni, Messelani, Des Jarlais, & Lechi,
2006).
Prevention 
Hepatitis A is preventable. The most effective 
way to prevent HAV infection is through vac­
cination. The vaccine is given in two doses, 6 
months apart. A combined HAV and HBV 
vaccine is also available.
The Centers for Disease Control and 
Prevention (CDC, 2010a) recommends 
hepatitis A vaccination for the following 
adults:
•	 People who use injection drugs 
•	 Men who have sex with men (MSM) 
•	 People with chronic liver disease 
•	 People who receive blood clotting-factor 
concentrates 
•	 People who travel to countries that have 
high rates of hepatitis A 
•	 People with occupational risks of infection
(e.g., workers in daycare centers, laboratories) 
Despite recommendations for vaccination,
many people are not vaccinated. Vaccination 
rates in high-risk groups range from 8 percent 
to 13 percent (Carey & Perlman, 2005; Chen 
& Cantrell, 2006). Moreover, half of those 
who had been vaccinated received only one 
dose instead of the two doses required for full 
protection. However, hepatitis A vaccination 
in the United States among children has been 
increasing since May 2006, when the universal 
vaccination of children (aged 12–23 months) 
was recommended. By 2008, coverage was 
estimated to be 40 percent in young children 
(CDC, 2010b).
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Contraindications to receiving the hepatitis 
A vaccine include having a severe allergy to 
vaccine components and being moderately 
or severely ill at the time the vaccination is 
offered. All clients, especially pregnant women,
should consult their medical care provider to 
determine whether they should get vaccinated 
against hepatitis A.
Washing hands frequently—especially after 
using the bathroom, changing a diaper, and 
before preparing food—helps prevent the 
spread of HAV.
hepatitis B 
Hepatitis B can be acute or chronic. More
than 90 percent of infants and 30 percent
of children ages 1–5 years who have been
exposed to HBV will remain chronically
infected with HBV. By contrast, approxi­
mately 90 percent of adults with HBV infec­
tion alone (i.e., without co-infection) recover 
completely from HBV infection and do not 
become chronically infected (CDC, 2010c).
For those with chronic infection, compromise 
of the immune system (e.g., by chemotherapy 
or HIV co-infection) places the person at risk 
for reactivation (Luetkemeyer, 2010; CDC,
2009).
Modes of Transmission 
HBV is very contagious; it is much more 
infectious than HIV (World Health 
Organization, 2009). HBV is spread through 
infected blood and other body fluids (e.g.,
semen) and can live outside the body for more 
than 7 days. Modes of transmission include: 
•	 Sharing IDU equipment (e.g., needles,
syringes, cookers, filters).
•	 Accidental needle sticks or other breaches 
of the skin, especially among those whose 
occupations expose them to blood (e.g.,
medical care workers, dentists).
•	 Unprotected sex with a partner who is 
infected with HBV.
•	 An infected mother passing the virus 

to her infant during delivery.
 
•	 Receipt of a blood transfusion or trans­
plantation surgery from an infectious 
donor. (This is rare in the United States 
since mandatory screening was imple­
mented in 1972.) 
Disease Burden 
Hepatitis B is a major cause of liver disease 
worldwide. In 2007, there were approximately 
43,000 new infections in the United States.
Between 800,000 and 1.4 million people in 
the United States live with chronic hepatitis B 
(Wasley et al., 2010; Daniels et al., 2009). In 
the United States, Asian and Pacific Islanders 
and MSM are disproportionately infected 
with HBV.
Disease Course 
Approximately 35 percent of those infected 
exhibit symptoms. Usually, acute HBV 
infection alone is not life threatening.
Up to 10 percent of people with acute hepatitis
B will develop chronic hepatitis after 6 months
(Exhibit 1-3). Most of those with chronic 
infection remain symptom free, although they 
can infect other people. Some experience seri­
ous illness. HBV infections become chronic 
more frequently in people with compromised 
immune systems (e.g., people with HIV infec­
tion). Worldwide, hepatitis B is the most 
likely form of hepatitis to cause liver cancer,
particularly hepatocellular carcinoma. Chronic 
hepatitis B can also result in cirrhosis of 
the liver, liver failure, and death. Daniels et 
al. (2009) estimate 3,000 people die in the 
United States per year from chronic HBV 
infection.
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exhibit 1-3 Disease course of hepatitis B 
100 people develop acute hepatitis B 
90–94 will no longer be 
infected in 6 months 
6–10 will still have the 
virus in 6 months 
Hepatitis B and Substance Use 
Three percent to 11 percent of people 
who inject drugs have chronic hepatitis B 
(Weinbaum et al., 2008). One study suggests 
that rates of asymptomatic HBV infection 
among clients on methadone maintenance 
may be as high as 25 percent (Bart et al.,
2008). Alcohol use by people with hepatitis B 
damages the liver, which is already compro­
mised with the hepatitis infection.
Prevention 
Vaccination is the most effective way to prevent
HBV infection. The consensus panel recom­
mends HBV vaccination for the following 
adults:
•	 People who are infected with HCV 
•	 People who are sexually active with or 

who share a household with a person 

with infectious HBV
 
•	 Men who have sex with men (MSM) 
•	 People who inject drugs 
•	 People with occupational exposure to 
blood (e.g., medical care workers, dentists) 
•	 People who attend or work at institutions 
for people with developmental disabilities 
•	 Hemodialysis patients or those with end-
stage renal disease 
•	 People who are infected with HIV 
•	 Anyone with liver disease 
•	 Anyone who lives in or travels to 

countries with high rates of HBV
 
•	 Adults in correctional settings 
The HBV vaccine is given in three doses 
within a 6-month period. However, the most 
convenient way to provide immunization is 
with the combined hepatitis A/hepatitis B 
vaccine (sold under the brand name, Twinrix).
It is administered in three intramuscular injec­
tions on a 0-, 1-, and 6-month schedule, or 
may be given on an accelerated schedule of 
four doses, given on days 0, 7, and 21–30 with 
a booster dose at 12 months (FDA, 2010a).
Despite the availability of the HBV vaccine,
many at-risk individuals have not been vac­
cinated. A study of people age 30 and younger 
who inject drugs found that only 22 percent 
had been vaccinated against HBV (Lum et 
al., 2008). Contraindications to getting the 
hepatitis B vaccine include having had a 
severe allergic reaction to a previous dose or 
to a component of the vaccine. Clients should 
discuss the vaccination with a medical care 
provider.
hepatitis c 
Hepatitis C can be acute or chronic, but 
it starts as an acute infection (that may go 
unrecognized). Unlike people with hepatitis 
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A and B, people who have hepatitis C and 
clear the virus do not develop immunity; they 
can become reinfected with the virus at a later 
date.
Modes of Transmission 
Hepatitis C is a blood-borne disease. IDU is 
the most common risk factor for acquiring
hepatitis C. The virus can enter the body 
through any puncture in the skin (e.g., cuts,
burns, sores), and travels, via the blood, to the 
liver. Risks of sexual transmission are unclear 
but appear to be low, especially compared with 
sexual transmission rates of HIV or HBV.
Nonetheless, HCV infection rates are higher 
in people who have multiple sex partners.
Infections have been reported in individuals 
with no known risk factors.
Disease Burden 
HCV infection is the most prevalent chronic,
blood-borne infection in the United States 
(Alter et al., 1999). Approximately 3.2 million
U.S. residents have chronic HCV infection 
(CDC, 2010c). Forty percent of chronic liver 
disease—the 10th leading cause of death 
in the United States—is caused by HCV.
Hepatitis C is most prevalent among people 
born between 1945 and 1965, the majority of 
whom were likely infected during the 1970s 
and 1980s, when infection rates were the 
highest. CDC (2010c) estimated 17,000 new
infections in 2007, and people who inject 
drugs account for more than half of the new 
cases.
Disease Course 
HCV can be detected in the blood within 1–3 
weeks of transmission. However, the majority 
of people with hepatitis C are asymptomatic.
Of people who contract hepatitis C, 15 percent
to 25 percent clear the infection, but 75 percent
to 85 percent do not and the infection becomes
chronic (CDC, 2010c) (Exhibit 1-4). Chronic 
HCV is insidious, usually progressing very 
slowly and with few or no symptoms for the 
first 20–30 years after infection. Symptoms 
often do not occur until the liver damage has 
advanced. As the disease progresses, the liver 
may develop fibrosis, which can progress to 
cirrhosis. Approximately 12,000 people die 
each year from HCV-related liver disease 
(IOM, 2010).
exhibit 1-4 Disease course of hepatitis c 
100 people develop acute hepatitis C 
15–25 will no longer be 
infected in 6 months 
75–85 will still have the virus 
in 6 months (chronic) 
8–17 will develop cirrhosis 
over 20 years 
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HCV infection appears to progress more 
quickly in men, people older than 50 at the 
time of infection, and people with concur­
rent HBV or HIV (Hézode et al., 2005).
Mortality is high in people with HCV/HIV 
co-infection. 
Hepatitis C and Substance Use 
HCV is highly contagious; people who inject 
drugs are more likely to contract hepatitis C 
than HIV (Garfein, Vlahov, Galai, Doherty,
& Nelson, 1996). People who inject drugs are 
at high risk for becoming infected with HCV 
from sharing needles and drug use parapher­
nalia. Up to 91 percent of people who inject 
drugs and share needles or other paraphernalia 
over a prolonged period will eventually acquire 
HCV infection (Abou-Saleh & Foley, 2008;
Macias et al., 2008; Maxwell, Shinderman,
Miner, & Bennet, 2002; Tseng et al., 2007).
Liver disease progresses more quickly in 
people who have HCV and abuse alcohol 
than in people with only one of the condi­
tions (Bhattacharya & Shuhart, 2003; Felsen,
Fishbein, & Litwin, 2010). 
Prevention 
There is no vaccine against hepatitis C. It can 
be prevented only by avoiding contact with 
contaminated blood.
hcv—True or False? 
You can get HCV infection by using the razor of a person who is infected with HCV. 
True. HCV is spread through contact with infected blood, such as may be found on a razor or 
toothbrush. 
You’ll probably get HCV infection if you eat food from a plate that wasn’t cleaned well. 
False. You can only get HCV infection through contact with infected blood. 
Hepatitis C is mostly spread through unprotected sex. 
False. The greatest risk factor is IDU. Sexual transmission of HCV is rare, except in people who are 
infected with HIV. However, some evidence suggests that HCV might be passed through sex, if the 
sex includes the possibility of blood exposure (Tohme & Holmberg, 2010). 
A vaccine has been developed to protect against HCV. 
False. There is no vaccine against HCV. 
Hepatitis C can be spread when people who inject drugs share their rinse water. 
True. When people who are infected with HCV use needles, drops of their blood are mixed with 
the rinse water. Anyone who uses the same rinse water could contract HCV. 
Most people who have HCV infection will become seriously ill and die from liver disease. 
False. One to five percent of people who have HCV will die from HCV-related diseases. People 
who have additional medical or substance use problems are at increased risk of developing serious 
liver disease, which can be fatal. People who have other types of viral hepatitis or HIV infection are 
also more likely to get serious liver disease. However, people who adhere to hepatitis C treatment 
and abstain from alcohol and drugs improve their chances for a healthy life. 
Adapted from Strauss et al., 2006. 
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other Types of viral hepatitis 
Hepatitis D virus (HDV) infects only people 
who are already infected with hepatitis B.
HDV is transmitted the same way as HBV—
through blood and other body fluids. Because 
hepatitis D can occur only in people with 
hepatitis B, vaccination against HBV infection 
also prevents HDV infection. When people 
who have hepatitis B contract hepatitis D, the 
result can be a superinfection, which has a poor 
prognosis. 
Hepatitis E virus (HEV) was first identified 
in 1980, and little is known about it. Hepatitis 
E manifests only as an acute infection. It is 
most often transmitted through the fecal–
oral route, with the highest rates in countries 
with poor sanitation. While vaccines are not 
available at this time, they are in development.
Hepatitis F virus (HFV) was identified in 
1991, and researchers disagree on whether it is 
a discrete type of viral hepatitis. No diagnostic 
tests exist for HFV infection.
Little is known about Hepatitis G virus 
(HGV) infection, which was identified 
in 1995, but it does not appear to cause 
significant liver damage.
co-Infection with Different Types 
of viral hepatitis 
Some people are infected with more than one 
type of hepatitis. Several studies (Cacopardo,
Nunnari, & Nigro, 2008; Crockett & Keeffe,
2005; Wietzke-Braun, Manhardt, Rosenberger,
Ramadori, & Mihm, 2007) indicate that when 
co-infection occurs, one of four scenarios is 
possible: 
•	 No effect. In some cases, there is no 

known effect from the concurrent 

infections.
 
•	 More severe disease. In most cases, co­
infection worsens the severity of one type 
of hepatitis.
clinical scenario 
Sarah:   “I don’t see what the big deal is about hepatitis. I feel fine.” 
Counselor:  “Hepatitis is a silent disease. You could go for years feeling fine while hepatitis 
damages your liver.” 
Sarah:    “So, I get a little liver damage. I know lots of people with hep who just live with 
it.” 
Counselor:   “Let’s work together during our sessions to better understand what hepatitis is 
really all about. It’s true that some people can live with degrees of liver damage, 
depending on their overall health, but if your liver gets damaged enough, it 
won’t work anymore. When your liver doesn’t work, you become very ill. Your 
liver performs hundreds of functions that keep you alive. Right now, your liver is 
removing toxins, storing the nutrients your body needs, producing the materials 
you need to digest food, and doing many other things. If your liver stops working 
properly, your quality of life can be seriously lowered. What kind of life do you 
want for yourself?” 
Sarah:    “I want to feel good and to be able to do all the things I like to do. I didn’t realize 
that when a disease is ‘silent,’ it can actually be doing a lot of damage. I guess I 
can’t just ignore my hepatitis and hope that it will go away.” 
11 
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•	 Activation of disease. To become an 
active disease, HDV infection depends 
on co-infection with HBV.
•	 Deactivation of disease. In rare cases,

co-infection may suppress previously 

active disease.
 
co-Infection with viral hepatitis 
and hIv 
HAV/HIV Co-Infection 
HIV treatment may need to be temporarily 
suspended if HAV infection is acquired. Most 
studies suggest that this delay does not affect 
HIV progression. However, hepatitis A may 
be more severe and last longer in people who 
have both infections than in people who do 
not have HIV (Ida et al., 2002).
HBV/HIV Co-Infection 
As many as 90 percent of people who have 
HIV infection have been infected with HBV 
(i.e., with prior resolved infections; Rodriguez-
Mendez, Gonzalez-Quintela, Aguilera, & 
Barrio, 2000; Scharschmidt et al., 1992), and 
10 percent to 15 percent of these people will 
become chronic carriers. Most studies suggest 
that this co-infection does not significantly 
change the likelihood that the HIV infection 
will progress to AIDS. However, the co­
infection increases the likelihood that HBV 
infection will become chronic and progress 
quickly and that liver damage might be more 
severe (Alberti, Vario, Ferrari, & Pistis, 2005;
Sulkowski, 2008). 
HCV/HIV Co-Infection 
HIV infection may increase a person’s risk 
of contracting HCV through sexual contact 
(Delwaide, Bourgeois, Colle, & Robaeys,
2002). Approximately 25 percent to 33 percent
of people who are infected with HIV are 
co-infected with HCV (Alberti et al., 2005;
Rockstroh & Spengler, 2004). Some studies 
(Eyster et al., 1993; Garcia-Samaniego et al.,
2001; Lesens, Deschenes, Steben, Belanger, & 
Tsoukas, 1999; Pol et al., 1998) suggest that 
people who have HCV/HIV co-infection are 
more likely to develop cirrhosis, liver cancer,
and liver failure than those with hepatitis 
only. The presence of both infections increases
the risk of liver toxicity from HIV medica­
tions. However, liver damage slows when 
HIV medications are taken by preserving 
or restoring immune function and reducing 
HIV-related immune activation and inflam­
mation. Therefore, the benefits of HIV 
medications may outweigh the risks (Panel 
on Antiretroviral Guidelines for Adults and 
Adolescents, 2011; Hammer et al., 2008;
Sherman, 2007). If untreated, HCV infection 
progresses more quickly in people who are 
co-infected with HIV than in those who are 
infected with HCV alone.
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chapter summary 
Viral hepatitis is an inflammation of the liver caused by a virus. Over time, inflammation can lead to 
scarring, which, in turn can lead to cirrhosis and eventually to liver failure. 
The most common types of hepatitis in the United States are hepatitis A, B, and C. 
hepatitis A: 
•	 Is spread through contaminated fecal matter. 
•	 Is never chronic and rarely serious (severity and mortality may increase with age and underlying 
chronic liver disease). 
•	 Leads to immunity to subsequent HAV infection for individuals who have been infected and 
cleared the virus. 
•	 Can be prevented through vaccination, abstinence, and safe injection practices. 
hepatitis B: 
•	 Is spread through blood and other body fluids. 
•	 Can be acute or chronic. 
•	 Is usually spread through IDU or sexual contact. 
•	 Can be prevented through vaccination, abstinence, and safe injection practices. 
hepatitis c: 
•	 Is the most prevalent blood-borne illness in the United States. 
•	 Is most commonly spread in the United States through IDU. 
•	 Becomes chronic in 75 percent to 85 percent of people who are infected. 
•	 Can take decades to develop symptoms. 
•	 No vaccine is available, but abstinence and safe injection practices can prevent transmission. 
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2 screening for viral hepatitis 
I didn’t know anything about [hepatitis C] so didn’t know 
what to think except feeling like my life was over. I was 
only 27 years old, and thought I would not reach 30. 
—Kathleen (Hepatitis C Support Project, 2007) 
The Treatment program’s role in the screening 
process 
Medical staff members at substance abuse treatment programs might
assume the primary role for screening individuals for hepatitis and 
explaining the screening process and test results. Opioid treatment 
programs with medical staff members should screen for hepatitis B 
and C at intake and periodically as indicated. In programs without 
onsite medical staff, clients may be referred elsewhere for screening 
with minimal (if any) involvement of the substance abuse treatment 
program.
Regardless of the type of program, counselors should have a basic 
understanding of the importance of screening, the screening process,
and the meaning of the results. Counselors can encourage clients 
referred for hepatitis screening to follow through and complete the 
screening and evaluation process (evaluation is addressed in Chapter 
3). Clients might feel anxious about being diagnosed with hepatitis,
and they might delay or avoid getting screened.
Antigens and Antibodies 
Hepatitis screening involves testing a small sample of blood for 
antigens and antibodies to determine whether the individual has 
been infected with viral hepatitis. Antigens are foreign substances,
such as microorganisms (e.g., bacteria, fungi, parasites, viruses) or 
chemicals, which invade the body. When the body is exposed to 
antigens, it produces antibodies as a part of its immune response.
Antibodies are proteins that bind to the antigens to try to clear them 
from the body. Hepatitis blood tests look for antigens or antibodies 
specific to each type of hepatitis virus.
13 
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hepatitis A screening 
Screening for hepatitis A involves testing the 
blood for antibodies to the hepatitis A virus 
(HAV). HAV screens sometimes are referred 
to as hepatitis A antibody tests or hepatitis A 
total antibody tests.
A positive antibody test result indicates that a 
person has or had HAV infection or has been 
vaccinated against hepatitis A. This person is 
immune to future HAV infection. A negative 
test result indicates that antibodies were not 
detected in a person’s blood. A person without 
antibodies has never been infected with HAV,
has never been vaccinated against HAV, and is 
still susceptible to HAV infection.
hepatitis B screening 
Hepatitis B virus (HBV) antigens are proteins
that appear in different areas of the virus. HBV
has three antigens (surface, core, and e), some 
of which can be detected in the blood. The 
body’s immune response produces antibodies 
tailored to each type of antigen (surface anti­
body, core antibody, and e antibody), which 
can also be detected from a blood test. The 
basic blood test for hepatitis B consists of 
three screening tests: a hepatitis B surface 
antigen test, which determines whether a 
person currently has the infection; a hepatitis
B core antibody test, which determines whether
a person has ever been infected; and a hepatitis
B surface antibody test, which determines 
whether a person has cleared the virus after 
infection, or has been vaccinated and is now 
immune to future infections. These are 
described below.
Is the person currently infected with HBV? The 
screening test for hepatitis B surface antigens 
detects the presence of HBV in the blood. The 
antigens are detectable 4–10 weeks after expo­
sure to HBV. A positive test result means the 
person is currently infected and can pass the 
infection to others. Most adults who acquire 
HBV clear the virus within a few months, and 
their hepatitis B surface antigen test result 
will be negative after that time. Some people 
remain infected and continue to test posi­
tive for hepatitis B surface antigen. If, after 
6 months, the person still tests positive, his 
or her HBV infection is considered chronic.
People diagnosed with chronic hepatitis B 
should have an evaluation (see Chapter 3).
Has the person ever been infected with HBV?
The hepatitis B core antibody screening test 
detects the presence of antibodies to the HBV 
core antigen. The antibody appears in the 
blood within a few weeks of HBV infection.
A positive result means the person has been 
infected with HBV, but it does not specify 
whether the person has cleared the virus, still 
has the infection, or is immune to reinfection.
Is the person immune to HBV? The hepatitis
B surface antibody screening test detects the 
presence of antibodies the immune system 
produces to attack the virus. These antibodies 
appear in people who have been vaccinated 
against HBV, or who had been infected and 
cleared the virus from their bodies. A positive 
hepatitis B surface antibody screening test 
means the person has lifetime immunity 
from hepatitis B (the Centers for Disease 
Control and Prevention [CDC], 2009). In 
some situations, hepatitis B screening may 
be unavailable, but the hepatitis B vaccine 
is available. People can be safely vaccinated 
against hepatitis B if they have been previously 
infected or vaccinated.
hepatitis c screening 
The most common test for hepatitis C virus 
(HCV) detects antibodies to HCV in the 
blood, but the results are not clear cut and 
should be interpreted carefully. A “positive”
HCV antibody test could mean the person 
is a chronic carrier of HCV (75 percent to 
15 
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85 percent), has been infected but has resolved 
infection (15 percent to 25 percent), or is one 
of the few recently (acutely) infected (CDC,
2010c). Following HCV infection, it usually 
takes at least 6–8 weeks for the body to 
develop enough antibodies to be measured 
in a screening test, but it can take longer. For 
example, people who have suppressed immune 
systems (e.g., people who have HIV infection) 
may not test positive for 15 weeks–6 months 
after exposure to the virus. An infection 
that has been present for less than 6 months 
may not be detected with an antibody test.
However, an infection that has been present 
for 6 months is almost always detectable with 
an antibody test.
A positive HCV antibody test means the 
person was infected with the virus; it does not 
always mean the person is still infected. Up 
to 25 percent of people infected with HCV 
successfully clear the virus from their systems 
within 6 months after being infected, but the 
antibody remains present in the screening test.
Most antibody testing requires a blood sample 
that is sent to a laboratory for processing.
However, in 2010, the U.S. Food and Drug 
Administration (FDA) approved a rapid 
antibody blood test for HCV (the first in the 
United States) that is available in some medi­
cal offices. The rapid test is for individuals 
15 years and older who are at risk for HCV 
infection or who have hepatitis symptoms.
The test still requires a blood sample, but it 
involves the use of a “test strip” that provides 
results in approximately 20 minutes. However,
the rapid test is not sufficient to make a final 
diagnosis of HCV infection. If the rapid test 
is positive, more traditional and sophisticated 
tests will be necessary to confirm the diagnosis 
(FDA, 2010b). 
People who have a positive result on an HCV 
antibody screening test should receive addi­
tional tests to get more information (Exhibit 
2-1). The most common followup test is a 
qualitative HCV RNA (ribonucleic acid) test.
RNA is the genetic material of the virus, and 
the qualitative test determines whether the 
virus is present. A quantitative RNA test—or 
quantitative viral load test—measures how 
much of the virus is present (see Chapter 3).
Because of the difficulty in interpreting an 
HCV antibody screening test, some medical 
care providers ask for a followup test before 
reporting the results of the antibody test to 
their patients. If HCV RNA is present for at 
least 6 months, the HCV infection is considered
chronic. 
Clients might need help deciding 

whether to get screened, 

understanding the test results, and 

determining their next steps.
 
In people who are at risk of HCV infection,
false positive antibody test results are rare.
Therefore, a positive result in a person with a 
history of drug use, particularly injection drug 
use (IDU), is a true positive more than 99 per­
cent of the time—meaning that the person has 
been infected with HCV. 
The accuracy of a negative HCV antibody test 
result is very high. However, to account for the 
6-month window period, people who inject 
drugs or engage in other high-risk behaviors 
should be retested every year (Backmund,
Reimer, Meyer, Gerlach, & Zachoval, 2005). 
counseling practices That 
educate, support, and motivate 
clients Undergoing screening 
Clients might need help deciding whether to
get screened, understanding the test results,
and determining their next steps. Even when 
services offered through the substance abuse 
treatment program are limited, discussing 
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exhibit 2-1 hcv screening process 
HCV screening (antibodies) test 
Positive Results 
Person has been infected with HCV 
Negative Results 
No detectable infection at this time. Retest! 
• If the person has engaged in risky 
behavior within 6 months 
• If the person relapses to IDU 
Is this person still infected?
HCV RNA test 
Positive 
Person is infected with HCV 
Complete Medical Evaluation 
(See Chapter 3) 
Negative 
No sign of infection
Retest in 6 months 
Positive after 6 months 
Person is infected with HCV 
Negative test after 6 months 
Person not currently infected 
with HCV; infection was likely 
cleared by the person’s immune 
system; person is susceptible 
to reinfection 
hepatitis testing with clients presents an 
opportunity for counselors to motivate clients 
for change by confronting substance use and 
by making choices that improve their overall 
health. However, this may also be true when 
services are offered on-site through substance 
abuse treatment programs. A study at one 
methadone clinic that offered hepatitis screen­
ing and vaccination revealed that although the 
majority of clients completed screening (for 
hepatitis A, B, and C), only 54.7 percent of 
clients who lacked immunity for hepatitis A 
received vaccinations and only 2.9 percent of 
clients who lacked immunity for hepatitis B 
received vaccinations (Felsen et al., 2010).
The Consensus Panel makes the following 
general recommendations while recognizing 
that, in some programs, the counselor’s role 
may be limited: 
•	 Consider screening to be more than just a 
blood test. It is an opportunity to educate 
the client about hepatitis, its effects on 
health, and prevention strategies. It is an 
opportunity for clients to identify their 
risk factors and learn how they can reduce 
the risk of contracting or transmitting 
viruses.
•	 Be aware that many clients may not 
know whether they have been screened 
for hepatitis in the past or they might 
not know the results. They might confuse 
17 
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HIV screening or any blood test with 
hepatitis screening, and they might 
erroneously believe that they are—or 
are not—infected.
•	 Clearly explain that the hepatitis test is 
optional. Clients may not understand 
what disease the test will detect or that 
they have the option not to give consent 
(Munoz-Plaza et al., 2005).
•	 Follow up with clients regardless of the 
results. Failure to follow up is a missed 
opportunity to deliver or reinforce pre­
vention messages (Munoz-Plaza et al.,
2005).
Discussing Screening for Viral 
Hepatitis 
Many clients entering substance abuse
treatment do not know their hepatitis status.
In two urban studies, as many as 68 percent 
of clients who did not know whether they 
had been infected with HCV tested positive 
(Kwiatkowski, Fortuin, Corsi, & Booth, 2002;
Felsen et al., 2010). In a five-city sample, 72 
percent of those who tested positive for HCV 
were unaware of their infection (Hagan et al.,
2006).
clinical scenario 
Counselor:   “Hi, Jim. I’m glad you came in today. We’ve focused a lot on your drug use and 
you’ve described a lot of consequences in terms of your relationships, job, and 
finances. Today, I wondered if it would be okay to talk about how your use has 
generally affected your health.” 
Jim:    “Sure, I guess so.” 
Counselor: “Gr eat! First I’d like to know how much you know about your risks of getting 
hepatitis due to your injection drug use.” 
Jim:     “Well, I know some folks who have gotten sick and died from it, but I also know 
some who got treated and seem to be okay. I’m worried that I may have this 
infection and will end up like the ones who died—I’m not very lucky.” 
Counselor:   “It is true that hepatitis can lead to death in some people, but there have been 
some important improvements in hepatitis treatment over the past few years. But 
before we talk about hepatitis treatment, I’d like to talk a bit about how the virus 
is spread, tests for hepatitis, and some factors, such as alcohol use, that can affect 
how the virus damages the liver. Is that okay?” 
Jim:     “It’s something that I’d rather not think about, but I know I should. I’ve avoided 
getting tested because I’m worried that I’ll test positive. I don’t have any health 
insurance and can’t afford treatment.” 
Counselor:  “That’ s a lot to worry about, so I do understand why you’re unsure about the next 
steps, if any, to take. So let’s talk a bit more about what you think your next step 
should be. I can tell you that we’ll do everything we can to help you. And please 
remember that not everyone who tests positive for hepatitis needs treatment.  
So, what do you think?” 
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For many clients, a discussion with the counselor
might be the first conversation they have 
about hepatitis. Clients might be uninformed 
about hepatitis or reluctant to discuss the 
disease. By using motivational strategies,
counselors can improve clients’ chances for 
engagement in a discussion about hepatitis.
It is crucial that a treatment counselor
or health professional use a non-
judgmental and compassionate tone. 
Addressing Hepatitis for the First 
Time 
It is crucial that a treatment counselor or 
health professional use a nonjudgmental and 
compassionate tone. Clients need to feel com­
fortable disclosing information about their 
health and risky behaviors. The following 
strategies can help initiate the conversation: 
•	 Display posters, literature, or other 
hepatitis-related items that could help 
prompt the client to ask questions about 
hepatitis. (See Appendix C for hepatitis 
resources).
•	 Assess clients’ ability to discuss hepatitis,
based on their degree of openness in the 
counseling session, the amount of detail 
they provide in their responses, and the 
length of the therapeutic relationship.
•	 Raise the subject in a way that avoids 
making clients feel defensive or afraid.
Consider introducing the subject by 
making parallels with other conditions 
that have been discussed. Say, for example,
“You said you were tested for HIV several 
times. Were you ever tested for viral 
hepatitis?” or “You mentioned that your 
friend is sick with HIV. Have you been 
tested for HCV or HIV? Tell me about 
those tests.” 
•	 Be patient and allow time for multiple,
short conversations about the subject.
This might ease feelings of fear, anxiety,
or shame.
Educating Clients About Viral 
Hepatitis 
Clients may believe they know about viral 
hepatitis, but their understanding of the 
disease may not be accurate. It is easy to 
confuse the three main types of viral hepatitis 
A, B, and C. Clients may have formed 
impressions based on limited or incorrect 
information. Counselors should briefly 
describe hepatitis A, B, and C, including their 
prevalence, transmission, and relationship to 
drug use, as well as to other infections, such 
as HIV and sexually transmitted diseases.
(Chapter 1 provides an overview of hepatitis.
Resources for online materials are in Appendix 
C.) Specific strategies for speaking with 
clients include: 
•	 Speak clearly and keep the message 

simple, focused, and brief.
 
•	 Use language, examples, and concepts 

that the client understands.
 
•	 Use appropriate visual aids. 
•	 Frame numerical statements in terms 
that are easy to visualize. Say “5 out of 
100 people” rather than “5 percent of the 
population”; say “more than half” instead 
of “the majority.” 
•	 Repeat the information at different times 
in different ways. The average client retains
only approximately one-third of what he 
or she is told. Summarize essential points.
•	 Pay attention to a client’s response to the 
information. For example, if a client stiff­
ens his or her posture, consider saying, “I 
notice that this topic seems to make you 
uncomfortable. It does for a lot of people.
Please tell me what you’re feeling right 
now. I’d really like to help you with this.” 
19 
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•	 Use the opportunity to describe the 
potential detrimental effects of alcohol 
and other substance use on the liver of a 
person who is infected with HCV. 
Identifying Patterns of Risky 
Behavior 
Screening is an opportunity to draw attention 
to the client’s behaviors that put him or her at
risk for contracting hepatitis:
•	 Ask for the client’s perception of his or 
her risk for having contracted hepatitis:
“How likely do you think it is that the 
test will be positive?” 
•	 Listen for and identify behaviors that put 
the client at risk for contracting hepatitis 
A, B, and C and HIV, especially unpro­
tected sex and sharing injection drug 
paraphernalia.
•	 Assess the client’s alcohol consumption.
Preparing Clients for Screening 
Once clients are comfortable talking about 
viral hepatitis, they might be more willing to 
undergo screening. However, clients might be 
anxious about the test itself; a reassurance that 
testing is a simple procedure can help allay 
these concerns. Many substance use treatment 
facilities do not offer screening, and clients 
might need to be referred elsewhere. The fol­
lowing strategies can enhance the discussion 
of the hepatitis screening process and hepatitis 
prevention:
•	 Ask the client whether he or she has ever 
had a hepatitis test: “Have you ever been 
tested before?” or “What did you do when 
you found out that you were positive [or 
negative] for hepatitis?” 
•	 Remember that information about screening
might need to be repeated, depending on
the rapport between client and counselor,
the client’s cognitive abilities and interest,
and other issues that come up during a 
session. 
•	 Discuss the benefits of screening, such 
as the possibility for early diagnosis and 
treatment (e.g., prevention of transmis­
sion to others, reduced risk of long-term 
complications). Clearly state that screening
is voluntary. 
•	 Describe the screening procedure and 
explain that blood samples are needed.
Be sensitive to potential relapse triggers.
For a person who injects drugs, the use 
of a needle in the blood draw might 
prompt cravings.
•	 Advise a client with a history of IDU that 
the blood draw might be difficult if his or 
her veins are damaged.
•	 Tell the client how long it generally takes 
to receive results (the timeframe varies by 
testing venue and the laboratory). A delay 
does not indicate a positive result. 
•	 Make a plan with the client to get to 
and from the appointment. 
•	 Ensure that the client has emotional 
support or referrals during the waiting 
period. If a support group is available,
encourage the client to attend to learn 
more about viral hepatitis and about 
others’ responses to it.
•	 Clarify the meaning of possible results.
Say, for example, “A positive HCV anti­
body test result means that you have been 
infected with HCV. It does not necessarily
mean that you are sick or that you are still 
infected. A negative result means that you 
have not been infected with hepatitis C 
or your infection occurred within the last 
6 months.” 
•	 Make a plan with the client for receiving 
the screening results; for example, call a 
member of a mutual support group or 
schedule an additional appointment with 
the counselor.
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Discussing Screening Results With 
Clients 
The medical personnel who ordered or 
arranged the screening test, not counselors,
usually explain the results. Hepatitis screen­
ing should be part of the intake physical 
examination in an opioid treatment program,
and medical personnel may report the results.
However, the client may want to discuss the 
results with the counselor or ask the counselor 
questions.
Anxiety might interfere with some 
clients’ ability to comprehend or 
retain information, which might need 
to be repeated. 
Suggestions for conversations with clients 
when the test results are negative include the 
following: 
•	 Explain results clearly and simply: “So the 
HCV antibody screening result was nega­
tive? This means that, as of 6 months ago,
you did not have hepatitis C.” 
•	 Emphasize that a negative result to an 
HCV test does not indicate immunity 
to hepatitis C and that the client should 
take precautions to avoid infection. If a 
relapse to drug use occurs, advise clients 
to avoid sharing any drug paraphernalia 
or equipment. Specify that this includes 
cookers, cotton, water, needles, syringes,
pipes, and straws.
•	 Emphasize the importance of getting 
HAV and HBV vaccinations. Provide 
information about the availability of 
low- or no-cost vaccinations. 
Clients whose screening test results are positive
for chronic hepatitis will need additional tests 
and examinations—usually with doctors who 
specialize in diseases of the liver (i.e., gastro­
enterologists)—to get accurate diagnoses and 
to determine their health status and the extent 
of liver damage. These tests are described in 
Chapter 3.
The following guidelines can help prepare 
clients for the next steps in evaluating their 
chronic hepatitis: 
•	 Ask clients whether they were referred 
to a medical care provider for additional 
tests. Encourage them to make and keep 
appointments.
•	 Explain that the screening test indicates 
only that clients have been infected with 
hepatitis and additional testing is neces­
sary to determine their health status.
•	 Prepare clients to consider getting further 
evaluation. Say, for example, “Depending 
on the results of the additional medical 
tests, you might be asked to make some 
important decisions about whether to 
undergo antiviral treatment.” 
•	 Identify barriers to further testing (e.g.,
transportation to medical appointments,
insurance coverage) and ways to overcome 
them.
Clients will react in a variety of ways to news 
of a positive result. Anxiety might interfere 
with some clients’ ability to comprehend or 
retain information, which might need to be 
repeated. Some clients might be worried 
about spreading the virus to others or about 
the reaction of family, friends, and others.
Impediments to clients’ coping with a positive 
screening test for HCV include their concern 
about any disclosure of the positive test result 
and fear of inappropriate or disrespectful 
treatment by medical staff members or other 
clients (Strauss et al., 2008). For others, a 
positive test might be of little concern because 
they are more concerned with treatment for 
a substance use disorder (SUD) and stressors 
in their life other than an asymptomatic viral 
infection.
21 
2—Screening for Viral Hepatitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
To help clients come to terms with their 
positive test results: 
•	 Explain results clearly and simply: “Let’s 
look at your test result, and then we’ll 
talk about how best to understand it. The 
HCV test result is positive, which means 
you have been infected with the hepatitis 
C virus.” 
•	 Assess reactions to the results: “How do 
you feel about knowing that you have 
been infected with hepatitis C? What 
does this result mean to you?” 
•	 Address immediate fears and concerns 
before providing further information. 
•	 Provide information on liver health in 
the client’s language of choice and at the 
client’s reading and comprehension levels.
•	 Provide reassurance and hope: “For some 
people, hepatitis is very serious, but for 
most people it never causes life-threat­
ening disease. You can do many things to 
protect your liver.” 
•	 Stress the importance of getting vac­
cinated against hepatitis A and B. “If you 
get hepatitis A or B, it can make your 
hepatitis C worse. There are vaccinations 
against hepatitis A and B. We can help 
arrange for you to get vaccinated.” 
•	 Reiterate the importance of not drinking 
alcohol: “Alcohol damages the liver faster 
in people who have hepatitis. It’s really 
important to stick with treatment.” 
•	 Caution against taking medications 
without first consulting a medical care 
provider. “Some medications—even ones 
you buy over the counter or those that 
are available by prescription—can harm 
your liver. Even some vitamins and herbal 
medications can be dangerous. Check 
with your medical care provider before 
you take anything.” 
•	 Encourage clients to learn their HIV 
status. HBV and HCV infections cause 
liver damage more quickly in people who 
also have HIV infection. Chronic hepatitis
can complicate the treatment of HIV. If 
clients are not HIV positive, urge them to 
take measures to avoid infection.
•	 Explain hepatitis transmission to promote 
prevention:
− HCV is easily spread through exposure
to infected blood by sharing drug use 
paraphernalia or equipment or any 
item that can have minute bits of 
blood on it, including toothbrushes 
and razors. 
− HCV is not spread by sneezing,
coughing, hugging, or sharing eating 
utensils or drinking glasses; it is not 
spread through casual contact. 
− The risk of spreading HCV by sexual 
contact is very low, but HBV can be 
spread by sexual contact (and any 
close personal contact). 
− Open sores or wounds should be 
treated and covered with a bandage.
Having hepatitis C does not exclude 
clients from work, school, or other 
settings.
− Clients who are infected with HCV 
cannot donate blood, body organs,
or semen. 
− In the event of a relapse, clients 
should not share any drug parapher­
nalia or equipment and should return 
to treatment.
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Screening for hepatitis A involves a blood test that detects antibodies produced by a person’s 
immune system to fight the virus. 
•	 A positive test result means the person is currently infected, had been infected, or has been 
vaccinated against infection and is immune to infection. 
•	 A negative test result means the person has never been infected or vaccinated. This person 
should probably be vaccinated against HAV. 
Screening for hepatitis B involves blood tests that measure HBV antigens and antibodies. 
•	 The test for hepatitis B surface antigen detects the presence of HBV. A positive result means the 
person is currently infected and can pass the infection to others. If, after 6 months, the person 
still tests positive, his or her HBV infection is considered chronic. 
•	 The test for hepatitis B core antibody detects the presence of the core protein of the virus. A 
positive result means the person has been infected with HBV, but it does not specify whether the 
person has cleared the virus, still has the infection, or is immune to reinfection. A negative result 
means the person has never been infected with HBV. This test does not tell whether a person is 
immune to infection or reinfection. 
•	 The test for hepatitis B surface antibody detects the presence of the surface protein (or the 
surface antigen) of the virus that appears after the virus has been cleared (or the person has 
been successfully vaccinated). People who have surface antibodies have lifetime protection from 
future HBV infection. In people who do not clear the virus but develop chronic infection, these 
antibodies never appear. 
Screening for hepatitis C involves a blood test to detect antibodies, but the results are not clear 
cut and should be interpreted carefully. 
•	 A positive test result means the person has been infected with HCV and might be chronically 
infected; it does not always mean the person is still infected. Diagnostic tests are needed. 
•	 A negative test result means either the person has not been infected or the person was infected 
recently and antibodies have not yet appeared. Another test might be needed in 6 months. 
Counselors can use the screening as an opportunity to: 
•	 Educate clients about hepatitis. 
•	 Identify patterns of risky behavior. 
•	 Urge clients to get vaccinated against HAV and HBV. 
•	 Educate clients to prevent hepatitis transmission. 
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After my f irst liver biopsy (and, yes, I was scared of the 
biopsy needle, but it was all over pretty fast), it was dis­
covered that I had stage 2 f ibrosis and inflammation. It 
was time for action. 
—Brian (Hepatitis C Support Project, 2006) 
The medical evaluation 
Clients diagnosed with chronic hepatitis require a full medical 
evaluation to gather information about the nature of their infection,
the severity of the disease, and factors that might affect the course 
of the disease and its treatment. At some point, clients will probably 
be referred to a specialist. This chapter focuses on the evaluation 
of chronic hepatitis, which is caused by the hepatitis B or C virus.
The evaluation of chronic hepatitis can involve several tests: 
•	 Liver panel and other blood tests 
•	 Viral load tests 
•	 Genotype test 
•	 Liver biopsy 
Taken together, the results of these tests help a physician assess 
the disease progression, its prognosis, and the risks and benefits 
of hepatitis treatment.
liver panel 
A liver panel, also referred to as liver function tests (LFTs), is a series 
of blood tests to measure the extent of liver injury. It is among the 
first tests for people who are diagnosed with chronic hepatitis. A 
liver panel measures levels of enzymes and proteins that, if not 
within the normal range, might indicate liver damage. However,
normal levels on a liver panel do not always mean that the liver is 
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not damaged. People who have cirrhosis, for 
example, can have normal LFTs. Exhibit 3-1 
identifies the tests in a standard liver panel 
and what each test measures. Other tests 
might include complete blood counts and 
other measures to help round out the overall 
assessment of liver health. 
viral load Tests 
Nucleic acid tests, which measure nucleic acid,
can indicate the quantity of virus present in 
the bloodstream; hence, they are referred to as 
quantitative viral load tests. These are the best 
and most specific tests to indicate the pres­
ence of viral hepatitis B or C. Nucleic acid is 
composed of molecules that carry the genetic 
information used in the development and 
functioning of organs, such as the liver. The 
nucleic acid test for hepatitis B is hepatitis B 
virus (HBV) DNA (deoxyribonucleic acid),
and the test for hepatitis C is hepatitis C virus 
(HCV) RNA (ribonucleic acid). Qualitative 
HCV RNA tests, which determine whether 
the virus is present, are used to screen for 
hepatitis C (see Chapter 2). 
The extent of liver damage does not correlate 
with measures of HBV DNA or HCV RNA.
A low viral load does not mean a person has 
little liver damage, nor does a high viral load 
necessarily indicate more severe infection 
or more advanced disease. Clients who are 
familiar with HIV testing often assume that 
viral load results for HBV and HCV mean 
the same as they do for HIV viral load results.
Exhibit 3-2 highlights the similarities and 
differences between the HIV and HBV/HCV 
viral load tests.
exhibit 3-1 The liver panel 
Test significance 
Alanine aminotransferase (ALT) Elevated levels of this enzyme indicate liver damage. 
Normal levels do not necessarily indicate healthy liver. 
Albumin Decreased levels of this protein indicate liver disease, 
such as cirrhosis (or other health conditions). Levels 
are often normal until liver disease is extensive. 
Alkaline phosphatase High levels of this enzyme indicate an obstruction in 
the liver (or bile ducts). 
Aspartate aminotransferase (AST) Elevated levels of this enzyme might mean liver 
damage. The enzyme is not specific to the liver, so 
high levels could mark problems elsewhere in the 
body. 
Total bilirubin Elevated levels of this blood byproduct cause 
jaundice. 
Gamma-glutamyl transpeptidase (GGT) Elevated levels of this enzyme indicate liver damaged 
by alcohol use or viral hepatitis. 
Prothrombin time (PT) This test measures the time it takes blood to clot. 
Longer than normal clotting time might indicate 
severe liver damage. 
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exhibit 3-2 comparison of hIv and hBv/hcv viral load Tests 
component hIv viral load Test hBv/hcv viral load Test 
What does the test measure? The presence or amount of 
HIV in the blood. 
The presence or amount of HBV 
or HCV in the blood. 
What does a negative result 
mean? 
In a person who is HIV 
positive, the person still has 
HIV infection but the virus’s 
replication is under control. 
In a person with HCV antibodies, 
the person has no evidence of 
chronic hepatitis. 
What does a positive result 
mean? 
The person is infected with 
HIV. 
The person is infected with the 
hepatitis virus. 
What do the levels mean? High levels correlate with 
disease severity and indicate 
a high likelihood of disease 
progression. 
High levels before hepatitis 
treatment might suggest a low 
likelihood of clearing the virus 
once antiviral treatment begins. 
People who have high levels 
might be more infectious to 
others. During treatment for 
hepatitis B or C, viral load tests 
can determine whether antiviral 
treatment is working. After 
treatment, increased viral load 
might indicate virologic relapse. 
Genotype Test 
This test identifies the type or strain of the 
hepatitis virus. HBV has eight genotypes,
labeled A–H; genotypes A–D constitute the 
most prevalent genotypes in the United States.
Knowing the genotype of HBV might predict 
how successful antiviral treatment will be, but 
more studies are needed. 
At least six genotypes (and some subtypes) of 
HCV exist, but genotypes 1, 2, and 3 are most 
common in the United States. The genotype 
of the virus does not change. Once the HCV 
genotype is determined, another genotype 
blood test is not needed unless the person 
clears the HCV infection and then acquires 
a new HCV infection.
No genotype causes more severe disease than 
any other, but the genotype has implications 
for response to antiviral treatment and the 
duration of treatment. Historically, genotype 
1 has been characterized as less treatable, or 
more difficult to cure, than genotypes 2 and 3.
People who had genotypes 2 or 3 were more 
likely to respond to hepatitis treatment than 
are people who had genotype 1. However,
people who have genotype 1 hepatitis have 
reason to be treated. Boceprevir and telaprevir 
were approved by the U.S. Food and Drug 
Administration (FDA, 2011a; FDA, 2011b) 
in 2011 to be used in combination with 
interferon and ribavirin for the treatment of 
adults with chronic hepatitis C, genotype 1.
These medications have demonstrated higher 
success rates and shorter treatment times for 
genotype 1, and other new medications are 
currently in development. Chapter 4 provides 
information on how genotype factors into 
hepatitis treatment decisions. Exhibit 3-3 
compares genotypes 1 with genotype 2 and 3. 
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Counselors can help clients understand the 
significance of their genotypes in the following
ways:
•	 Ask clients what they have been told 

about genotypes.
 
•	 Respond accordingly. Although genotype 
1 has historically been less responsive to 
antiviral treatment than other genotypes,
as many as 68 percent of clients who have 
genotype 1 respond to newer treatments.
Types 2 and 3 are more responsive to 
antiviral treatment than type 1. 
•	 Assure clients that having genotype 1 does
not mean that the disease will progress 
more quickly or that the symptoms will be
more severe.
•	 Tell clients that the most important 
thing is to follow up with their physician,
because all genotypes have possible treat­
ments that are rapidly improving. 
•	 Ask clients, “What does this information 
mean to you? Does it make sense? How 
might this information help you decide 
your next step?” 
exhibit 3-3 comparison of the most common hcv Genotypes in the United 
states 
component Genotype 1 Genotypes 2 and 3 
Frequency The most common genotype 
in the United States; accounts 
for approximately 75% of HCV 
cases. 
Combined, they account for 
approximately 25% of HCV 
cases in the United States. 
Response to antiviral 
treatment* 
Nearly 50% of people respond 
successfully to hepatitis 
treatment with interferon 
and ribavirin. The addition of 
telaprevir or boceprevir can 
increase this to as much as 
67%–68% (McHutchison, 2009; 
Poordad et al., 2011). 
Approximately 80% of people 
respond successfully to 
treatment and clear the virus. 
Length and dose of antiviral 
treatment* 
Antiviral treatment with 
interferon and ribavirin lasts 12 
months and involves a higher 
dose of medication compared 
with genotypes 2 or 3. The 
addition of boceprevir or 
telaprevir can reduce treatment 
time to 24 weeks (FDA, 2011a; 
FDA, 2011b). 
Antiviral treatment lasts 6 
months and involves a lower 
dose of medication compared 
with genotype 1. 
*Applies only to people who have HCV alone, not to people who have co-infections with other forms of viral hepatitis or HIV. 
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liver Biopsy 
A liver biopsy involves removing and examining
a small number of liver cells that can reveal:
•	 The extent of liver inflammation.
•	 The amount of scarring (fibrosis) present. 
•	 Presence or absence of cirrhosis. 
•	 Lesions in the liver. 
•	 Other conditions (e.g., alcoholic liver 
disease) that might be damaging the liver 
and the severity of the conditions. 
•	 Possible effects of hepatitis treatment. 
Reasons to have a liver biopsy include the 
following: 
•	 It is the best way to evaluate the health 
of the liver and the only way to reveal the 
extent of scarring (if any).
•	 It can help the physician decide whether 
antiviral treatment is advisable or needed.
Treatment might not be necessary if the 
liver is healthy, or it might be inadvisable 
if the patient has other issues that might
contraindicate treatment.
•	 The results can be used when deciding 
whether to continue antiviral treatment if 
side effects are severe. Chapter 4 addresses
factors to consider in making medical 
decisions about hepatitis treatment.
As with any surgical procedure, liver biopsies 
have risks, including pain and internal bleed­
ing. Some clients might feel the risks of 
biopsy are not worth the potential informa­
tion gleaned from the procedure. Increasingly,
people who have genotype 2 or 3 HCV start 
antiviral treatment without having a liver 
biopsy. People who have these genotypes 
might decide that, because treatment is likely 
to succeed, they will try treatment regardless 
of their biopsy results. People for whom anti­
viral treatment is not as likely to be successful 
might decide not to go through treatment 
unless their liver disease is progressing. Thus,
the most important factor in determining 
whether individuals should have a biopsy is 
how essential the results are to them and to 
their medical care provider.
Helping Clients Decide Whether to 
Have a Liver Biopsy 
Following are suggestions to help clients 
decide whether to have a liver biopsy: 
•	 Help clients weigh the potential risks 
and benefits. Counselors cannot provide 
medical advice, but they can, with the 
clients’ medical care providers, help clients 
understand their choices.
•	 Listen to clients’ fears, and respond with 
accurate information.
•	 Help clients plan how they will cope 
with pain after the procedure. Some will 
require medications to treat pain. Taking 
any medication may be a relapse trigger 
for someone with a history of drug use.
Counselors can explain that taking medi­
cations under a medical care provider’s 
supervision is appropriate to relieve pain;
these medications do not necessarily lead 
to relapse. Untreated pain might be as 
likely to trigger craving for opioids as the 
appropriate use of pain medications.
•	 Help clients find someone to accompany 
them to the procedure. Patients are required
to have someone take them home 
afterward. A substance abuse treatment 
program can offer to find a peer or staff 
person who could take a patient to and 
from the procedure (Litwin, Soloway, & 
Gourevitch, 2005). 
•	 Address the positive aspects of a biopsy 
(e.g., it provides important information 
that can help clients move forward).
•	 Help clients work out logistical issues.
For some clients, arranging for child care 
or taking care of other logistical issues 
present problems.
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clinical scenario 
Counselor: “Hi, Susan. Tell me about your recent doctor’s visit for your HCV evaluation.” 
Susan: “Yeah, I went. I found out that my liver is fine and I don’t have to worry.” 
Counselor: “That’s great news! What else did the doctor say?” 
Susan: “She said that the liver tests—the enzymes—are real good and low.” 
Counselor: “Terrific news! You must be very relieved.” 
Susan: “Yeah, I am. I was really worried after the last relapse. The discussions that we had 
really helped me to see how my drug use might be causing more problems with 
my liver and in other areas of my health. My doctor said she’d like me to get a 
biopsy, but if my liver enzymes are okay, I’m not sure why I should do that.” 
Counselor: “It sounds confusing that your health seems to have improved and yet your doctor 
wants more information. So what are you thinking at this point?” 
Susan: “Well, I’m not sure. I mean, how is this possible, you know, how could my liver be 
improved and yet I still have HCV?” 
Counselor: “Well, let’s talk about that for a few minutes, if that’s okay.” 
Susan: “Sure, can you make sense of this? I really don’t want to have a biopsy.” 
Counselor: “You know, this happens quite often. People who have HCV will see improvements 
in their enzyme numbers, but those tests are only one piece. It’s really important to 
get more testing to get the whole picture of what’s going on in there. What do you 
think?” 
Susan: “Well, I guess that makes sense. Would I really have to get a biopsy?” 
Counselor: “Well, that’s really up to you to decide, with information from your doctor. But it 
sounds as if you might be willing if she could tell you more about why it’s really 
important.” 
Susan: “Yeah, maybe I should. Could you help me with that?” 
Counselor: “Sure. Let’s see how you might start that conversation with her, and you could 
make another appointment right now from my office if that would help.” 
•	 Help clients explore ways to pay for the 
biopsy. Be familiar with medical assistance 
programs for uninsured clients, and keep 
a list of physicians who are willing to 
perform biopsies on people who have a 
history of drug use. Insured clients need 
to make sure that their insurance covers 
the procedure.
•	 Help clients identify support from family
and peers. The additional burden of an 
illness can make people who are already 
marginalized feel more isolated. Supportive
people can help clients cope with the 
disease and antiviral treatment side effects 
and identify potentially dangerous side 
effects.
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Liver Biopsy Procedure 
The physician should thoroughly inform 
the patient about the procedure, including 
alternatives, risks, benefits, and limitations.
The procedure typically takes place at an 
outpatient surgical center or in a hospital. The 
patient will need to sign an informed consent 
form before the procedure. The physician 
determines preprocedure orders (e.g., when 
the patient needs to stop eating and drinking;
special diet, if necessary; which medications,
including over-the-counter, to stop taking 
(Rockey, Caldwell, Goodman, Nelson, & 
Smith, 2009).
The biopsy procedure involves the following: 
•	 Patients receive a local anesthetic on 
the right side of the abdomen to numb 
the area. The degree of pain anticipated 
during and after the procedure should be 
taken into account. 
•	 The surgeon inserts a needle into the liver 
and extracts a small piece of liver tissue.
•	 Laboratory personnel examine the liver 
tissue and provide the physician with the 
results within a few days. 
•	 Nurses observe the patients for a few 
hours before they are discharged.
Following the procedure, it usually is 
necessary for patients to lie on their right 
sides for 3–4 hours to prevent bleeding.
Precautions to take after the biopsy include 
the following: 
•	 For at least 24 hours, patients should not 
lift objects heavier than 15 pounds.
•	 Some patients might be sore where the 
needle was inserted, or they might experi­
ence pain in their right shoulders. These 
symptoms are temporary and usually go 
away in a few days. 
•	 With the physician’s approval, patients 
might take acetaminophen for pain. As 
is the case for most medical procedures,
patients should not take aspirin or ibupro­
fen for 7 days before or after the biopsy. 
Resources for information about liver biopsy 
are in Appendix C. 
chapter summary 
A hepatitis evaluation provides information for making informed decisions about antiviral 
treatment. 
HCV evaluation can include the following: 
•	 Liver panel 
•	 Viral load tests 
•	 Genotype test 
•	 Liver biopsy 
Counselors can help clients cope with an evaluation of chronic hepatitis by: 
•	 Helping them identify and weigh the risks and benefits of evaluation. 
•	 Exploring the client’s feelings. 
•	 Helping clients plan how they will cope with waiting for and receiving evaluation results. 

In ThIs ChapTer  
 
 
 
 
 
  
 
 
 
 
 
  
 
c A  
•	 The Counselor’s Role 
•	 Factors to Consider 
About Hepatitis 
Treatment 
•	 Counseling Clients 
Diagnosed With Chronic 
Hepatitis 
•	 Supporting the Decision 
to Treat Hepatitis 
•	 Special Populations: 
Barriers to Hepatitis 
Treatment 
•	 Chapter Summary 
4 
helping clients make 
medical Decisions About 
hepatitis Treatment 
When I was trying to decide whether I should get on the 
interferon or not, I was hammered until I made a decision.
Some medical staff and some clinical staff think because 
you use drugs that you’re totally stupid, or you’re playing to 
get time off. There’s got to be a little more compassion and 
a little more education. They definitely need to let the resi­
dents be part of the decision. I mean, it’s their lives. 
—Counselor and Former Client in “Program C”
(Strauss et al., 2005, p. 1821) 
The counselor’s role 
Medical care providers that once would have denied hepatitis 
treatment to people with substance use disorders (SUDs) now 
routinely screen and evaluate such people and often recommend 
antiviral treatment. Pharmacotherapy for an opioid addiction, for 
example, is no longer considered a contraindication to evaluation,
care, or treatment of chronic hepatitis (Kresina et al., 2008).
Informed counselors can help their clients make decisions about 
medical care for hepatitis and can support the clients in managing 
the risks and benefits that come with any decision.
Factors to consider About hepatitis Treatment 
People who have chronic viral hepatitis have three options:
1. They can be treated with potent antiviral medications. 
2. They can defer antiviral treatment. 
3. They can decide not to be treated.
Although antiviral treatment holds the best promise of eliminating 
chronic hepatitis, the treatment is long, could be difficult, and could 
be expensive without insurance. (Sources for financial assistance are 
listed in Appendix H.) Undergoing treatment might not be the best 
choice for everyone.
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The decision to start antiviral treatment 
should be made by the patient and the medical 
treatment team, based on the patient’s charac­
teristics, circumstances, and an overall assess­
ment of the treatment risks and benefits. Many
times, a patient needs to consult a specialist,
such as a hepatologist, to get all the informa­
tion needed to make a sound decision. Before 
developing the hepatitis treatment plan, the 
physician and patient need to consider several
factors: 
•	 Timing of hepatitis treatment 
•	 Treatment contraindications 
•	 Presence of more urgent problems 
•	 Likelihood of adhering to hepatitis 

treatment
 
•	 Likelihood of treatment success 
Timing of Hepatitis Treatment 
Timing is primarily a factor of how much 
damage the hepatitis has done to the liver.
Patients with mild liver disease (mild scarring),
detected by biopsy, might be able to defer 
hepatitis treatment. Some people, however,
might want to do what they can to get rid 
of their hepatitis C virus (HCV) infection 
regardless of the state of their liver disease.
In this situation, a patient’s feelings about 
being infected and his or her level of interest 
in undergoing treatment can be the deciding 
factors.
Those with intermediate liver disease (intermediate
scarring) should seriously consider hepatitis 
treatment, weighing all relevant factors. For 
example, people who have HIV co-infection 
who face the likelihood of an accelerated 
progression of liver disease have an increased 
incentive to treat their hepatitis C.
For people who have cirrhosis (severe scarring),
timely treatment of hepatitis treatment might 
be warranted, unless the liver disease has 
advanced beyond the point that it will respond 
to antiviral treatment, or the risks of treatment 
outweigh possible benefits.
Patients with end-stage liver disease (decom­
pensated cirrhosis) might not be appropriate 
for treatment, unless they are on a transplant 
waiting list and/or being cared for by experts.
Information on hepatitis treatment options,
including transplantation, is included in 
Chapter 5. 
Hepatitis Treatment 
Contraindications 
Some co-occurring medical or behavioral 
health conditions, certain lifestyle choices,
or pregnancy can contraindicate treatment 
for chronic hepatitis (Ghany, Strader, Thomas,
& Seeff, 2009). Contraindications include:
•	 Major uncontrolled psychiatric disorders 
(e.g., depression, bipolar, schizophrenia).
•	 Prior solid organ (i.e., renal, heart, lung) 
transplantation. 
•	 Pregnancy or unwillingness to use 
adequate contraception (see Exhibit 4-1). 
exhibit 4-1 pregnancy and Antiviral Treatment 
•	 Interferon and ribavirin can cause birth defects, so pregnant women (or their sexual partners) 
should not be administered these medications. Women who are breastfeeding should not 
undergo antiviral treatment for hepatitis. 
•	 A man receiving antiviral treatment for HCV should not impregnate a woman during his 
treatment and for 6 months thereafter because of the possible risk of birth defects. 
•	 Women with HCV have to decide whether to complete antiviral treatment before trying to 
become pregnant or to delay treatment until after delivery. 
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•	 A condition that would make hepatitis 
treatment dangerous (e.g., severe uncon­
trolled hypertension, untreated heart fail­
ure, significant and uncontrolled coronary 
heart disease, poorly controlled diabetes,
chronic pulmonary disease). 
•	 An allergy or hypersensitivity to medica­
tions (e.g., interferon, ribavirin). 
Use of drugs and alcohol is no longer an 
absolute contraindication to antiviral treatment
(see Exhibit 4-2). Many people who actively 
inject drugs are not willing to undergo antivi­
ral treatment or might have difficulty adhering 
to treatment. However, some people who use 
drugs, including people who inject drugs, are 
willing and able to undergo and adhere to 
antiviral treatment (Ghany et al., 2009). 
Presence of More Urgent Problems 
Some health issues might take precedence 
over beginning treatment for hepatitis, par­
ticularly if the extent of liver damage is mild 
or intermediate: 
•	 Treatments for HIV infection or other 
life-threatening conditions might need 
to begin first.
•	 Stabilization of a mental or substance use 
disorder might be necessary.
•	 The priority of some clients might be to 
meet basic needs (e.g., finding housing;
getting regular, nutritious meals).
•	 Clients in crisis might need to stabilize 
before antiviral treatment can begin,
depending on the number and severity of 
stressors in their lives. 
Likelihood of Adhering to Hepatitis 
Treatment 
It is difficult to predict which individuals can 
or will adhere to hepatitis treatment. Until 
recently, the standard practice was to recom­
mend against treating chronic hepatitis in 
people whose circumstances or conditions 
might interfere with their ability to adhere to 
treatment (e.g., continued substance abuse,
mental illness). But this is no longer the case.
The following points summarize the current 
thinking on treating people who have condi­
tions previously considered contraindications 
to antiviral treatment:
•	 Hepatitis C treatment is associated 
with exacerbation of existing psychiatric 
exhibit 4-2 statements and recommendations on hepatitis Treatment 
Agency Treatment Guideline 
National Institutes of Health 
Consensus Statement on the 
Management of Hepatitis C 
Decisions about treatment of hepatitis C in people who 
inject drugs should be made on a case-by-case basis; drug 
use itself is not an absolute contraindication to antiviral 
treatment for hepatitis C (National Institutes of Health [NIH], 
2002). 
New York State Department of 
Health Guidelines for the Medical 
Management of Hepatitis C 
“Patients actively using injection drugs should be offered 
drug counseling and psychiatric support services.… [T] 
reatment of the actively injecting drug using person should 
be based upon the willingness of the client to undergo 
therapy, ability to regularly attend appointments for close 
monitoring, and agreement to use of contraception to 
prevent pregnancy” (New York State Department of Health, 
2005a, p. 11). 
American Association for the 
Study of Liver Diseases Guidelines 
on Diagnosis, Management, and 
Treatment of Hepatitis C 
Therapy should be individualized for people who currently 
use alcohol and who are willing to participate in a substance 
abuse or alcohol treatment support program (Ghany et al., 
2009). 
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symptoms, new symptoms, and thoughts 
of suicide. Depression is a common side 
effect of antiviral treatment and a main 
reason people stop treatment. However, 
with psychiatric treatment and monitor
ing, people who have psychiatric disorders 
have rates of adherence and successful 
outcome comparable with rates of those 
who do not have psychiatric disorders 
(Martin-Santos et al., 2008). 
•	 People in opioid treatment programs 
sometimes have structured support, which 
helps them adhere to antiviral treatment 
and have successful outcomes. 
•	 People who relapse to alcohol or injec
tion drug use can sometimes successfully 
complete antiviral treatment at rates that 
do not significantly differ from those 
of people who do not abuse substances
(Anand et al., 2006; Backmund, Meyer, 
& Edlin, 2004; Dalgard, 2005; Robaeys, 
Van Vlierberghe, Mathei, Van Ranst, & 
Buntinx, 2006; Van Thiel, Anantharaju,  
& Creech, 2003). 
Likelihood of Hepatitis Treatment 
Success 
Hepatitis C treatment success is defined as 
achieving a sustained virologic response (SVR) 
­
­
(see Exhibit 4-3)—when the virus cannot be 
detected for up to 24 weeks (and usually many 
years) after therapy. If the virus cannot be 
eradicated, treatment is generally considered 
unsuccessful, even though the progression of 
liver disease might have slowed during treat
ment. For individuals with mild liver disease, 
a higher predicted likelihood of achieving an 
SVR might make them more interested in 
antiviral treatment than individuals whose 
expected likelihood of responding is lower. 
Historically, success rates for those who 
received hepatitis treatment were between  
40 percent and 50 percent (Heathcote & 
Main, 2005), but new therapies promise higher 
success rates and shorter treatment times. 
Several factors affect the likelihood of treatment 
success: 
•	 Genotypes. Clients who are infected with 
HCV genotype 2 or 3 have approximately  
an 80 percent chance of success, as 
opposed to as much as a 67 percent to 68 
percent chance for those who are infected 
with genotype 1 (see Chapter 3). 
•	 Viral load. Treatment response rates tend 
to be low for those with genotype 1 HCV 
infection and high pretreatment viral load 
(see Chapter 3). 
­
exhibit 4-3 hepatitis c Treatment response classifications 
Treatment outcome Description 
Sustained virologic response (SVR) The virus is absent from the blood at the end of treatment 
and 6 months later. SVR is considered a successful 
treatment response. 
Non-response Antiviral treatment does not work, meaning the virus 
can be detected in viral load tests. If the level of virus 
does not decrease by one hundredfold after 12 weeks of 
treatment, or if it does not go away completely after 24 
weeks, treatment is unsuccessful and can be stopped. 
Virologic relapse The virus disappears from the blood during antiviral 
treatment but returns when treatment is stopped. 
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•	 Ethnicity. For reasons that are not under­
stood but might be related to genetic 
factors (Balagopal, Thomas, & Thio,
2010), hepatitis treatment response rates 
are low among Blacks and Hispanics,
compared with rates among Whites 
and Asians (Conjeevaram et al., 2006;
Rodriguez-Torres et al., 2009).
•	 HIV co-infection. Response rates are lower 
in individuals with HIV co-infection. 
•	 Liver damage. People who have extensive 
liver damage are less likely to respond 
to hepatitis treatment than those with 
moderate or low liver damage, although 
treatment is more urgent for people who 
have severe liver damage.
counseling clients Diagnosed 
With chronic hepatitis 
Exhibit 4-4 lists potential counseling approaches
to various HCV evaluation results. Individual 
circumstances vary, and treatment decisions 
will ultimately reflect advice from a medical 
professional working in concert with the client.
For clients who are considering antiviral treat­
ment, counselors can: 
•	 Encourage clients to ask their medical 
care provider for the information needed 
to make informed decisions about 
treatment. 
•	 Encourage thorough, informed consider­
ation of treatment.
exhibit 4-4 counseling Approaches Based on hcv status 
evaluation result hepatitis Treatment 
Approach 
counseling Approach 
•	 No evidence of liver 
damage 
•	 No HCV found in blood 
(negative antibody test); 
might need to retest in 6 
months 
•	 No HCV antiviral treatment 
needed 
•	 Educate client about liver 
health 
•	 Create risk-reduction plan 
•	 Encourage vaccination 
against hepatitis A virus (HAV) 
and hepatitis B virus (HBV) 
•	 Evidence of mild liver 
damage 
•	 HCV ribonucleic acid (RNA) 
found in blood 
•	 Stable mental/physical 
health and life circumstances 
•	 Consider antiviral treatment 
•	 Monitor liver health 
•	 Educate client about liver 
health 
•	 Create risk-reduction plan 
•	 Encourage vaccination 
against HAV and HBV 
•	 Encourage thorough, 
informed consideration of 
hepatitis treatment 
•	 Evidence of mild liver 
damage 
•	 HCV RNA found in blood 
•	 Unstable mental/physical 
health or life circumstances 
•	 Defer antiviral treatment 
•	 Stabilize health and life 
circumstances 
•	 Monitor liver health 
•	 Educate client about liver 
health 
•	 Create risk-reduction plan 
•	 Encourage vaccination 
against HAV and HBV 
•	 Encourage action toward 
improved health and/or life 
circumstances 
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 exhibit 4-4 counseling Approaches Based on hcv status (continued) 
evaluation result hepatitis Treatment 
Approach 
counseling Approach 
•	 Evidence of severe liver 
damage 
•	 HCV RNA found in blood 
•	 Stable or unstable mental/ 
physical health and life 
circumstances 
•	 Consider antiviral treatment 
•	 Monitor and stabilize health 
or life circumstances 
•	 Encourage treatment 
adherence 
•	 Educate client about liver 
health 
•	 Create risk-reduction plan 
•	 Encourage vaccination 
against HAV and HBV 
•	 Encourage action toward 
improved health and/or life 
circumstances 
•	 HCV RNA found in blood 
•	 Genotype 2 or 3 
•	 Stable or unstable mental/ 
physical health or life 
circumstances 
•	 Urge antiviral treatment 
•	 Stabilize health and life 
circumstances as necessary 
•	 Encourage treatment 
adherence 
•	 Educate client about liver 
health 
•	 Create risk-reduction plan 
•	 Encourage vaccination 
against HAV and HBV 
•	 Encourage action toward 
improved health and/or life 
circumstances 
•	 End-stage liver disease, 
regardless of other factors 
•	 Consider liver 
transplantation 
•	 Encourage vaccination 
against HAV and HBV 
•	 Encourage action toward 
meeting requirements for 
transplantation 
•	 Encourage clients to take action toward 
improved health or life circumstances. 
•	 Assess mental health and SUD recovery 
statuses. 
•	 Emphasize the importance of alcohol 

abstinence.
 
•	 Help clients strengthen their support 

systems.
 
Counselors can explain the following informa­
tion to clients: 
•	 If hepatitis treatment does not completely 
clear the virus, some benefit might still 
occur (e.g., lower viral levels, less inflam­
mation or fibrosis) (NIH, 2002). Also,
many people who have hepatitis C do not 
develop cirrhosis, end-stage liver disease,
or liver cancer. 
•	 The length of antiviral treatment varies. 
•	 Clients will need to get frequent lab 
tests to ensure medication tolerance and 
effectiveness. 
•	 If side effects are too severe or if the 
medication is not working, the medical 
care provider might reduce the dose or 
stop treatment altogether. This does not 
mean the client failed; it means that 
the treatment failed. It should be noted,
however, that the client might still receive 
some benefit from treatment even though 
treatment was not completed (NIH,
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2002). Nonresponse to treatment does 
not mean that liver damage is more 
severe.
supporting the Decision to Treat 
hepatitis 
For many clients who have chronic hepatitis,
the decision to initiate hepatitis treatment is 
difficult. Some clients might feel an urgent 
need to undergo aggressive antiviral treat­
ment. Others might feel that treatment, even 
if strongly recommended by their medical care 
provider, is not right for them, or they want to 
wait until they are further along in their recov­
ery from substance use. Questions to help 
clients weigh their hepatitis treatment options 
include the following: 
•	 “What are the possible gains and losses of 
your decision to get or not to get antiviral 
treatment?” 
•	 “Which of these are most important to 
you?” 
•	 “If you’re not ready to begin hepatitis 
treatment now, what would have to happen
to get you ready or make you decide to 
begin treatment?” 
•	 “What would you be interested in doing 
now?” 
Only the client, in conjunction with his or 
her medical care provider, can decide whether 
antiviral treatment is the right choice. After 
discussing the benefits and risks of treatment 
in the context of the client’s life, the counselor 
should respect and support the client’s decision.
Counselors can help clients who undertake 
antiviral treatment adhere to the regimen, as 
well as help those who defer treatment under­
stand how to promote and maintain liver 
health. 
clinical scenario 
Selena is a 36-year-old Hispanic woman who has been in outpatient treatment for opioid 
dependence for 2 months after completing detoxification and a residential treatment program. 
Her HCV treatment has caused side effects that feel like opioid withdrawal, which has triggered 
cravings for oxycodone. She stated in her last meeting with her counselor that she is going to stop 
taking her hepatitis medications to avoid relapsing. What should the substance abuse treatment 
team do in response to this situation? 
primary concerns 
•	 Selena wants to stop taking her hepatitis medications. 
•	 Selena might not be ready to tolerate the side effects of antiviral treatment. 
•	 Selena needs stronger coping skills for managing her cravings. 
Intervention options 
•	 In consultation with her medical care provider, help her weigh the risks and benefits of stopping 
antiviral treatment and how it can be done safely. 
•	 Discuss ways to help Selena manage her current cravings (e.g., ongoing counseling, support 
groups, referral to an intensive outpatient program or a residential treatment program, increased 
or random urine drug testing and other monitoring, waiting until she is further along in her 
recovery from using opioids to resume hepatitis medications). 
•	 Help Selena understand that she can restart antiviral treatment at a later date. 
•	 Discuss the possibility of starting opioid maintenance treatment if she is not already on 
medication-assisted treatment. 
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special populations: Barriers to 
hepatitis Treatment 
Many people might have to overcome barriers 
to screening and treatment of chronic hepatitis,
including people who are homeless or incar­
cerated; people who have mental illness; mem­
bers of ethnic, racial, or gender minorities;
people whose first language is not English;
and others. Although conditions differ among 
populations and individuals, the needs of mar­
ginalized people are often similar. Counselors 
can assist these clients by: 
•	 Helping them obtain basic information 
about all types of hepatitis in a format or 
language they can understand.
•	 Encouraging them to get vaccinated 

against hepatitis A and B.
 
•	 Advocating screening and treatment 
when the medical care provider’s reluc­
tance to treat is based solely on the SUD 
diagnosis.
•	 Helping clients find medical care provid­
ers who are familiar with and understand­
ing of their culture or subculture. 
•	 Making referrals to specialized case 
management services for shelter services,
housing, food, and other basic needs. 
•	 Understanding marginalized clients’ dis­
trust of medical care systems and public 
health surveillance requirements. 
•	 Helping clients understand and navigate 
complex medical care requirements. 
•	 Monitoring for the co-occurrence of 
mental and substance use disorders,
especially for the worsening of psychiatric 
symptoms when HCV treatment begins,
and managing care or referring for spe­
cialized care, as indicated. 
Appendix C includes resources available for 
people facing particular barriers to treatment.
chapter summary 
In determining eligibility for treatment of viral hepatitis, medical care providers consider: 
•	 Timing of hepatitis treatment. 
•	 Treatment contraindications. 
•	 The presence of more urgent problems. 
•	 The likelihood of patients’ adhering to hepatitis treatment. 
•	 The likelihood of treatment success. 
Medical care providers, clients, and counselors should work together to consider the advisability of 
antiviral treatment. 
There is growing consensus that people who have injected or still inject drugs can be successfully 
treated for hepatitis. 
Steps to help clients decide whether to begin antiviral treatment include: 
•	 Helping clients understand the meaning of evaluation results for hepatitis treatment. 
•	 Assessing clients’ SUD recovery, mental health issues, support systems, and life circumstances. 
•	 Educating clients about their choices. 
•	 Helping clients reframe goals of recovery to include a meaningful, healthy life. 
Once a client makes a decision about hepatitis treatment, the counselor should support that 
decision and offer to reconsider in the future if circumstances change. 
Clients from special populations might require additional education or advocacy. Their unique 
needs must be considered in antiviral treatment planning. 
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5 hepatitis Treatment 
It was late July 2006 and I was ready to commit to getting
myself better. I remember taking my f irst ribavirin pill 
and knowing that this is the start of a new life for me.
I had help with my f irst pegylated interferon shot. I 
scheduled my shots for Friday nights just in case I got sick 
afterwards. I was nervous and scared. That f irst night 
I had a fever and just felt very tired and weak. But the 
end of the next day I was ok.… The f irst doctor’s appoint­
ment after starting treatment went very well. My liver 
enzymes were already back to normal. I felt so happy.
Twelve weeks into treatment they checked my viral count 
and it was undetectable. I knew I was going to make it 
through this. 
—Kathleen (Hepatitis C Support Project, 2006) 
overall Treatment recommendations 
Clients who become infected with hepatitis and seek antiviral 
treatment—especially for hepatitis C—face long and in some 
cases difficult treatment regimens that, in the end, might not clear 
the virus from their bodies. Clients in treatment for chronic viral 
hepatitis might have to manage serious side effects of the treatment 
while striving to manage their behavioral health issues. People who 
decide to delay or forgo hepatitis treatment must learn new skills to 
live with their disease.
Facing these difficult decisions, some clients will feel overwhelmed,
fearful, and hopeless. Counselors who understand hepatitis treatment
options and their side effects can better support their clients in 
recovery from substance use disorders (SUDs).
Clients who have any form of viral hepatitis will benefit from:
•	 Resting. 
•	 Avoiding alcohol and discontinuing drug use. 
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•	 Avoiding other substances that can 
harm the liver, including acetaminophen 
(Tylenol) in large doses. 
•	 Eating nutritious, well-balanced meals.
•	 Getting vaccinated against hepatitis A 
and hepatitis B. 
Treatment for hepatitis A 
Because hepatitis A is always acute, its treat­
ment is generally limited to addressing symp­
toms, monitoring liver health, and letting the 
virus run its course. Clients recently exposed 
to hepatitis A virus (HAV) might be advised 
by their medical care providers to receive the 
HAV vaccination or immunoglobulin injec­
tion to reduce the likelihood of becoming ill 
(Franciscus, Highleyman, & Kukka, 2007;
Victor et al., 2007). 
In rare cases, hepatitis A leads to severe liver 
problems that require medication, hospitaliza­
tion, or transplantation. If left untreated, liver 
problems can lead to life-threatening condi­
tions. Therefore, a client who might have been 
infected with HAV should seek the care of a 
medical care provider.
Suggestions for counseling clients who have 
hepatitis A include the following: 
•	 Assure clients that their symptoms are 
temporary.
•	 Reinforce prevention with messages such 
as, “You will recover from hepatitis A;
let’s talk about what you can do to make 
sure you never get the more serious types.
A vaccine against hepatitis B can protect 
you, and there are ways to reduce the risk 
of getting hepatitis C.” 
•	 Encourage clients to take care of them­
selves. Say, for example, “Your body is 
working hard to fight off the hepatitis 
infection. It is very important that you 
take care of yourself now.” 
•	 Reinforce the importance of maintaining 
SUD recovery activities. Say, “Your liver 
is injured. If you drink or use drugs, you 
could make it worse. Let’s talk about 
everything you’re doing to stay free of 
alcohol and other substances.” 
Treatment for hepatitis B 
All cases of hepatitis B begin as an acute 
infection and most cases resolve without 
treatment. However, if the person does not 
recover completely within 6 months, the 
infection is considered chronic. Clients diag­
nosed with chronic hepatitis B should get 
regular monitoring by a medical care provider,
and some might undertake treatment. Several 
medications are used for chronic hepatitis B.
Treatment might be started with any of the 
U.S. Food and Drug Administration (FDA)­
approved antiviral medications, but interferon,
tenofovir, or entecavir are preferred (Lok & 
McMahon, 2009). These medications might 
be prescribed individually or in combination 
(see Exhibit 5-1).
Any treatment for hepatitis B has benefits 
and risks. Antiviral treatment generally lasts 6 
months–1 year and can extend for years longer 
(possibly for life). Managing side effects can 
be difficult. The decision to undertake treat­
ment should not be made in haste because 
ending some antiviral medications early can 
reactivate the HBV infection. Many people 
elect to delay hepatitis B treatment until they 
are better able to adhere to it. Exhibit 5-2 
provides counseling tips for addressing clients’
concerns about hepatitis B.
Treatment for hepatitis c 
Because most people who have hepatitis C 
have mild symptoms or no symptoms, clients 
often do not know they are infected and,
therefore, do not seek hepatitis treatment 
until severe hepatitis C virus (HCV)-related 
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exhibit 5-1 medications for chronic hepatitis B 
medication Administration side effect 
Short-acting 
interferon 
Injected several times a 
week for 6 months–1 year, 
sometimes longer 
Depression, suicidal behavior, aggression, 
homicidal behavior, flu-like symptoms, 
diarrhea, nausea, taste alteration, anorexia, 
weight gain, liver and biliary system 
disorders, bone pain, arthritis, leg cramps, 
blood disorders 
Long-acting 
(pegylated) 
interferon 
Injected once per week for 
6 months–1 year 
Dry mouth, flushing, headache, fatigue, 
malaise, dizziness, hypothyroidism, nausea, 
anorexia, diarrhea, blood disorders, liver 
and biliary system disorders, musculoskeletal 
system disorders, insomnia, depression, 
anxiety, emotional lability, impaired 
concentration, menstrual disorders, 
coughing, sinusitis, rash, dry skin, taste 
alteration, blurred vision, conjunctivitis 
Lamivudine Tablet taken once per day 
for 1 year or longer 
Headache, fever, nausea and vomiting, 
malaise, fatigue, cough, diarrhea, insomnia, 
rash, shortness of breath; hepatitis B virus 
(HBV) infection might worsen if medication is 
stopped 
Adefovir dipivoxil Tablet taken once per day 
for 1 year or longer 
Lactic acidosis, fluid retention, nausea and 
vomiting, pain in abdomen or stomach, 
jaundice, drowsiness, kidney problems, 
liver problems; hepatitis might worsen if 
medication is stopped 
Entecavir Tablet taken once per day 
for 1 year or longer 
Lactic acidosis, liver problems, headache, 
fatigue, dizziness, nausea; hepatitis might 
worsen if medication is stopped 
Telbivudine Tablet taken once per day 
for 1 year or longer 
Fatigue, cough, diarrhea, headache, 
abdominal pain, rash, fever, back pain, 
muscle pain, sore throat, joint pain, nausea, 
lactic acidosis, liver problems; hepatitis 
worsens if medication is stopped 
Tenofovir Tablet taken once per day 
for 1 year or longer 
Lactic acidosis, liver problems, serious 
psychiatric symptoms, depression, diarrhea, 
dizziness, fatigue, headache, kidney 
problems, nausea, vomiting, stomach pain, 
rash, insomnia, weakness, bone problems 
(pain, softening of bones, decreased bone 
density); hepatitis worsens if medication is 
stopped 
Source: Physicians’ Desk Reference 2010 (64th ed.), 2009. 
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exhibit 5-2 counseling Tips for Addressing concerns About chronic hepatitis B 
•	 Help clients understand that although their symptoms might have diminished, they remain 
infected. Explain, “I know you feel better now, but remember that you still have the infection and 
could spread it to others. Have other members of your household been tested or vaccinated?” 
•	 Help clients understand the importance of seeing a medical care provider for regular monitoring. 
Ask, “Have you talked to your doctor lately about your chronic hepatitis B? What decisions have 
you made about hepatitis treatment?” 
•	 If clients are treating their hepatitis B, ask, “What are you doing to help yourself adhere to 
treatment?” 
•	 For clients who do not have hepatitis A, hepatitis C, or HIV co-infection, stress the importance of 
prevention. Say, “It’s great that you are addressing your HBV infection. It is very important that 
you make sure you don’t get other forms of hepatitis or HIV. These can make your HBV infection 
worse. Let’s make a plan to make sure you don’t contract another infection and that you get 
vaccinated.” 
•	 Reinforce the importance of maintaining substance abuse recovery activities. 
diseases have produced other symptoms or 
their infections are found in a screening test.
Approximately one in five people clears HCV 
infection without treatment. In rare cases,
acute HCV infection quickly leads to liver 
failure (for example, following reinfection 
after a liver transplant). Therefore, any client 
diagnosed with hepatitis C is a potential
candidate for antiviral treatment.
Acute Hepatitis C 
Treating hepatitis C early might greatly increase
a patient’s chances of sustained virologic 
response (SVR) and prevent long-term liver 
damage (Kresina et al., 2008). Response rates 
in acute HCV infection are radically better 
than in chronic infection, but to maximize 
the likelihood of viral clearance, treatment 
should be initiated within the first 20 weeks.
Therefore, counselors should encourage clients 
who have hepatitis C to seek specialized care 
immediately. No clear regimen exists for treat­
ing acute hepatitis C. Currently, treatment is 
a shortened form (approximately 12 weeks) of 
the antiviral treatment for chronic hepatitis C.
Chronic Hepatitis C 
Treatment options for people who have chronic
hepatitis C include: 
•	 Antiviral treatment. A course of potent 
medications might slow disease progres­
sion or eliminate the disease.
•	 Deferring treatment. Not all patients 

want treatment, even if it is advised.
 
•	 Liver transplantation. For people who 
have end-stage liver disease, transplanta­
tion surgery might be the only option.
However, the waiting list for such surgery 
can be long.
Antiviral Treatment 
Antiviral treatment helps the body fight off 
HCV infection (i.e., weakens the virus). When 
the virus is not detected in the blood of a 
patient who is receiving antiviral treatment,
and when it remains undetected for 6 months 
after treatment is completed, the patient is 
said to have an SVR. The virus does not return
in 95 percent to 99 percent of patients who 
achieve an SVR, and it does not appear to 
cause further damage (McHutchison et al.,
2006; Swain et al., 2007).
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However, an SVR does not make a person 
immune to reinfection. If reexposed to HCV, 
a person could be reinfected. Clearing HCV 
does not make a person immune to other 
forms of hepatitis or to liver disease. For 
instance, drinking heavily can still cause liver 
damage, even after successful treatment of 
hepatitis C. 
The standard recommended treatment for 
hepatitis C is a combination of pegylated 
interferon injections and ribavirin (Exhibit 
5-3). However, in 2011, the FDA approved 
two new oral medications, boceprevir and tela­
previr. They represent a new type of medica
tion for HCV infection that works differently 
than interferon and ribavirin and works in 
combination with those traditional medications 
(FDA, 2011a; FDA, 2011b). 
Hepatitis C treatment works well for most 
people, whereas for a minority it produces 
little or no improvement. Counselors can help 
their clients improve their chances for successful 
hepatitis treatment by encouraging them to: 
•	 Take all medications as prescribed, keep 
all medical appointments, and reschedule 
missed appointments as soon as possible. 
•	 Maintain a healthful lifestyle. 
­
•	 Learn about HCV medications, includ
ing special risks and warnings even after 
antiviral treatment has finished. 
•	 Always carry a list that includes the 
prescribing medical care provider’s name 
and phone number and the names and 
dosages of the medications. 
•	 Check with their medical care provider 
before starting new medicines, including 
vitamins, supplements, herbal remedies, 
prescription medications, and over-the­
counter medications. 
•	 Avoid drinking alcohol or taking drugs 
with no known medical use. 
•	 Maintain as many recovery activities as 
possible. 
•	 Report side effects to their medical care 
provider. 
Side effects of antiviral medication differ 
from person to person. Some side effects are 
mild to moderate and remain so. But in some 
people, side effects become more severe with 
continued hepatitis treatment. HCV treatment 
is long, and having to manage side effects for 
the duration of treatment can strain individu
als and those they turn to for support. Side 
effects—particularly flu-like symptoms and 
­
­
exhibit 5-3 medications Approved for Treating chronic hepatitis c 
medication Administration 
Long-acting (pegylated) interferon Injected weekly for 6 months–1 year 
Ribavirin Tablet or capsule taken orally, usually twice per day for 6 
months or longer 
Boceprevir Capsule taken orally, three times per day (with food). 
The length of dosing time varies based on viral response 
and the extent of liver disease. It must be taken in 
combination with interferon and ribavirin. 
Telaprevir Tablet taken orally, three times per day (with food) for 12 
weeks (another 12–36 weeks may be required, depending 
on viral response). It must be taken in combination with 
interferon and ribavirin. 
44 
 
 
 
 
 
 
 
 
 
 
 
 
depression, which are common side effects 
of interferon—are the primary reason people 
stop hepatitis C treatment. Because people are 
more likely to clear the virus if they complete 
their antiviral treatment, it is crucial that they 
get the support they need to manage side 
effects so the side effects do not cause them 
to discontinue treatment (Exhibit 5-4).
Although most side effects are manageable by 
the patient, others require medical interven­
tion. Conditions requiring medical attention 
include the following:
•	 Depression or mania. Counselors need 
to be particularly attuned to the develop­
ment of these neuropsychiatric symptoms,
routinely assess for them, and refer 
clients for mental health treatment as 
appropriate.
•	 Anemia (reduced red blood cell count).
Ribavirin often leads to anemia that can 
cause fatigue and increase the risk of 
chest pain, shortness of breath, or heart 
attack.
•	 Neutropenia (reduced white blood cell 
count resulting in an increased risk of 
infections). Neutropenia is rarely severe 
enough to terminate antiviral treatment.
•	 Pulmonary conditions. Shortness of 
breath or cough might develop during 
hepatitis treatment. People who develop 
these symptoms should consult their 
medical care provider to rule out other 
causes. 
•	 Eye problems. Antiviral treatment 
can induce or aggravate eye problems,
especially in people who have diabetes or 
hypertension. Clients who complain of 
blurry vision, any obstruction to vision, or 
loss of vision should receive an immediate 
medical examination. 
Appendix D provides practical approaches to 
managing common side effects of hepatitis 
C antiviral treatment. The U.S. Department 
of Veterans Affairs, National Hepatitis C 
Program, offers information on managing side 
effects on its Web site (http://www.hepatitis.
va.gov/pdf/treatment-side-effects.pdf ). 
Deferring Treatment 
Some clients might choose to postpone 
antiviral treatment. They might have more 
urgent health problems to tend to, or they 
might feel they are not strong enough in their 
SUD recovery to undergo hepatitis treatment.
exhibit 5-4 Adhering to Antiviral Treatment 
Substance abuse treatment counselors can help clients adhere to antiviral treatment by: 
•	 Explaining intended effects and side effects of medication. 
•	 Paying attention to side effects and advising clients to report them to their medical care 
providers. 
•	 Being respectful and nurturing. 
•	 Providing reminder services (e.g., cell phone reminders, pill organizer boxes). 
•	 Addressing depression, when appropriate. 
•	 Striving for multidisciplinary collaboration among all professionals caring for the client. 
Where possible, observed dosing might also encourage treatment adherence. 
Source: Robaeys & Buntinx, 2005 
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Medical care for clients who choose to defer 
treatment generally involves: 
•	 Getting regular medical evaluations. 
•	 Having liver enzyme and cancer screening 
tests once or twice every year. 
•	 Getting a liver biopsy every 3–5 years. 
•	 Adopting a lifestyle that promotes liver 
health.
It is critical for clients with compromised 
liver functions to take precautions against 
contracting HIV and to get vaccinated against 
HAV and HBV. Clients who are co-infected 
with HCV and HIV should be encouraged 
to get treated for their HIV. Clients who are 
HIV negative should be retested for HIV 
at the advice of their medical care provider.
Counseling tips for working with clients who 
have chronic hepatitis include:
•	 Help clients understand that they should 
see a medical care provider regularly.
“When was the last time you saw your 
doctor about your hepatitis?” 
•	 Encourage patients to adopt habits that 
support liver health, such as avoiding 
alcohol and eating a healthful diet.
•	 Help clients think about how to create 
or improve their support networks so 
that no matter what hepatitis treatment 
choices they eventually face, they have 
help from others. “Would you like to 
create a list of people you know and list 
the help they could provide you as you 
cope with hepatitis?” 
Liver Transplantation 
Although many people who have hepatitis 
C respond to antiviral treatment or can live 
indefinitely with their illness, in some people,
liver damage will be extensive and a liver 
transplantation is needed. Counselors should 
be prepared to support clients who have 
been told that liver transplantation surgery 
is necessary. They might also need to educate 
the transplantation team about the value of 
medication-assisted treatment (MAT) for 
opioid dependence. The following factors 
influence a patient’s acceptance to a transplant 
waiting list: 
•	 Urgency of need 
•	 Willingness and ability to endure the 
extensive preoperative and postoperative 
tests and procedures 
•	 Willingness and ability to follow physi­
cian’s instructions 
•	 Willingness to adjust to the postoperative 
lifestyle 
•	 Access to caregivers who can provide 
support during the lengthy transplanta­
tion process 
•	 Ability to stop all alcohol use 
Patients obtaining a liver transplant generally 
go through the following phases: 
1. Contacting a transplant center. People 
who have been told that a liver transplant 
is their only hope should obtain a physi­
cian’s referral to a transplant center as 
soon as possible. Each transplant center 
has its own criteria for placing patients 
on its waiting list. Clients who are not 
accepted for a waiting list might be 
deferred until the conditions that pre­
vented the client from being accepted 
are resolved.
2. Waiting for the transplant. The time 
between being put on a waiting list and 
receiving the transplant can be as short 
as a few days or as long as several years.
While waiting, patients must keep their 
records updated at the transplant center 
and stay as healthy as possible to be ready 
for surgery when a liver becomes available.
They must avoid consuming alcohol or
drugs and continue to take medications as
prescribed. 
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complementary or Alternative medicine 
Clients might turn to complementary or alternative medicine (CAM), believing it will bolster 
nutrition, attack the hepatitis, protect or strengthen the liver, or mitigate side effects of viral 
hepatitis treatment. As many as 20 percent of people who have liver disease use herbal remedies. 
No conclusive scientific evidence supports the use of CAM for hepatitis C; herbal treatments, 
dietary supplements, alternative medicines, and acupuncture have not been proven to cure or 
relieve symptoms of hepatitis C (Dieticians of Canada, 2003; National Center for Complementary 
and Alternative Medicine, 2008). In addition, some herbal treatments might harm the liver, further 
damaging an already compromised organ. Plants and alternative treatments that can harm the liver 
are provided in Appendix E. 
3. Getting the transplant. The surgery itself 
takes up to 12 hours. Recovery can take 
months.
4. Living with the transplant. Following 
a transplantation procedure, patients 
must take medication for the rest of 
their lives to reduce the chance of their 
bodies rejecting the donated liver. This 
medication weakens the immune system.
Patients might experience an array of 
intense emotions following the surgery.
Counselors can help clients explore their 
emotions while developing realistic expec­
tations for their futures. Liver transplants 
buy some time, but not necessarily a lot 
of it. Within 5–10 years, many patients 
contract hepatitis C again and, because 
medications suppress their immune 
response, the disease progresses much 
more rapidly (Berenguer et al., 2006;
National Institutes of Health [NIH],
2002). In fact, the recurrence of HCV 
after a transplant is universal unless viral 
eradication occurs before the transplant.
In such cases, progression of the disease 
might be rapid, sometimes resulting in 
cirrhosis within 1 year of transplant. 
Counselors can play a critical role with clients
who have end-stage liver disease or liver cancer
and are not likely to obtain a liver transplant
in time, who have been rejected from waiting
lists, or who cannot go through the procedure.
Specifically, counselors can help clients with 
end-of-life decisions, help ensure that those 
decisions are respected, and obtain palliative 
care. This work might be enhanced by 
collaboration with medical care providers,
social workers, ethicists, family, hospice care,
spiritual advisors, and therapists. Resources for 
liver transplantation are provided in Appendix C.
people receiving medication-
Assisted Treatment for opioid 
Dependence 
Some medical care providers and clients 
believe that people on methadone or 
buprenorphine are ineligible for, or will not 
benefit from, antiviral treatment. However,
research suggests that treatment for hepatitis 
C can be effective for people receiving MAT 
for opioid dependence (Kresina, Bruce, Cargill,
& Cheever, 2005; Mauss, Berger, Goelz, Jacob,
& Schmutz, 2004; Sylvestre, Litwin, Clements,
& Gourevitch, 2005). NIH (2002) hepatitis 
C treatment guidelines state that MAT has 
been shown to reduce risky behaviors that can 
spread HCV infection, and it is not a contra-
indication to HCV treatment.
Many clients receiving methadone, buprenor­
phine, or naltrexone might want antiviral 
treatment, but it is not offered to them by 
their medical care providers. Counselors can 
provide a crucial service by informing clients 
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that their receipt of MAT for opioid depen­
dence does not exclude them from hepatitis 
treatment. Counselors can help clients search 
for medical care providers who are open to 
assessing them for hepatitis treatment, and 
counselors can advocate treatment if they 
perceive that clients are being discriminated 
against because of their past or current sub­
stance use status.
Adherence to antiviral treatment is an
important factor in treatment success, and
studies show that individuals receiving metha­
done treatment can adhere to treatment for
hepatitis C (Schaefer et al., 2007; Sylvestre 
& Clements, 2007). Modifying treatment for 
clients receiving MAT for opioid dependence 
might help them adhere to antiviral treatment 
(Exhibit 5-5). Chapter 7 provides more infor­
mation on program-level modifications. 
people Who relapse to 
substance Use 
People who relapse, continue to use, or have 
only recently quit using drugs or alcohol are 
often denied treatment for viral hepatitis.
One study found that more than one-third 
of substance abuse treatment programs listed 
recent drug use as a reason their clients had 
not been treated for HCV infection (Astone-
Twerell, Strauss, Hagan, & Des Jarlais, 2006).
Several factors determine whether a person 
is a good candidate for antiviral treatment,
and recovery status is just one factor. Clients 
should not be denied hepatitis treatment 
for this reason alone. Other misperceptions 
abound. NIH (2002) indicates that treatment 
of chronic hepatitis C can be successful even 
when patients have not abstained from active 
drug use.
exhibit 5-5 sUD Treatment modifications for clients receiving mAT for opioid 
Dependence 
Type of Interaction recommendation 
Support meetings, peer 
support, and counseling 
sessions 
These activities might help clients cope with side effects and 
urges to relapse that result from injecting medication (Litwin 
et al., 2005). If an opioid treatment program (OTP) is the only 
source of counseling, additional referrals for more intensive 
individual or family counseling might help clients with the 
multiple psychosocial issues that might arise. 
Flexible counseling schedules 
while maintaining medication 
schedules 
If licensure standards allow, 15-minute sessions four times 
monthly instead of monthly 1-hour sessions might be more 
realistic for clients with fatigue from chronic hepatitis or antiviral 
treatment. Programs could allow one outside support group 
meeting to substitute for a monthly group session. 
Flexible individual dosing 
regimens 
Clients in OTPs who undergo treatment for HCV infection 
often report increased opioid cravings and request increased 
methadone doses. It is unclear why hepatitis treatment is 
associated with increased cravings, but for some clients the 
side effects of antiviral medications might mimic withdrawal. 
Increasing methadone doses might help relieve the flu-like 
side effects caused by hepatitis treatment. Research has not 
confirmed that interferon lessens the effects of methadone. 
Observed dosing by staff Some people might better adhere to antiviral treatment if they
take their oral medication or interferon in the presence of SUD
treatment staff. Residential programs and OTPs might be better
able to offer medication observation than non-OTP outpatient
programs. 
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Misperception 1. Antiviral Treatment Is Ineffective in People Who Continue to Abuse 
Substances 
People who have recently used injection drugs or who relapsed to drug use during hepatitis 
treatment have SVRs comparable with SVRs in other groups (Robaeys & Buntinx, 2005; Van Thiel et 
al., 2003). However, SVR is more likely in people who have at least 6 months of abstinence than in 
people who continue to abuse substances regularly (Robaeys & Buntinx, 2005). 
Misperception 2. People Who Abuse Substances Do Not Adhere to Antiviral Treatment 
Research suggests that, with support, people who use substances can adhere to antiviral 
treatment. Clients who are not in OTPs are more likely to discontinue treatment early, particularly 
in the first 8 weeks of therapy (Schaefer, Heinz, & Backmund, 2004). Sylvestre et al. (2005) found 
that individuals with occasional drug use had adherence rates that were comparable with rates of 
those who were abstinent. However, people who relapsed to regular heavy drug use showed a 
significantly lower level of adherence. 
Misperception 3. People Who Continue to Abuse Substances Will Be Reinfected With HCV 
Even if SVR Is Achieved 
Although data are limited, evidence suggests that the risk of reinfection with HCV is low, even 
among people who relapse to injection drug use (Backmund et al., 2004; Dalgard et al., 2002; 
Robaeys & Buntinx, 2005; Schaefer et al., 2004). 
Strategies for helping clients who relapse to 
substance use include: 
•	 Developing an SUD treatment plan that 
includes a range of effective treatment 
options; additional testing to evaluate 
HAV, HBV, and HCV status; and a 
hepatitis treatment referral. 
•	 Using motivational interviewing to 
engage clients in treatment to improve 
their quality of life.
•	 Providing education on HCV transmis­
sion and treatment and helping with 
psychosocial difficulties.
•	 Recognizing clients’ ambivalence, efforts 
in SUD treatment, and attempts to 
reduce substance use.
•	 Referral to mental health treatment, if 
warranted. 
people Who have hcv/hIv
co-Infection 
People who are co-infected with HCV and 
HIV must adjust to two major diagnoses that 
can have difficult treatment regimens. In cli­
ents with HIV, hepatitis C treatment is gener­
ally advised when the likely benefits outweigh 
the risks of serious side effects (Ghany et al.,
2009). Approximately 35 percent of people 
who have HCV/HIV co-infection achieve an 
SVR (Sherman, 2007), and this success rate 
might be improved with new medications.
Counselors can help clients understand the 
implications of HCV/HIV co-infection and 
provide support. Strategies to address the 
issues include the following: 
•	 Educate clients about HCV/HIV co­
infection. Many people who have HIV 
might be aware of the health conse­
quences of HIV but be unaware that HIV 
infection greatly increases the progression 
of HCV, increasing the likelihood of 
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cirrhosis, end-stage liver disease, and liver 
cancer. In fact, liver disease—from under­
lying hepatitis B, C, or alcohol abuse—is 
the major non-AIDS cause of death in 
HIV-infected persons. 
•	 Stress the importance of being tested for 
hepatitis and receiving antiviral treatment 
as soon as possible. All individuals who 
are infected with HIV should be screened 
annually for HCV.
•	 Screen for and address cognitive deficits.
People who are co-infected are more 
likely to suffer cognitive deficits in mul­
tiple areas, including learning, abstraction,
motor abilities, memory, and informa­
tion processing (Cherner et al., 2005).
Counselors should be attentive to signs 
of these problems, conduct assessments,
help clients cope with these issues, and 
advocate on behalf of their clients with 
HCV treatment providers.
•	 Help clients manage side effects.
Individuals who have HIV often receive 
medications that can have significant side 
effects. People who are co-infected with 
HCV and HIV might experience many 
side effects with antiviral treatment (Gish,
Afdhal, Dieterich, & Reddy, 2005).
•	 Encourage clients to seek and receive 
compassionate medical care. Medical care 
providers who have not received training 
in managing HCV/HIV co-infection 
can present barriers to effective hepatitis 
treatment. Clients might also be negatively
influenced by judgmental approaches,
frustration, and unrealistic expectations 
for treatment (Kresina et al., 2005).
These attitudes can result in distrust 
and poor communication between client 
and provider, as well as in frustration 
and lack of adherence by the client.
Counselors can help clients find medical 
care providers who are familiar with and 
able to treat this population.
•	 Help coordinate care. People who have 
HCV/HIV have multiple needs requiring 
an array of medication and treatment.
Counselors can coordinate with medical 
care providers to address these needs.
A multidisciplinary approach can help 
clients access the treatment that they 
need and increase treatment retention.
•	 Emphasize adherence to treatment.
Effective results depend on close 
adherence to all treatment regimens.
Counselors should explain the importance 
of taking medications exactly as directed.
people Who have co-occurring 
Behavioral health Disorders 
Studies have demonstrated that completion 
and outcome of antiviral treatment can be 
similar for clients who have co-occurring 
substance use and mental disorders com­
pared with clients who do not have these 
co-occurring conditions (Chainuvati et al.,
2006; Guadagnino, Trotta, Carioti, Caroleo, & 
Antinori, 2006; Sylvestre & Clements, 2007).
People who have and do not have psychiatric 
histories had similar rates of HCV treatment 
adherence. In people who have depressive 
symptoms, medications to treat depression 
should be given early in HCV treatment to 
improve treatment adherence. Freedman and 
Nathanson (2009) suggest that optimal results 
are obtained when coordinated substance 
abuse and psychiatric treatment occurs before 
and during treatment for hepatitis C. 
Counselors can help their clients with co­
occurring substance use and mental disorders 
cope with hepatitis. Suggestions for initiating 
conversations follow:
•	 “Your doctor expressed some concern 
about your candidacy for treatment 
because of your depression. How do you 
see things?” 
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•	 “What would be helpful for your 
depression?” 
•	 “Your doctor says you can go ahead with 
hepatitis treatment. What do you think 
you need to do for this to be successful?”
 
mental disorders and hepatitis is provided in 
Information specific to supporting clients 
who have co-occurring substance use and 
Appendix F.
 
chapter summary 
•	 Hepatitis A rarely requires treatment. 
•	 Chronic HBV can be treated with several oral antivirals; currently, tenofovir or entecavir are the 
recommended first-line options for initial oral treatment options. 
•	 Hepatitis C can be treated effectively if discovered early (i.e., in its acute phase), but it is rarely 
discovered early. 
•	 Treatment for chronic hepatitis C is lengthy, can cause side effects that are difficult to manage in 
some people, and requires good adherence. It is not appropriate for everyone. 
•	 Some clients might elect (or be advised) to defer antiviral treatment. 
•	 For some people, a liver transplant is the only option. Counselors can help clients through the 
process. 
•	 Clients in OTPs are eligible for antiviral treatment. 
•	 Clients who use substances or relapse can achieve SVR comparable with that of other groups if 
they adhere to hepatitis treatment. 
•	 HCV/HIV co-infection can be very serious. 
•	 Clients with co-occurring behavioral health disorders can adhere to—and respond to—antiviral 
treatment. 
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6 
counseling Approaches 
for people Who have 
viral hepatitis 
c A  
•	 The Need for Counseling 
Strategies 
•	 Ensuring Safety 
•	 Providing Reliable 
Information 
•	 Building the Therapeutic 
Relationship 
•	 Helping Clients 
Understand Their 
Diagnoses 
•	 Incorporating Client 
Needs in Substance 
Abuse Treatment 
Planning 
•	 Developing a Prevention 
Plan 
•	 Using Motivational 
Approaches 
•	 Confronting the Social 
Factors of Hepatitis 
•	 Addressing Relapse 
•	 Building Support 
Systems 
•	 Providing Effective Case 
Management 
•	 Chapter Summary 
When I found out that I had hepatitis C, I was really 
angry. I worked so hard to get off drugs and was just 
starting to get my life together. Then they told me I had 
this disease. I couldn’t believe it. I didn’t go back to the doc­
tor for a while—I didn’t want to deal with it. 
—Carlos (New York State Department of Health,
2005b) 
The need for counseling strategies 
Counselors are in a unique position to provide education, emotional 
support, and other types of assistance for clients who have hepatitis 
and substance use disorders (SUDs). However, most treatment pro­
grams do not have components in place to address viral hepatitis.
According to the 2007 National Survey of Substance Abuse 
Treatment Services, only 22 percent of treatment facilities offer 
onsite screening tests for hepatitis B; 23 percent offer onsite screen­
ing for hepatitis C (Office of Applied Studies, 2007). Other studies 
have shown that only 54 percent of treatment programs provide 
education about hepatitis, and many counselors are uninformed 
or misinformed about the disease (Astone, Strauss, Vassilev, & Des 
Jarlais, 2003).
Depending on the resources available, counselors might be able 
to implement only some of the strategies presented for supporting 
clients who have hepatitis. Readers are encouraged to accomplish 
what they can to improve SUD treatment practices for their clients 
and to advocate for client access to services that cannot be imple­
mented immediately. Information specific to supporting clients 
who have co-occurring mental disorders and hepatitis, absent a 
co-occurring SUD, is provided in Appendix F. 
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ensuring safety	 These include: 
If a client with infectious hepatitis becomes 
injured and bleeds, staff members are at risk 
of contracting the infection. Counselors should
use universal precautions, such as wearing 
gloves and other protective gear when exposure
to infected blood or other body fluids is pos­
sible. Counselors should take care to avoid 
accidental needle sticks, which can transmit 
hepatitis and HIV. Counselors should also 
know their hepatitis status and take cautions 
to protect clients and coworkers, if necessary. 
Counselors can discuss hepatitis
 
in ways that build the therapeutic
 
relationship.
 
providing reliable Information 
Providing current, accurate information is an 
important counseling service. Misinformation 
obtained by word of mouth or on the Internet 
can increase clients’ fears and feelings of hope­
lessness. Counselors can dispel misinformation 
about hepatitis by providing educational ses­
sions incorporated into treatment program­
ming. Chapter 1 gives an overview of viral 
hepatitis, and Appendix C provides a list of 
resources that are available on the Internet.
Building the Therapeutic 
relationship 
Counselors can discuss hepatitis in ways that 
build the therapeutic relationship. Clients are 
more likely to ask questions and express con­
cerns and fears about screening, a diagnosis 
of chronic hepatitis, and its treatment if the 
counselor and client have a good working rela­
tionship. There are a number of ways in which 
a counselor can help clients (Astone, Strauss,
Munoz-Plaza, Hagan, & Des Jarlais, 2005).
•	 Being well informed about hepatitis,
especially chronic hepatitis C. 
•	 Talking to clients about their diagnoses 
and medical treatment with empathy. 
•	 Assuring clients that the counselor will 
help them negotiate necessary services,
either within or outside the treatment 
program. 
•	 Helping clients overcome possible barriers
to hepatitis treatment. 
•	 Interpreting information clients receive 
from medical care providers, the Internet,
family, friends, and other clients. 
•	 Repeating information in different ways 
until clients understand it. 
•	 Asking about clients’ families’ responses 
to their diagnoses and helping clients 
cope with those responses. 
•	 Educating clients about the liver and how 
to stay healthy with hepatitis and stating 
that the majority of people who have 
chronic hepatitis C and who do not use 
alcohol will not develop life-threatening 
complications. 
•	 Offering messages of hope about living 
with hepatitis.
•	 Emphasizing consistently the importance 
of clients’ addressing their health-related 
issues. 
•	 Explaining complex hepatitis treatment 
and test results or collaborating with 
medical professionals who can provide 
necessary explanations to clients. 
•	 Helping to make medical appointments 
and advocating for clients with medical 
care providers. 
•	 Helping clients devise strategies for
remembering medical and other scheduled
appointments. 
53 
6—Counseling Approaches for People Who Have Viral Hepatitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
helping clients Understand Their 
Diagnoses 
Clients’ reactions to a diagnosis of viral hepatitis
vary. For some clients, the possibility that they 
might become ill in 20–30 years might be the 
least of their concerns as they face the imme­
diacy of their potentially life-threatening SUD 
and other life stressors. For others, a diagnosis 
might present a crisis. Those who have been in 
substance abuse treatment for many years, for 
example, might view a diagnosis as a threat to 
their hard-won sense of stability (Litwin et al.,
2005). New clients might feel overwhelmed by 
the extra complications placed on the already 
daunting prospect of recovery. Some might 
use their diagnoses of hepatitis as an excuse 
to start using substances again.
Counselors need to be prepared for a range 
of reactions. Some clients might need to talk 
through fears and anger many times before 
moving forward with medical treatment. In 
these situations, counselors might need to 
schedule more individual sessions with clients 
to discuss these issues. Other clients might 
need prodding to understand their diagnoses 
and take appropriate steps to reduce their 
risks of spreading the illness or worsening 
their prognosis. Clients might be concerned 
about how to tell loved ones about their diag­
noses and worried about transmitting the virus 
to others. Women might be concerned about 
pregnancy and hepatitis treatment or viral 
transmission.
Incorporating client needs in 
substance Abuse Treatment 
planning 
Substance abuse treatment planning might be 
complicated by both hepatitis symptoms and 
potential side effects of the antiviral treatment.
Counselors might need to adjust substance 
abuse treatment for clients who have hepatitis-
related symptoms or antiviral treatment side 
effects.
Facets of substance abuse treatment might 
need to be flexible for clients who have hepatitis
(within accreditation and licensing guidelines) 
and allow for the following: 
•	 Individualized, flexible substance abuse 
treatment planning to permit missed 
sessions resulting from hepatitis symp­
toms, antiviral treatment, or medical 
appointments
•	 Time for clients to rest 
•	 Time for hepatitis-specific support 
groups for clients in residential treatment 
(individual sessions could be scheduled to 
replace missed group sessions) 
•	 More frequent sessions or more intensive 
programs 
•	 Longer duration of substance abuse treat­
ment to make up for missed sessions and 
to provide ongoing support during the 
hepatitis treatment regimen 
Ongoing screening and assessment for 
depression and other mental disorders are 
necessary for all clients but are particularly 
important for clients with hepatitis who are 
receiving interferon. Depression is a major 
side effect of interferon treatment, and clients 
with a history of depression are at particular 
risk for worsening of symptoms. Treatment 
plans for clients who have co-occurring 
substance use and mental disorders should 
include: 
•	 Periodic screening for depression, referral 
for evaluation by a mental health profes­
sional, and consideration of initiating 
antidepressant treatment, if warranted. 
•	 Regular medication adherence checks 
for clients who are taking antidepressant 
medication. 
•	 Frequent communication among substance
abuse, mental health, and medical care 
providers, with permission of the client. 
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Developing a prevention plan 
Clients might continue to put themselves or 
others at risk for contracting viral hepatitis,
especially early in recovery. By identifying 
a client’s risky past or current behavior, the 
counselor can help the client create a plan 
to reduce the chances of contracting or spread­
ing viral hepatitis. The following steps are
suggested: 
•	 Identify a specific high-risk incident.
Focusing on past behavior might be diffi­
cult for a client who feels shame or regret.
Discussing one specific incident might 
be less onerous for the client. Ask the 
client to describe the “who, what, where,
when, and how” of the most recent risky 
experience. Ask whether the client talked 
about hepatitis risks with partners. Try to 
determine whether the client’s patterns 
of risky behavior are chronic, episodic, or 
a single incident. Ask, for example, “Was 
that the first time you let someone inject 
you?” 
•	 Start where the client is. Keep in mind 
that some clients will not know how 
they became infected. Developing a 
risk-reduction plan for this type of cli­
ent might require a gradual, supportive 
approach to identifying risk factors. 
•	 Identify a situation when the client mini­
mized his or her risk. Ask the client to 
describe what precautions he or she took 
and why. Offer positive reinforcement,
such as “So you refused to share a needle.
That must have been hard to do. Good 
for you.” 
•	 Synthesize patterns of behavior. Identify 
the client’s pattern of risky behavior and 
the specific circumstances that lead to the 
behavior. 
•	 Negotiate a prevention plan. Clients might
feel besieged by the many changes they 
are asked to make. Develop incremental 
and achievable steps to minimize risk 
for transmitting viral hepatitis. Put the 
behavioral change plan in writing, and 
give a copy to the client.
•	 Revisit the plan periodically, and assess 
progress. Check with the client periodi­
cally to determine whether new behaviors,
stressors, or circumstances need to be 
addressed in the plan. Renegotiate the 
plan if necessary.
•	 Include vaccinations against hepatitis A 
or hepatitis B and prevention strategies 
for other infections, such as HIV, that are 
spread in the same way as different types 
of hepatitis. 
Using motivational Approaches 
Using motivational approaches, the counselor 
can help clients understand the relationship 
between good health and recovery (Litwin
et al., 2005). Counselors can identify the
strengths clients have demonstrated in
counseling sessions and encourage clients
to develop ways to use those strengths to
cope with current health challenges. Appendix
G provides sources of information about 
motivational interviewing and counseling.
confronting the social Factors of 
hepatitis 
Many people who have viral hepatitis report 
that the social ramifications of a hepatitis C 
diagnosis are severe (Astone-Twerell, Strauss,
& Munoz-Plaza, et al., 2006). Many people 
who have SUDs and chronic hepatitis feel 
they are judged as immoral and blameworthy 
because the infection results primarily from 
the sharing of contaminated injection drug 
use equipment (Astone-Twerell, Strauss,
Munoz-Plaza et al., 2006). People who have 
hepatitis C virus (HCV) infection might be 
viewed by some as having made poor choices 
because they engaged in dangerous and illegal 
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behaviors that resulted in their illnesses.
Negative attitudes about people who have 
chronic hepatitis remain, even among some 
medical professionals (Brener, Von Hippel, & 
Kippax, 2007; Paterson, Backmund, Hirsch,
& Yim, 2007; Von Hippel, Brener, & Von 
Hippel, 2008). Counselors can advocate non­
discriminatory treatment for clients who have 
hepatitis. 
For some clients, a diagnosis of hepatitis can 
generate feelings of low self-worth. Some 
clients who have viral hepatitis report that 
their diagnoses caused them to develop a 
negative sense of self (Astone-Twerell, Strauss,
Munoz-Plaza, et al., 2006). The majority of 
clients reported experiencing fear, shame, and 
social rejection (Brener et al., 2007; Conrad,
Garrett, Cooksley, Dunne, & MacDonald,
2006; Zickmund, Ho, Masuda, Ippolito, & 
LaBrecque, 2003).
Clients might need to use discretion in revealing
their diagnoses. Counselors can help clients 
decide whom they can tell by encouraging
clients to ask themselves the following 
questions: 
•	 Does this person need to know? 
− Household members need to know,
particularly if they are sex partners 
or likely to share things like razors 
or hair clippers. Extended family 
members might not need to know. 
− Under some circumstances employers 
might need to know. For example, if a 
client’s work is affected by the illness 
or if he or she frequently misses work 
because of illness or medical appoint­
ments, a supervisor might need to be 
told.
•	 What is the person likely to do with the 
information? Is this person trustworthy? 
•	 Is this the right time to tell this person? 
•	 What are the risks in telling the person? 

Is a negative reaction likely?
 
•	 What questions might the person have 

about the client’s diagnosis? Can the cli­
ent answer those questions?
 
A diagnosis of viral hepatitis might 

increase a client’s potential for 

relapse to alcohol or drug use.
 
Clients might need help with talking to their
families, employers, and friends about their 
hepatitis. Counselors can help by: 
•	 Role playing with clients, allowing them 

to practice how they tell various people.
 
•	 Offering to be present when clients talk 

to family members.
 
•	 Providing family members and friends 

with information about the symptoms,

treatment, and transmission of the 

disease.
 
Addressing relapse 
A diagnosis of viral hepatitis might increase 
a client’s potential for relapse to alcohol or 
drug use. The diagnosis might also exacerbate 
depression and anxiety, which are known trig­
gers for an SUD relapse. Treatment for HCV 
infection itself also can trigger relapse. The 
reasons for this are unknown, although the 
act of injecting medication might trigger crav­
ings in clients who injected drugs. Side effects 
from antiviral treatment might also mimic 
withdrawal. Increases in methadone doses 
might be appropriate (Sylvestre & Clements,
2007).
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The counselor can start conversations about 
relapse by asking the client the following 
questions: 
•	 “What kinds of things make you think 
about using again?”
•	 “Do you consider getting injections during
treatment a possible trigger to drug use?” 
•	 “What kinds of things could help you 
avoid substance use?” 
•	 “Who could support you in these efforts?” 
•	 “How worried are you about the possibil­
ity of a relapse?” 
Clients might need the counselor’s 
help in telling family members 
about a hepatitis diagnosis. 
Counselors can give clients the following tips 
(U.S. Department of Veterans Affairs, 2004): 
•	 “Remind yourself that interferon is work­
ing to heal your liver from the damage 
caused by HCV infection.” 
•	 “Try not to isolate yourself while injecting 
interferon. It might be helpful to inject 
interferon around people you trust, such 
as family members.” 
•	 “Talk openly about your feelings of inject­
ing interferon with members of your sup­
port group and other people you trust.” 
•	 “Remind yourself that being abstinent is 
the best thing you can do to keep yourself 
healthy when you have HCV infection.” 
•	 “Get help managing side effects.
Remember to talk with your doctor if you 
are experiencing side effects from your 
HCV treatment.” 
•	 “Do not skip or change doses of interferon.
Try to make the injections part of your
routine.” 
Building support systems 
Support Groups 
Hepatitis groups are a widely used source of 
ongoing support for clients living with hepa­
titis and might help demystify treatment for 
participants. In these groups, clients educate 
and support one another about the infection,
the treatment process, and managing medica­
tion side effects. Support groups help clients 
“believe that good outcomes are attainable”
(Litwin et al., 2005, p. S342).
Support groups in substance abuse treatment 
settings can be facilitated by a counselor,
nurse, or peer. The choice of facilitator should 
be based on a program’s resources and the 
needs of its clients. Support groups can also 
be found at hospitals and clinics. Appendix C 
lists national organizations that help people 
find local resources or that offer online sup­
port communities. Counselors can help clients 
get the support they need by asking clients the 
following questions: 
•	 “How can you get professional help if you 
need it?” 
•	 “It takes courage to take on this chal­
lenge. Would you be interested in the 
names and numbers of people you could 
talk to?” 
•	 “Talking to others in drug recovery who 
have successfully been through hepatitis 
treatment can be really helpful. Do you 
see this as being part of your hepatitis 
recovery?” 
Peer Counseling and Support 
In a study at a residential treatment program 
(Munoz-Plaza et al., 2004), clients most 
frequently recommended the use of peer 
counselors as a way to enhance hepatitis treat­
ment services. These clients found that peers 
who had experience with HCV infection were 
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more valuable than “even the most knowledge­
able and well-trained staff person” (Munoz-
Plaza et al., 2004, p. 874). Peers can facilitate 
or co-facilitate support groups; act as mentors 
to newly diagnosed clients; and provide infor­
mation, support, and assistance (e.g., provide 
transportation, accompany clients to medical 
appointments). Peers can be clients who are 
farther along in hepatitis treatment, graduated 
clients, or volunteers from the community. 
Family Support 
Families might be supportive or might react 
badly to a family member’s diagnosis of hepati­
tis. Clients might need the counselor’s help in
telling family members about a hepatitis diag­
nosis. Families might not be willing or able to 
support the client (e.g., family members might 
be using drugs). However, counselors can 
reduce families’ fears and encourage families 
through the following:
•	 Educate family members about hepatitis.
Families need the same information as 
clients about the illness, its treatment,
the potential effects on a client’s SUD 
recovery, and the increased risk of relapse 
to substance use.
•	 Help families adjust to lifestyle changes.
Some clients might make lifestyle 
changes, particularly in diet and sexual 
behavior, following a diagnosis of hepatitis
or as part of their substance abuse treat­
ment (Castera, Constant, Bernard, de 
Ledinghen, & Couzigou, 2006; Fabris 
et al., 2006). These changes affect family 
members.
•	 Help family members adopt new roles 

and routines. Clients might need time 

away from their families to attend 

support group meetings and medical 

appointments. These added demands,

coupled with the symptoms of the 

disease and possible side effects of 

antiviral treatment, can affect a person’s 
ability to meet family obligations. Clients 
might need help negotiating with family
members to establish new roles and 
routines that accommodate the client’s 
treatment for hepatitis and an SUD.
•	 Help family members determine how 
best to support their loved one. Counselors
can help the client identify needs and 
encourage family members to decide what
they can do to support the client. 
•	 Help family members recognize changes 
in behavior. Family members living with 
the client might be the first to notice an 
adverse reaction to antiviral treatment.
Ask family members to provide feedback 
on any changes in mood, either elevated 
or depressed, and encourage the client to 
heed a family member’s observations. 
•	 Help family members find support for 
themselves. Family members who have 
lived with a client who abused substances 
are now faced with helping that individu­
al cope with another illness. Some might 
resent the additional burden. Family 
members can find support at hepatitis 
support groups. Some families need more 
education and support than do others.
Counselors should be prepared to make 
referrals to local resources for couples or 
family therapy, if needed. 
providing effective case 
management 
Clients who have hepatitis might need intensive
case management. Some clients receive case
management services through their medical
care providers, but many do not. Some 
substance abuse treatment programs have 
designated case managers to assist clients.
Counselors or program nurses sometimes 
perform these functions. A program’s struc­
ture and administrative decisions about staff 
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roles influence the level of case management 
counselors provide. Counselors should clearly 
convey the expectations of their programs 
to clients. If they cannot provide the level of 
case management a client needs, they should 
do what they can to connect the client with a 
case manager in another healthcare or social 
services system.
Case management for clients who have
hepatitis is often the same as that for clients 
with SUDs, but clients who have hepatitis 
might need more intensive and specialized 
help. Some clients who have hepatitis might 
be unable to work because of illness or hepatitis
treatment side effects. Counselors can help by: 
•	 Working with clients on budgeting or 
referring clients to consumer counseling 
agencies for debt management. 
•	 Referring clients to local food banks,

utility assistance programs, and rent 

assistance programs.
 
•	 Assisting in negotiating short-term 

disability claims or emergency family 

assistance.
 
Clients might need help accessing and 
navigating medical care systems. Counselors 
can help by: 
•	 Identifying local providers who treat 
hepatitis; have experience working with 
people who have SUDs; and, when rel­
evant, are comfortable treating people 
in medication-assisted treatment. 
•	 Establishing relationships with clients’
medical care providers and staying abreast 
of clients’ hepatitis treatment. 
•	 Helping clients understand and complete 
written documents and consent forms. 
•	 Working with clients to establish proce­
dures that help them remember medical 
appointments and adhere to medication 
regimens. 
•	 Ensuring that clients have transportation 
to medical appointments. 
Clients might need help understanding insur­
ance requirements and, possibly, challenging 
insurers’ coverage decisions. If clients are unin­
sured, counselors can: 
•	 Identify government sources of healthcare 
and support benefits (e.g., Medicaid,
Medicare, food stamps, unemployment 
insurance). (See Appendix H.) 
•	 Look for assistance programs in medical 
centers and clinics. 
•	 Identify local, private nonprofit clinics 
that offer many types of services; public 
health departments might be a source 
of information about community health 
resources. 
Even if clients are insured, co-payments
might be very high. Counselors can help
clients identify sources of assistance, such as 
State medication assistance programs and
local and national medication assistance pro­
grams. Appendix H lists resources for patient 
financial assistance with medications and 
transplantation surgeries.
Sources of information on SUD treatment 
and medical case management procedures 
include Treatment Improvement Protocol 27,
Comprehensive Case Management for Substance 
Abuse Treatment (Center for Substance Abuse 
Treatment, 1998) and Case Management 
Adherence Guidelines, Version 2.0 (Case 
Management Society of America, 2006). 
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chapter summary 
Counselors are in a unique position to provide education, emotional support, and tangible help for 
clients who have hepatitis. 
To be effective, counselors must first be well educated about hepatitis. 
Key counselor goals should include: 
•	 Ensuring the safety of clients. 
•	 Providing reliable information to clients and their families. 
•	 Building the therapeutic relationship with clients. 
•	 Helping clients understand their diagnoses. 
•	 Incorporating client needs in substance abuse treatment planning. 
•	 Developing a prevention plan. 
•	 Using motivational interviewing. 
•	 Confronting the social ramifications of hepatitis. 
•	 Addressing relapse issues. 
•	 Building support. 
•	 Providing case management. 
Counselors also can help by: 
•	 Being flexible about treatment logistics (e.g., participation, treatment duration), within 
accreditation and licensing guidelines. 
•	 Being alert to co-occurring mental disorders, particularly depression. 
•	 Assessing clients’ readiness and using motivational approaches to help clients make medical 
treatment decisions. 
•	 Assessing and mobilizing clients’ strengths. 
Counselors can help clients develop social support systems by: 
•	 Providing onsite support groups. 
•	 Helping clients locate community-based support groups. 
•	 Facilitating onsite peer counseling and support programs. 
•	 Facilitating family support through education and counseling. 
Counselors can provide effective, targeted case management, such as: 
•	 Helping clients understand and complete written documents and consent forms. 
•	 Helping clients obtain medical care and adhere to medical regimens. 
•	 Helping clients find sources for financing medical treatment and medications for hepatitis. 

In ThIs ChapTer
 
 
 
 
 
 
 
 
c A  
•	 Program Assessment 
and Planning 
•	 Screening for Viral 
Hepatitis 
•	 Medical Evaluation and 
Diagnosis 
•	 Treatment for Chronic 
Hepatitis 
•	 Prevention and 
Vaccination 
•	 Education 
•	 Support Services 
•	 Outreach 
•	 Integrating Hepatitis 
Interventions With 
Existing HIV Services 
•	 Developing Policies and 
Procedures 
•	 Evaluation 
•	 Successful 
Implementation 
•	 Legal and Ethical Issues 
•	 Chapter Summary 
7 
Adding or Improving 
hepatitis services: A 
Guide for Administrators 
program Assessment and planning 
A significant positive correlation has been found between admin­
istrators’ beliefs about the value of hepatitis services and the avail­
ability of hepatitis-related services at their substance abuse treat­
ment programs (Astone, Strauss, Hagan, & Des Jarlais, 2004). To 
determine the types of services to implement or enhance treatment,
administrators must consider the client population, staffing patterns 
and issues, availability of local resources, potential partners, and 
sources of funding. Program administrators can support the provi­
sion of hepatitis services by allocating a budget for implementation 
and by training or hiring appropriate staff members to implement 
the new services.
Hepatitis services include the following:
•	 Screening for viral hepatitis 
•	 Medical evaluation and diagnosis 
•	 Treatment for chronic hepatitis 
•	 Prevention and vaccination 
•	 Education 
•	 Support services 
•	 Outreach 
A first step toward implementing change is to assess the hepatitis 
services currently offered by the substance abuse treatment program 
and identify components that could be implemented or expanded.
This assessment can be performed by a workgroup or task force con­
sisting of staff members interested in implementing or expanding 
hepatitis services. A group comprising staff members from different 
disciplines can provide diverse information and viewpoints. The next 
step is to consider the staff at hand, possible funding sources, and 
local agencies that could partner with the treatment program to 
provide hepatitis services.
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Once these steps are completed, an implemen­
tation plan should be written. Organizational 
change might be needed to develop and
sustain hepatitis treatment services. Technical
Assistance Publication (TAP) 31, Implementing 
Change in Substance Abuse Treatment Programs
(Center for Substance Abuse Treatment 
[CSAT], 2009a), provides practical advice 
regarding this topic and about incorporating 
new components into a treatment program.
screening for viral hepatitis 
Screening activities include: 
•	 Assessing a client’s risks of acquiring 

or transmitting hepatitis.
 
•	 Obtaining a client’s history of hepatitis 
infection or vaccination. 
•	 Conducting blood tests for hepatitis or 
working with local health departments 
and other medical facilities that provide 
screening tests. 
Because drug use is a risk factor for contracting
viral hepatitis, the Centers for Disease Control 
and Prevention recommends that all clients 
in substance abuse treatment programs have 
routine access to hepatitis screening services.
Clients who use or have used injection drugs 
are at particular risk of contracting viral
hepatitis. (Chapters 1 and 2 provide informa­
tion on risk factors and screening, respectively.)
Substance abuse treatment programs can 
screen for viral hepatitis during the intake 
medical examination (Hagan, Strauss, Astone,
& Des Jarlais, 2005). Treatment Improvement 
Protocol (TIP) 40, Clinical Guidelines for 
the Use of Buprenorphine in the Treatment 
of Opioid Addiction (CSAT, 2004); and TIP 
43, Medication-Assisted Treatment for Opioid 
Addiction in Opioid Treatment Programs
(CSAT, 2005), provide information about 
screening and assessing clients.
Most opioid treatment programs (OTPs) 
have onsite medical staff members who can 
draw blood samples for hepatitis screening 
tests. With the client’s consent, an OTP that 
routinely provides physical examinations could 
add a hepatitis test to a client’s initial blood 
work. Because viral hepatitis is a communi­
cable disease, new cases must be reported. In 
many cases, the laboratory reports the case,
but program administrators should contact 
local or State health departments for current 
information about reporting requirements and 
procedures; this information should be included
in the program’s written procedures. 
medical evaluation and Diagnosis 
Evaluation and diagnosis activities include 
providing onsite medical evaluations after a 
screening, or referring clients to local providers 
for evaluation and diagnosis. 
The medical screening and evaluation of 
hepatitis B and C can be complicated, and 
the required laboratory tests are expensive.
However, a qualified and experienced medical 
care provider can order proper tests, evaluate
the results, provide an accurate diagnosis, and
make treatment recommendations. Evaluative
services are needed after a positive test result 
for hepatitis B and C. The Institute of Medicine
(2010) recommends that the inability of a
facility to provide evaluation and diagnosis
services should not be an impediment to its
providing screening services.
Treatment for chronic hepatitis 
Hepatitis treatment activities include providing
treatment onsite at the substance abuse treat­
ment program or referring clients to local
partners, establishing a multidisciplinary treat­
ment team, and obtaining clients’ permission 
to share information among team members. 
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case study: Funding comprehensive services, project samaritan health 
services, new York city 
Project Samaritan Health Services provides hepatitis C care at four residential treatment facilities 
and a community-based facility in the New York City area. The program was established in 
response to State recommendations that substance abuse treatment centers provide hepatitis 
screening and education to clients—a recommendation the program fully supported. Project 
Samaritan administrators also wanted to help all clients with hepatitis obtain proper treatment. 
Project Samaritan provides education and training to its counselors and medical health care 
personnel so that they are well versed in working with clients who have hepatitis. 
More than 25 percent of Project Samaritan’s clients do not have medical insurance. By forming a 
coalition of several large substance abuse treatment programs in New York State that collectively 
serve approximately 10,000 clients, Project Samaritan and its partners persuaded State officials 
to expand Medicaid to cover hepatitis-associated services, including testing for hepatitis C. 
The coalition also persuaded the State to convene a workgroup that created comprehensive 
guidelines for hepatitis care. Administrators worked with compassionate care programs to 
provide medications to eligible individuals; they also worked with a national medical laboratory 
to provide laboratory testing at no charge for individuals with incomes below the poverty level, 
and they negotiated with a local hospital to provide a substantially discounted rate for liver biopsy 
procedures. 
Other hepatitis services are provided by Project Samaritan’s medical staff. Physicians specializing 
in gastroenterology or hepatology provide hepatitis treatment. A nurse practitioner works 
approximately 8 hours per week; a physician, approximately 12 hours. 
Despite a rigorous treatment regimen and limited hours dedicated to providing hepatitis care, 
Project Samaritan has a low rate of attrition. The program’s hepatologist attributes the low dropout 
rate, in large part, to two factors: (1) extensive education offered to patients about treatment 
and its implications; and (2) patient empowerment to make decisions about their treatment. The 
program works to be client centered and strives to positively engage clients in treatment by 
emphasizing the steps that clients can take to improve their health. 
Interviews by a JBS International, Inc., consultant with Administrators Marguerite Gebhardt and Pat 
Kennedy on April 22, 2008, and with hepatologist Nicholas Triantafillou, M.D., on April 23, 2008. 
Substance abuse treatment program adminis­
trators tend to agree that hepatitis treatment 
for clients in recovery from substance use 
disorders (SUDs) is important. However,
opinions diverge on when and how to treat 
clients for chronic hepatitis while they are in 
early recovery (Strauss, Astone, Hagan, & Des 
Jarlais, 2004). Some administrators are reluc­
tant to refer clients for hepatitis treatment,
citing difficult treatment regimens and seri­
ous side effects that could jeopardize a client’s 
recovery. Research suggests, however, that 
people in recovery from substance abuse can 
successfully adhere to the prescribed course of 
antiviral medication. Some clients will need 
financial assistance for hepatitis treatment.
Low- and no-cost healthcare sources are listed
in Appendix H. 
Onsite Treatment 
Onsite medical care in substance abuse treat­
ment programs has been shown to be more 
effective than outside referrals for improving 
clients’ overall health and their access to com­
prehensive medical care (Samet, Saitz, & 
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Larsen, 1996; Umbricht-Schneiter, Ginn,
Pabst, & Bigelow, 1994). Advantages of pro­
viding onsite medical care include the ability 
to address both needs in one visit and stream­
lined communication between substance abuse 
treatment counselors and medical care provid­
ers (Sorensen, Masson, & Perlman, 2002).
Onsite medical care providers learn more about
clients’ substance use behaviors and can moni­
tor and manage psychiatric disorders (Vassilev,
Strauss, Astone, Friedmann, & Des Jarlais,
2004), which might encourage adherence to 
treatment. Communication among counseling 
and medical staff members about a client’s 
hepatitis status, while maintaining appropri­
ate client confidentiality, can improve client 
care. Administrators should keep abreast of 
guidelines about hepatitis treatment eligibility 
(Exhibit 7-1). 
Referring Clients to a Hepatitis 
Treatment Provider 
In referring clients for hepatitis care, a major 
undertaking is finding medical care providers 
who understand the challenges facing people 
who have co-occurring hepatitis and SUDs 
and developing cooperative working relation­
ships with them. Medical care providers might 
not have the experience or training needed to 
work with people who have SUDs and hepati­
tis. When medical care providers lack knowl­
edge about how to treat clients with SUDs,
clients are less likely to follow medical advice 
and more likely to relapse to substance use 
(Astone-Twerell, Strauss, Hagan, et al., 2006).
To locate health professionals who are expe­
rienced in treating hepatitis and sensitive to 
the needs of people in early recovery, admin­
istrators can contact potential partners who 
indicate an interest in reducing the spread of 
hepatitis in the community. These partners 
can include public health departments, nearby 
teaching hospitals and medical schools, non­
profit hepatitis organizations, and programs 
that offer HIV treatment. Health departments 
might be able to provide some hepatitis care 
for clients and assist with transportation 
needs. Many clients need assistance in con­
tacting medical service providers (Sylvestre & 
Zweben, 2007).
Multidisciplinary Teams 
Once a relationship is established with in­
house or external medical care providers, a 
treatment team should be developed. Explicit 
permission must be obtained from clients to 
share information among identified clinical 
staff members. After permission is obtained,
collaborative communication among the medi­
cal care and substance abuse treatment provid­
ers can begin. A case manager, either within 
the healthcare system or at the substance 
abuse treatment facility, can promote com­
munication between clients and staff members 
and treatment providers.
exhibit 7-1 hepatitis Treatment Guidelines 
•	 Substance Abuse and Mental Health Services Administration’s Division of Pharmacologic 
Therapies: http://www.dpt.samhsa.gov/comor/hepatitis.aspx 
•	 Practice Guidelines of the American Association for the Study of Liver Diseases: http://www. 
aasld.org, Practice Guidelines section 
•	 Centers for Disease Control and Prevention: http://www.cdc.gov/hepatitis 
•	 U.S. Department of Veterans Affairs: http://www.hepatitis.va.gov 
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prevention and vaccination 
Prevention activities include: 
•	 Providing counseling before and after 

hepatitis screening.
 
•	 Educating clients about the role of 
injection drug use (IDU), sharing drug 
paraphernalia, and risky sexual behaviors 
in virus transmission. 
•	 Providing vaccinations against hepatitis A 
and B. 
Vaccines against hepatitis A virus (HAV) 
and hepatitis B virus (HBV) exist, but vac­
cination can be provided most efficiently with 
the combined hepatitis A/hepatitis B vaccine 
(sold under the brand name, Twinrix). It is 
the only U.S. Food and Drug Administration-
approved combination hepatitis A and hepatitis
B vaccine. The vaccine is administered in three
intramuscular injections on a 0-, 1-, and 6-month
schedule, or may be given on an accelerated 
schedule of four doses, given on days 0, 7,
and 21–30 with a booster dose at 12 months 
(FDA, 2010a). Vaccinating clients for HAV 
and HBV can be done onsite or by referral.
State-by-State information on obtaining no-
cost vaccinations is available at http://www.
hepclinics.com/templates/hepclinic/index.
html. 
OTPs, which maintain frequent interactions 
with clients over a long period, are good set­
tings in which to offer hepatitis vaccinations 
because clients are likely to complete the full 
vaccination course during treatment. When 
determining whether to offer onsite hepatitis 
vaccinations, some questions to consider are:
•	 Does the facility have sufficient space to 
store the vaccine and give the injections 
in private? 
•	 Does the facility have the proper 

equipment?
 
•	 Can the facility follow cold chain 

(temperature control) procedures to 

ensure the vaccine is effective?
 
•	 Does the facility have staff members 

licensed to give injections? 

Full adherence to HAV and HBV vaccination 
regimens can be challenging because months 
separate immunizations. Whether clients are 
vaccinated at the substance abuse treatment 
program or at another program or agency, sub­
stance abuse treatment program administrators 
can take the following steps to ensure that 
clients complete their vaccination regimens: 
1. Keep medical records of client’s completed
and needed vaccinations. 
2. Use reminder tools to alert clients when 
the next vaccination is scheduled. 
3. Allow flexible vaccination schedules 
(higher doses in a condensed timeframe).
4. Provide transportation to the clinic if the 
vaccine is administered offsite. 
5. Offer incentives if the program’s budget 
allows (National Alliance of State and 
Territorial AIDS Directors [NASTAD],
2005). 
education 
Based on research and clinical expertise, the 
Consensus Panel strongly recommends an 
increased substance abuse treatment program 
investment in hepatitis education for all staff 
members and clients. These investments begin 
with training staff, learning about community 
resources available to clients who have chronic 
hepatitis, and designing education protocols in 
line with substance abuse treatment programs’
missions and approaches.
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Staff Education 
To properly inform clients about hepatitis,
staff members must be adequately trained to 
convey information accurately and completely,
and they must be proficient in teaching meth­
ods that help clients understand and retain the 
information presented. Staff preferences and 
program resources need to be considered when 
designing hepatitis training. Literature, manu­
als, and other print materials can be valuable 
sources for training, but alone they are insuf­
ficient. Hands-on opportunities (e.g., classes 
and workshops that provide an opportunity 
for role play), are generally more effective 
than reading print material. Staff members 
want to learn, for example, how to educate 
clients about hepatitis C virus (HCV) with­
out alarming clients to the point of impeding 
their recovery from substance abuse (Munoz-
Plaza et al., 2004). Hepatitis training can be 
incorporated into inservice training schedules.
Some training needs are presented in Exhibit 
7-2.
Several training resources are available, and 
many are free. Resources for hepatitis training 
programs developed for substance abuse treat­
ment program staff are presented in Appendix I. 
Client Education 
Most substance abuse treatment programs do 
not offer education about hepatitis to their 
clients (Strauss, Astone, Hagan, & Des Jarlais,
2004; Strauss et al., 2007). Program budget 
and audience determine the format and deliv­
ery of hepatitis education, which can range 
from printed matter to educational sessions.
Hepatitis education can be incorporated into 
the general educational component of the 
treatment program, with one or more ses­
sions devoted to hepatitis, for example. For 
clients in OTPs who have chronic hepatitis,
more extensive education sessions could be 
developed. Individual sessions with counselors 
or other treatment staff members allow clients 
the opportunity to ask questions, review infor­
mation, and learn how SUDs affect hepatitis.
Chapter 6 provides information for counselors 
to use to educate their clients. Resources for 
information on hepatitis are presented in 
Appendix C. 
support services 
Some clients will need additional support 
services, such as services to obtain healthcare 
coverage from Medicaid or other sources.
These clients might also need incentives and 
intensive case management services to adhere 
to hepatitis treatment, keep medical appoint­
ments, and locate hepatitis support groups.
Administrators might need to assign staff 
members as case managers or work with the 
medical team to access these services. For 
example, a medical facility might have trans­
portation services, but the clients might not 
be aware of them. Information on support
groups is in Appendix C. Resources for
financial assistance are in Appendix H. 
outreach 
Outreach activities include: 
•	 Joining community leaders, client repre­
sentatives, and public health officials 
in providing information about viral 
hepatitis and substance use. 
•	 Participating in health fairs and taking 
advantage of other outreach opportunities. 
•	 Building ties to outreach agencies (e.g.,
HIV counseling and testing centers, com­
munity outreach agencies, public health 
departments, correctional facilities, local 
hospitals). 
In addition to partnering with local agencies 
and organizations, substance abuse treatment 
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exhibit 7-2 staff Training for hepatitis in substance Abuse Treatment programs 
service Topic 
Assessment and screening •	 Assessing a client’s risk factors of acquiring or transmitting 
infection 
•	 Obtaining a history of hepatitis disease or vaccination when 
collecting medical information 
•	 Knowing the procedures for conducting or referring for 
hepatitis screening 
•	 Counseling before and after screenings 
•	 Assessing potential barriers to screening 
Preventing infection (primary 
prevention) 
•	 Educating clients about the use of drug paraphernalia 
and risky sexual behaviors to prevent their contracting or 
transmitting the virus 
•	 Identifying clients in need of hepatitis C treatment or HAV/ 
HBV vaccinations 
•	 Understanding the procedures for referring or providing 
HAV/HBV vaccinations 
•	 Including hepatitis in client/family educational components 
•	 Collaborating with other agencies (e.g., HIV counseling and 
testing centers, nonprofit organizations, community outreach 
agencies, community health clinics, private medical care 
providers) that treat hepatitis B and C 
•	 Retaining clients who relapse 
Limiting disease consequences 
(secondary prevention) 
•	 Linking clients to hepatitis medical care or providing care 
onsite 
•	 Promoting medication adherence (e.g., through reminder 
systems, social support, incentives) 
General information and 
communication 
•	 Research, ethical, and legal issues 
•	 Coordinated care with medical staff members while 
maintaining client confidentiality 
•	 Quality improvements identified by regular assessment of 
program components and processes related to hepatitis 
•	 Followups with clients and other medical care providers 
•	 Case management 
programs that implement hepatitis services 
can direct outreach and educational activities  
toward populations at risk for SUDs and 
viral hepatitis—particularly toward people 
who inject drugs—to raise awareness of liver 
disease and risky behaviors, promote screening 
and early treatment, and encourage vaccina
tion against hepatitis A and B. 
­
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case study: support Groups at oAsIs, oakland, california 
The Organization to Achieve Solutions in Substance-Abuse (OASIS) developed a peer-based hepa
titis C group that provides education, testing, and treatment of HCV infection among people who 
abuse substances (Sylvestre & Zweben, 2007). It integrates services for hepatitis C, IDU, mental 
disorders, and psychosocial issues for an inner-city population. The OASIS model demonstrates the 
ability of a small clinic not associated with major healthcare facilities to implement hepatitis care. 
At the model’s core are support groups called Educate-Motivate-Facilitate, in which HCV-
knowledgeable peers and a medical provider co-lead groups that address a range of topics. The 
groups include clients with different knowledge levels and who are at different stages, from hepa
titis screening through treatment. As participants become knowledgeable and stable in recovery, 
they are encouraged to serve as group leaders. 
The groups discuss participants’ experience with HCV treatment and side effects, substance use, 
depression, and other topics. Medical staff members interject correct information or add informa
tion, as needed. The interactive format and peer support seem to improve attendance and adher
ence to medical recommendations. 
­
­
­
­
Integrating hepatitis Interventions 
With existing hIv services 
Some substance abuse treatment facilities have 
programs for managing blood-borne infections,
such as HIV. The benefits of incorporating 
hepatitis services within existing HIV services 
include the following:
•	 Counselors working with HIV/AIDS
are familiar with the challenges of chronic 
infection and complex therapeutic regimens,
as well as with psychosocial issues that 
accompany a chronic disease.
•	 Relationships are already established with 
medical care providers and public health 
departments.
•	 Federal or State funding might be 
available (Strauss et al., 2005; Stringari-
Murray, Clayton, & Chang, 2003). 
Some substance abuse treatment program staff 
members have described integrated HCV
and HIV services as a “natural fit” (Strauss et
al., 2005). With adequate training, counselors
can adapt HIV/sexually transmitted disease 
prevention messages to HCV prevention.
Integration need not entail providing all 
services onsite; it could mean a simple
coordinated referral system (NASTAD,
2005).
Administrators who would like to incorporate 
hepatitis services into existing HIV services 
should consider the following (Strauss et al.,
2005): 
•	 There are different prevention messages 
for HIV and hepatitis, which are based 
on different rates of parenteral and sexual 
transmission. 
•	 Clients often know less about HCV than 
about HIV. 
•	 Some funding might be dedicated to 
support services for one virus, while pro­
hibiting funds from being redirected to 
or shared with other activities. 
•	 Counselors and staff might be reluctant 
to integrate services. 
69 
7—Adding or Improving Hepatitis Services: A Guide for Administrators
 
 
 
 
 
 
 
  
 
 
 
Developing policies and 
procedures 
Once the workgroup decides which services to 
implement, policies and procedures need to be 
established. Examples include:
•	 Developing an overall policy regarding 
the program’s approach to providing 
hepatitis services.
•	 Implementing and revising policies and 
procedures to reflect the organization’s 
goal to provide quality services to clients 
who need screening or treatment for 
hepatitis.
•	 Establishing a system to monitor and 
evaluate policies and procedures and to 
revise them, as needed.
•	 Providing staff development and educa­
tional opportunities related to hepatitis. 
Writing and implementing new policies and
procedures often involve adapting existing
ones. Programs might already have a variety 
of policies and procedures that apply to clients
who have hepatitis. For example, most programs
probably have policies on what actions to take 
when a client has an infectious disease, who 
will work with the client, or where the client 
could be referred for additional medical treat­
ment. The workgroup can review current poli­
cies and procedures to see which ones need to 
be adapted and revised. Exhibit 7-3 provides 
an example policy. 
evaluation 
Once the treatment program implements 
hepatitis services, it can incorporate quality 
improvements identified by regular evalu­
ation of the new program components and 
processes. The program can use the existing 
quality assurance function to develop a track­
ing system, which could measure the number 
of clients with hepatitis A, B, and C; hepatitis-
related treatment outcomes; and the severity 
of co-occurring substance use and mental 
disorders. This information can be used to 
improve services, to request funding, and to 
motivate staff. 
exhibit 7-3 sample policy: screening for hepatitis 
Policy Statement: All counseling staff members will receive training in screening for viral hepatitis 
and will demonstrate competence in supporting, educating, and referring clients for hepatitis 
screening. 
Procedures: 
1. All counselors will participate in training about hepatitis and its relationship to substance 
abuse, attitudes toward clients who have hepatitis, and hepatitis screening intervention and 
referral resources. 
2. The clinical supervisor of new employees will provide site-specific information on the 
procedures for facilitating the screening, treatment, or referral of clients who either are already 
diagnosed with hepatitis or are at risk for developing hepatitis. 
3. Clinical competence checklists completed at hire and annually thereafter will ensure that all 
clinical staff members (1) have basic knowledge of the benefits of addressing hepatitis with 
clients who abuse substances, (2) understand the protocols for assessing key risk factors for 
hepatitis, and (3) are aware of appropriate referral procedures. 
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case study: overcoming staff resistance, minneapolis healthy liver program 
The Minneapolis Healthy Liver Program was established in the Minneapolis Veterans Affairs 
Medical Center Substance Use Disorder Clinic (Hagedorn et al., 2007). A stakeholders group 
composed of clinical and administrative personnel from the medical center’s substance abuse 
treatment clinic and hepatitis clinic designed the program. Components included screening for 
hepatitis A, B, and C, which was added to routine blood work during intake, and intervention, 
which included a 60-minute group educational session and vaccinations against HAV and HBV, if 
indicated. As a result: 
•	 Testing rates for HCV increased from 72 percent to 98 percent. 
•	 Testing rates for HAV and HBV increased from less than 20 percent to 98 percent. 
•	 Referral rates of clients newly diagnosed with chronic hepatitis C to a hepatitis clinic increased 
from 50 percent to 100 percent. 
A major challenge was addressing staff resistance to accepting additional responsibility. Lessons 
learned include: 
•	 Invite staff representatives at all levels—from administration to support— to be represented in a 
stakeholders’ group. 
•	 Keep general staff informed of stakeholders’ group’s progress via meeting announcements and 
emails. 
•	 Give staff members an opportunity to comment on the program’s plans and revise the plans 
based on their concerns. 
•	 Provide staff with ongoing education about potential medical services to improve treatment 
retention and outcomes. 
successful Implementation 
Munoz-Plaza et al. (2006) analyzed four treat­
ment programs that implemented or expanded
hepatitis services. The programs provided
educational and social support services (e.g.,
health education class, hepatitis C education 
and support sessions, a peer-led hepatitis C 
seminar). The researchers identified three 
features that facilitated the implementation 
of hepatitis services in these programs:
•	 At least one program administrator 
promoted efforts to incorporate hepatitis 
services into the treatment program.
At all four programs, supervisory staff 
encouraged adoption and innovation 
regarding hepatitis services.
•	 At least one change agent on staff advo­
cated for the services. One or more people 
were generally credited for increasing 
staff awareness about hepatitis, promoting 
the implementation of hepatitis services,
leading the incorporation of hepatitis 
education and support services, and often 
taking on associated responsibilities 
without significant additional compensa­
tion. These change agents frequently had 
a commitment to incorporating hepatitis 
services, and they often identified them­
selves as having hepatitis C. 
•	 There was collective buy-in from the 
substance abuse treatment team. A major­
ity of the staff members at each program 
eventually supported the incorporation 
of hepatitis services once they were 
implemented. 
Buy-in from staff members is necessary for 
success. Administrators can encourage prog­
ress by advocating change or supporting staff 
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members’ efforts to implement change. Some 
staff members are resistant to implementing 
hepatitis services because they believe these 
services are outside the scope of substance 
abuse treatment. Information in Chapters 
1–6 of this TIP can mitigate staff members’
resistance for implementing change by helping 
them understand the numerous links between 
viral hepatitis and substance use.
legal and ethical Issues 
Substance abuse treatment program admin­
istrators need current knowledge of the legal 
and ethical issues about providing hepatitis
care and, in particular, about providing medical
care to people in their programs. The most
significant issues concern confidentiality,
informed consent, and staff member rights.
Programs that include a peer education com­
ponent must ensure that peers, like others
involved in care, maintain client confidentiality
as required by applicable laws and regulations.
Confidentiality and Privacy Issues 
Programs must closely guard information 
about clients. Although information must be 
shared with program staff members to the 
extent necessary to support clients’ needs, its 
dissemination must be carefully restricted to 
protect client confidentiality.
The privacy rule under the Health Insurance 
Portability and Accountability Act (HIPAA) 
sets limits on how health plans and covered 
providers might use health information. It 
allows healthcare providers to share infor­
mation needed to provide treatment, but 
it prohibits most other releases of medical 
information without the client’s authorization.
Information about the HIPAA privacy rule 
as it pertains to substance abuse treatment is 
available at http://www.hipaa.samhsa.gov. 
Substance abuse treatment programs covered 
under HIPAA must generally comply with 
longstanding requirements under 42 Code 
of Federal Regulations (CFR), Part 2,
Confidentiality of Alcohol and Drug Abuse 
Patient Records, which gives substance abuse 
treatment clients a right to confidentiality.
These requirements largely parallel those 
under the HIPAA privacy rule and prohibit 
most disclosures of client information unless 
the client provides consent. Information about 
42 CFR is at http://www.gpoaccess.gov/cfr/
retrieve.html.
Other Federal and State laws and regulations 
might govern confidentiality of drug referral 
and treatment information. For assistance in 
complying with applicable requirements, treat­
ment programs can request input from State 
agencies, provider organizations, and legal 
counsel.
Informed Consent 
Where testing or treatment is involved,
informed consent is a legal and ethical pre­
requisite to administering care. Informed
consent ensures that a client understands the 
therapeutic approach and has the power to 
make medical decisions. In addition to receiv­
ing descriptions of therapeutic options, the 
client must be informed of the expected risks 
and benefits. Clients generally have the right 
to refuse therapeutic interventions and must 
not be discriminated against based on such 
decisions.
Staff Member Rights 
All employees whose jobs involve the risk of 
direct contact with blood or other potentially 
infectious materials must be offered the
hepatitis B vaccination without charge. If they
decline, they must sign a form to document 
the decision. 
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chapter summary 
Administrators can add a variety of viral hepatitis services to their programs, such as: 
•	 Hepatitis screening, evaluation, and diagnosis. 
•	 Hepatitis prevention activities, including education and vaccination. 
•	 Hepatitis treatment or referral to vetted medical care providers for treatment. 
•	 Support services for clients needing hepatitis treatment. 
•	 Outreach to at-risk groups. 
Successful programs tend to have: 
•	 At least one administrator to promote efforts to incorporate hepatitis services into the treatment 
program. 
•	 At least one change agent on staff who advocated for the services. 
•	 Collective buy-in from the treatment team. 
Administrators should be familiar with: 
•	 Confidentiality and privacy issues. 
•	 Legal requirements for informed consent. 
•	 Staff member rights pertaining to risks of hepatitis exposure. 
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Appendix B—Glossary 
acetaminophen—The generic name for a common nonprescription medication 
used to treat mild pain or fever. 
acute hepatitis—An inflammatory process in the liver that resolves in 6 months.
adefovir dipivoxil—A U.S. Food and Drug Administration-approved antiviral 
medication for treating chronic hepatitis B, taken orally. 
alanine aminotransferase (ALT)—An enzyme found in the liver; an increased 
level of ALT in the blood indicates liver inflammation. 
albumin—A protein made in the liver that helps move small molecules through 
the bloodstream. It plays an important role in keeping the fluid from the blood 
from leaking into the tissues. If albumin drops to very low levels, fluid might leak 
into tissues from the blood vessels, resulting in edema (swelling). 
alkaline phosphatase (ALP)—An enzyme found in the liver and other parts of 
the body; elevated levels might indicate liver injury.
antibody—A type of protein produced by the body’s immune system. Antibodies 
protect the body from disease by binding to antigens (see below) and destroying 
them. 
antigens—Foreign substances (e.g., bacteria, viruses) in the body that are capable 
of causing disease. The presence of antigens in the body triggers an immune 
response, usually the production of antibodies (see above). 
antiviral (literally against-virus)—Any medicine capable of destroying or weak­
ening a virus or suppressing its ability to replicate. 
aspartate aminotransferase (AST)—An enzyme found in the liver; an increased 
level of AST in the blood indicates liver inflammation. 
asymptomatic—Presenting no symptoms of disease. 
boceprevir—A U.S. Food and Drug Administration-approved medication for 
treating chronic hepatitis C, taken orally. 
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chronic hepatitis—An inflammatory process 
in the liver that lasts longer than 6 months. 
cirrhosis—Irreversible scarring of the liver 
caused by ongoing damage, which might affect 
liver function. Cirrhosis in some cases can lead 
to liver failure, liver cancer, and death.
co-infection—The condition of an organism 
or cells being infected simultaneously by two 
different pathological microorganisms, such as 
infection with both hepatitis C virus and HIV. 
contagious—Capable of being transmitted 
from one person to another by contact or close 
proximity. 
coronary heart disease—A narrowing of the 
small blood vessels that supply blood and oxy­
gen to the heart. Also called coronary artery 
disease. 
decompensated cirrhosis—A progression 
of cirrhosis that can be life threatening.
Symptoms include internal bleeding, large 
amount of fluid in the abdomen, encephalopa­
thy (confusion), and jaundice.
end-stage liver disease—Severe damage to 
the liver. End-stage complications include liver 
failure and liver cancer. These conditions occur 
primarily in people who develop permanent 
scarring of the liver (cirrhosis). 
entecavir—An oral prescription medicine 
used for chronic infection with hepatitis B 
virus in adults. 
enzyme—A protein (or, rarely, ribonucleic 
acid) that catalyzes a chemical reaction; it is 
produced by living cells and catalyzes specific 
biochemical reactions at body temperatures. 
exposure—Coming in direct contact with an 
agent that might cause a disease or infectious 
process (e.g., exposure to hepatitis B virus 
might result in hepatitis B infection).
fecal–oral route—A mode of transmission of 
an infectious agent from person to person by 
putting something in the mouth that has been 
contaminated with infected stool (feces).
fibrosis—Scar tissue developed as a result of 
chronic infection and inflammation. The pres­
ence of fibrosis usually means infection has 
been active for several years. 
genotype—The genetic makeup of the virus 
that describes the “family” to which the spe­
cific virus belongs. 
hepatitis—Inflammation of the liver. The 
most common cause is infection with a hepa­
titis virus, but hepatitis can also be caused 
by other viruses, bacteria, parasites, and toxic 
reactions to drugs, alcohol, and chemicals. 
hepatitis A—An inflammatory process of the 
liver caused by the hepatitis A virus.
hepatitis B—An inflammatory process of the 
liver caused by the hepatitis B virus.
hepatitis B core antibody—A protein that 
appears at the onset of symptoms in acute 
hepatitis B and persists for life. Its presence 
indicates previous or ongoing infection with 
the hepatitis B virus. 
hepatitis B surface antibody—A protein that 
the immune system produces to attack hepa­
titis B virus. Its presence generally indicates 
recovery and immunity from the hepatitis B 
virus.
hepatitis B surface antigen—A serologic 
marker on the surface of the hepatitis B
virus. It can be detected in high levels in
serum during acute or chronic hepatitis.
hepatitis B virus DNA (deoxyribonucleic
acid)—A molecule that controls the manu­
facture of the hepatitis B virus. Its presence 
indicates active viral replication; high levels 
correlate with high rates of replication. Levels
predict response to antiviral therapy. 
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Appendix B—Glossary 
hepatitis C—An inflammatory process of the 
liver caused by the hepatitis C virus. 
hepatitis C virus RNA (ribonucleic acid)—A 
fragment of the replicating hepatitis C virus.
It can be detected using sophisticated tests to 
determine the level of the virus in serum.
hepatocellular carcinoma—The most com­
mon primary liver cancer.
high-risk behavior—Behavior that puts a
person at risk of contracting hepatitis (e.g.,
sharing needles or drug paraphernalia; having 
multiple sex partners). 
high-risk group—A group with an elevated 
risk of disease.
immune system—The complex system in 
the body responsible for fighting disease. It 
identifies foreign substances in the body (e.g.,
bacteria, viruses, fungi, parasites) and develops 
a defense against them known as the immune 
response. It produces protein molecules called 
antibodies to eliminate foreign organisms that 
invade the body.
immunity—Protection against a disease.
There are two types of immunity: passive and 
active. Immunity is indicated by the presence 
of antibodies in the blood and can usually be 
determined with a laboratory test.
immunization—The process by which a 
person or animal becomes protected against a 
disease. 
immunoglobulin—Proteins found in the 
blood that function as antibodies that fight 
infection.
infection—An invasion of an organism by 
a pathogen such as bacteria or viruses. Some 
infections lead to disease. 
infectious—Capable of spreading disease.
Also called communicable. 
interferon—A group of proteins produced 
naturally by the cells of human bodies; inter­
feron increases the resistance of surrounding 
cells to attacks by viruses.
jaundice—Yellow color in the skin, the 
mucous membranes, and the eyes.
lamivudine—A U.S. Food and Drug 
Administration-approved antiviral medication 
for treating chronic hepatitis B, taken orally.
liver enzyme—A protein that catalyzes 
chemical reactions needed for body functions.
Levels of certain enzymes, such as alanine 
aminotransferase and aspartate aminotrans­
ferase, are higher when the liver is injured, as 
they leak into the bloodstream when the cell is 
inflamed, injured, or destroyed. 
liver panel—Common blood tests that are 
used to evaluate liver function. Also called 
liver function tests.
medication-assisted treatment (MAT)— 
Treatment for substance use disorders 
that uses medications such as methadone,
buprenorphine, or naltrexone.
neutropenia—Low count of a type of white 
blood cell. Neutropenia has several causes 
including side effects of medications, viral 
infections, and autoimmune diseases.
pulmonary disease—A disease of the lungs. 
ribavirin—A U.S. Food and Drug 
Administration-approved antiviral medication 
that improves the effectiveness of interferon in 
treating chronic hepatitis C, taken orally.
ribonucleic acid (RNA)—Chemical found in 
the nucleus and cytoplasm of cells; plays an 
important role in protein synthesis and other 
chemical activities of the cell.
sustained virologic response (SVR)— 
Achieving and sustaining a virus negative state 
for 6 months or longer after completing treat­
ment for a virus, such as hepatitis C.
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telaprevir—A U.S. Food and Drug 
Administration-approved medication for 
treating chronic hepatitis C, taken orally. 
telbivudine—A U.S. Food and Drug 
Administration-approved medication for 
treating hepatitis B, taken orally. 
tenofovir—A U.S. Food and Drug 
Administration-approved medication for 
treating hepatitis B, taken orally. 
transmission—An incident in which an 
infectious agent is passed from one person to 
another. 
viral load—Measurement of the amount of 
virus in the bloodstream.
virologic relapse—A return of the hepatitis C 
virus after antiviral treatment. 
virus—An organism that multiplies within 
cells and causes diseases such as chickenpox,
measles, mumps, rubella, pertussis, and hepati­
tis. It is not affected by antibiotics, the medi­
cations used to kill bacteria. 
Appendix c—hepatitis 
resources 
organization contact Information Topics covered 
American Association http://www.aasld.org/ •	 Hepatitis A 
for the study of liver Pages/Default.aspx •	 Hepatitis B
Diseases 
1-703-299-9766 •	 Hepatitis C 
•	 Biopsy 
•	 Transplantation (members 
only) 
American liver http://www.liverfoundation. •	 Hepatitis A 
Foundation org 
1-800-405-4837 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Support groups 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and 
other languages 
centers for Disease http://www.cdc.gov/ncidod/ •	 Hepatitis A 
control and prevention diseases/hepatitis 
1-800-232-4636 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and 
other languages 
Department of http://www.hepatitis.va.gov •	 Hepatitis A 
veterans Affairs •	 Hepatitis B 
•	 Hepatitis C 
•	 Biopsy (for medical care 
providers) 
•	 Transplantation 
•	 Information for special 
populations 
•	 Patient education materials 
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organization contact Information Topics covered 
hcv Advocate http://www.hcvadvocate.org •	 Hepatitis B 
•	 Hepatitis C 
•	 Biopsy 
•	 Support groups 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and other 
languages 
hepatitis B Foundation http://www.hepb.org 
1-215-489-4900 
•	 Hepatitis B 
•	 Support groups 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and other 
languages 
hepatitis c Association http://www.hepcassoc.org 
1-866-437-4377 
•	 Hepatitis C 
•	 Support groups 
•	 Information for special 
populations 
•	 Patient education materials 
hepatitis c University http://www.hcvu.org/et_patient.php 
1-877-428-8123 
•	 Resources for medical care 
providers 
hepatitis education 
project 
http://www.hepeducation.org 
1-206-732-0311 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Support groups 
•	 Transplantation 
•	 Information for special 
populations 
•	 Patient education materials 
hepatitis Foundation 
International 
http://www.hepfi.org 
1-800-891-0707 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Support groups 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and other 
languages 
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Appendix C—Hepatitis Resources 
organization contact Information Topics covered 
hepclinics http://www.hepclinics.com/ 
templates/hepclinic/index.html 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Information for special 
populations 
•	 Patient education materials 
Immunization Action 
coalition 
http://www.immunize.org 
1-651-647-9009 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Information for special 
populations 
•	 Patient education materials 
•	 Resources in English and other 
languages 
Indian health service http://www.ihs.gov •	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Information for special 
populations 
•	 Patient education materials 
massachusetts General 
hospital 
http://www.mgh.harvard.edu/ 
default.aspx 
1-617-726-2000 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Biopsy 
medline plus http://www.nlm.nih.gov/medlineplus/
tutorials/hepatitisc/htm/index.htm
•	 Hepatitis C 
methadone Anonymous 
support 
http://www.MethadoneSupport.org •	 Hepatitis C 
•	 Support groups (for methadone) 
•	 Resources in English and other 
languages 
national AIDs Treatment 
Advocacy project 
http://www.natap.org 
1-888-266-2827 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Transplantation 
•	 Patient education materials 
national Digestive 
Diseases Information 
clearinghouse 
http://digestive.niddk.nih.gov 
1-800-891-5389 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Biopsy 
•	 Transplantation 
•	 Resources in English and other 
languages 
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organization contact Information Topics covered 
national Foundation for 
Transplants 
http://www.transplants.org 
1-800-489-3863 
•	 Transplantation 
•	 Resources in English and other 
languages 
national hepatitis c
Advocacy council 
http://www.hepcnetwork.org •	 Hepatitis C 
•	 Resources in English and other 
languages 
national Transplant 
Assistance Fund 
http://www.ntafund.org 
1-800-642-8399 
•	 Transplantation 
•	 Resources in English and other 
languages 
new York state office 
of Alcoholism and 
substance Abuse 
services 
http://www.oasas.state.ny.us/ 
admed/documents/HEPATITIS.pdf 
•	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
stophep.com http://www.stophep.com/StopHep •	 Hepatitis A 
•	 Hepatitis B 
•	 Hepatitis C 
•	 Patient education materials 
•	 Special populations 
Transplant recipients 
International 
organization 
http://www.trioweb.org 
1-800-874-6386 
•	 Support services 
•	 Transplantation 
 
Appendix D—managing 
side effects of hepatitis c
Antiviral Treatment 
side effect potential management strategy 
Bad taste in mouth •	 Try sugar-free lemon drops or lemon wedges. 
•	 Eat a small amount of yogurt ½ hour before meals. 
•	 Eat dark chocolate or drink lemonade or cranberry 
juice. 
•	 Eat food cold or at room temperature. 
•	 Brush teeth frequently. 
•	 Use plastic utensils if experiencing metallic taste. 
cough •	 Increase fluid intake (noncaffeinated). 
•	 Use a humidifier. 
•	 Try sugar-free hard candy or cough drops. 
Diarrhea •	 Eat more fiber foods like bananas, white rice, 
applesauce, and white toast (the BRAT diet). 
•	 Avoid spicy or acidic foods (like citrus) and dairy 
products for several days after diarrhea resolves. 
•	 Drink plenty of fluids (six to eight 8-oz glasses/day). 
Dry mouth or mouth ulcers •	 Brush teeth frequently, especially after eating. 
•	 Avoid mouthwash containing alcohol. 
•	 Drink plenty of water or use ice chips or sugar-free 
lemon drops. 
•	 Ask medical care provider about medications for 
mouth sores/ulcers. 
Dry skin/rashes •	 Avoid long, hot showers or baths. 
•	 Use moisturizing soap and lotions, sunscreen, and 
mild unscented laundry detergents. 
•	 Avoid fabric softeners. 
•	 Rub or press on the itchy areas rather than scratch 
them. 
•	 Use petroleum jelly on affected areas and ask 
medical care provider about other solutions. 
Fatigue •	 Try low-impact exercise such as walking or low-
impact aerobics, if approved by medical care 
provider. 
•	 Drink plenty of fluids and get plenty of rest. 
•	 Lessen work schedule if possible. 
•	 Eat well-balanced meals every day. 
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side effect potential management strategy 
Fever/chills •	 Notify medical care provider if the temperature is above 101ºF for 
more than 24 hours. 
•	 Inject interferon at bedtime. 
•	 Take acetaminophen 30–60 minutes before weekly interferon 
injection and repeat 4–6 hours later, if approved by medical care 
provider. 
•	 Use ibuprofen or naproxen, if approved by medical care provider. 
•	 Try a cool sponge bath, ice pack, or cold pack. 
•	 Use extra blankets and clothes. 
hair thinning or hair loss •	 Avoid harsh hair products such as dyes, perms, gels, sprays, and 
mousses. 
•	 Use mild shampoo such as baby shampoo. 
•	 Avoid braiding hair. 
•	 Use a wide-tooth comb or soft brush. 
headaches •	 Drink plenty of fluids and get plenty of rest. 
•	 Try taking acetaminophen or ibuprofen, if approved by medical care 
provider. 
•	 Keep lights dim, wear sunglasses, or stay in darkened rooms. 
Injection site reactions •	 Warm the vial by gently rolling it in between two hands for a minute 
before injecting. 
•	 Rotate injection sites—thigh, upper arm, and abdomen. 
•	 Do not inject into an area that is irritated, bruised, or red. 
•	 Do not rub injection site. 
•	 Apply a cold pack. 
•	 Apply hydrocortisone cream or other medications, if approved by 
medical care provider. 
Insomnia •	 Go to bed and get up at the same times every day. 
•	 Do not read or watch TV in bed. 
•	 Limit daytime naps. 
•	 Take ribavirin in the late afternoon instead of before bedtime, if it 
causes the jitters. 
•	 Limit fluid intake for 2 hours before bedtime to avoid getting up to 
go to the bathroom. 
•	 Avoid caffeinated products, especially in the afternoon and at night. 
•	 Avoid heavy meals close to bedtime. 
•	 Take warm baths, read or listen to music, get a massage. 
•	 Drink a glass of warm milk (contains tryptophan, a natural sleep 
agent). 
•	 Take diphenhydramine (Benadryl) or other medications 
recommended by medical care provider. 
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Appendix D—Managing Side Effects of Hepatitis C Antiviral Treatment 
side effect potential management strategy 
muscle and body aches •	 Try low-impact exercise such as walking or low-impact aerobics, if 
approved by medical care provider. 
•	 Drink plenty of fluids, at least six to eight noncaffeinated 8-oz 
glasses/day. 
•	 Apply warm moist heat or massage affected areas. 
nausea and vomiting •	 Take ribavirin with food. 
•	 Eat small meals. 
•	 Avoid foods or smells that trigger nausea; eat cold foods and avoid 
cooking smells. 
•	 Eat healthful foods; avoid greasy, spicy, acidic, or sweet foods. 
•	 Try ginger tea, ginger ale, or gingersnaps. 
•	 Eat crackers or dry white toast for morning nausea. 
poor appetite •	 Eat small, more frequent (4–6) meals throughout the day. 
•	 Try protein drinks and snacks (cheese, peanut butter, eggs). 
•	 Eat whatever appeals to you even if not hungry; eat a variety of 
foods. 
•	 Walk before a meal. 
Source: National Hepatitis C Program, U.S. Department of Veterans Affairs, 
http://www.hepatitis.va.gov/pdf/treatment-side-effects.pdf 

 
 
Appendix e—medicinal 
plants/Alternative Treatments 
potentially harmful to people 
Who have hepatitis 
Clients who have hepatitis should check with their medical care providers before 
taking nutritional supplements or alternative treatments. The substances listed 
below might harm the liver.
Artemisia (mugwort, sagebrush, wormwood)
 
Aspalathus linearis (bush tea)
 
Atractylis gummifera (pine thistle)
 
Callilepis laureola 

Crotalaria
 
Ephedra sinica (ma huang)
 
Gnaphalium (Gordolobo herbal tea)
 
Hedeoma (pennyroyal, squaw mint oil)
 
Heliotropium
 
Iron supplements 
Kombucha mushroom tea 
Larrea tridentata (chaparral leaf, creosote bush, greasewood) 
Margosa oil 
Mate (Paraguay) tea 
Myristica (nutmeg) 
Piper methysticum (kava) 
Sassafras 
Scutellaria lateriflora (skullcap) 
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Senecio aureus
 
Senecio jacobaea (tansy ragwort, variation of ragwort)
 
Senna
 
Symphytum off icinale (comfrey)
 
Valeriana off icinalis (valerian root)
 
Viscum album (mistletoe)
 
Vitamin A supplements
 
Yerba tea
 
Source: Alternative and Complementary Therapies, U.S. Department of Veterans Affairs, http://www.hepatitis.va.gov/ 
patient/alternative-therapies/index.asp 
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Appendix F—mental health 
Treatment considerations for 
people Who have chronic 
viral hepatitis c 
Mental illness and hepatitis frequently co-occur (Rosenberg et al., 2001;
Rosenberg et al., 2003). People who have mental illness are at greater risk than 
the general public for exposure to infectious diseases, including chronic hepatitis 
(Rosenberg et al., 2001). For instance, in a study of veterans with hepatitis C,
Fireman, Indest, Blackwell, Whitehead, and Hauser (2005) found that 93 percent 
of subjects had one or more psychiatric or substance use disorders at the time of 
or before the study.
Behavioral health conditions are not absolute contraindications for chronic hepatitis
treatment. As healthcare providers increasingly consider treating hepatitis in 
patients with mental disorders, they might turn to behavioral health providers 
to assess their patients for readiness for antiviral treatment. In addition, behav­
ioral health treatment providers might have clients who have chronic hepatitis 
and who require support through the lengthy and challenging hepatitis treatment
process. 
Behavioral health counseling 
Goldsmith and Hauser (2003) advocate the participation of an informed 
behavioral health treatment provider in a client’s antiviral treatment for chronic 
hepatitis. They assert that, to provide effective support in the treatment process,
behavioral health treatment providers need to know:
•	 The natural history of hepatitis C virus infection (see Chapter 1 in this 
Treatment Improvement Protocol [TIP]). 
•	 Standard treatment for chronic hepatitis (Chapter 5). 
•	 Common adverse effects of treatment (Chapter 5). 
•	 How to manage side effects of treatment (Appendix D). 
•	 How to work with high-risk populations (Chapters 4, 5, and 6). 
•	 How to manage (particularly with psychotropic medications) a client’s mood 
and cognitive changes that might result from antiviral treatment (see below). 
Behavioral health treatment providers can partner with healthcare providers to 
help patients with chronic hepatitis get evaluated for treatment (see Chapter 3) 
and adhere to treatment (Chapter 6). Psychiatrists are especially well suited 
to monitor patients being treated for hepatitis for psychiatric side effects of 
treatment (Straits-Tröster, Sloan, & Dominitz, 2003).
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Issues clients Who have chronic 
hepatitis B or c might Bring to 
counseling 
Treatment for chronic hepatitis is challenging 
for most people. Behavioral health treatment 
providers might have clients who need assis­
tance with making psychological adjustments 
to having a chronic disease (e.g., coping with 
a chronic disease, learning about hepatitis,
making healthful lifestyle changes) and mak­
ing decisions related to having hepatitis (e.g.,
whether/how to disclose the condition to oth­
ers, deciding on whether to undertake antiviral 
therapy, adhering to the treatment regimen).
Helping clients make medical decisions about 
hepatitis treatment is the subject of Chapter 4.
Chapter 6 of this TIP includes the following 
relevant topics:
•	 Using effective counseling strategies,

including motivational approaches
 
•	 Ensuring safety of the counselor 
•	 Providing reliable information about 

hepatitis

•	 Building the therapeutic relationship 
•	 Helping clients understand their 

diagnoses

•	 Incorporating client needs in substance 
abuse treatment planning 
•	 Developing a plan to prevent infecting 
others and to prevent further liver damage 
•	 Using motivational approaches 
•	 Confronting the social ramifications of 
disclosing hepatitis status 
•	 Addressing relapse 
•	 Building support systems 
•	 Providing effective case management 
Patients with baseline depression, anxiety,
bipolar disorder, post-traumatic stress disorder 
(PTSD), or other behavioral health condi­
tions might face additional challenges that 
come with the neuropsychiatric side effects of 
hepatitis treatment, such as worsening of their 
symptoms, or relapse. Therefore, the issue of 
readiness for treatment is particularly relevant 
for mental health care professionals. 
readiness for Treatment 
Many clients who have mental illnesses do 
not receive hepatitis pharmacotherapy because 
they are not prepared (in their view or in a 
care provider’s view) to successfully complete 
the regimen. For example, some healthcare 
providers might defer treatment until an 
individual’s mental illness, such as depression,
can be stabilized. Individuals might choose to 
defer treatment until they are in stable hous­
ing or until they have built strong support 
networks.
Little information is available on how frequently
clients receive a second referral for chronic 
hepatitis treatment if they are initially deferred 
but later become eligible for treatment. One 
study reported that none of the 306 patients 
who deferred had a second referral for treat­
ment (Yawn, Wollan, Gazzuola, & Kim, 2002).
A more recent study reported that of 111 
patients deferred for psychiatric issues (includ­
ing psychiatric instability and suicidal ide­
ation), 53 percent received a followup referral,
of which only 18 percent (20 individuals) were 
ultimately treated (Evon et al., 2007). These 
rates suggest that, if treatment for hepatitis is 
deferred at the initial assessment, few clients 
have opportunities to receive treatment after 
they become eligible.
In addition, although some clients might have 
healthcare providers who defer hepatitis treat­
ment because of the client’s behavioral health 
issues, some data suggest that some individuals 
do not follow through with steps necessary 
to get treatment (Butt, Wagener, Shakil, & 
Ahmad, 2005).
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Appendix F—Mental Health Treatment Considerations for People Who Have Chronic Viral Hepatitis C 
Behavioral health treatment providers can 
help clients who are currently ineligible for
hepatitis treatment become eligible. For exam­
ple, they can motivate clients to attend medi­
cal appointments. Helping a client become 
ready for treatment can take several months 
(Scheft & Fontenette, 2005). Behavioral 
health treatment providers can work with a 
client’s healthcare provider and advocate a 
referral for hepatitis treatment when clients 
are ready. 
An expanded psychiatric evaluation can 
enhance the assessment of client readiness 
for hepatitis treatment (Scheft & Fontenette,
2005; Silberbogen, Mori, & Sogg, 2005).
Silberbogen et al. (2005) developed a struc­
tured interview to help determine a client’s
readiness for treatment. Facets of the structured
interview include the following: 
•	 Hepatitis C history 
•	 Social support network 
•	 Understanding of chronic hepatitis C 

and its treatment
 
•	 History of motivation and adherence 

to treatment
 
•	 Psychiatric history 
•	 Mental status exam 
Tools that might assist the psychiatric assess­
ment include the following: 
•	 Beck Anxiety Inventory 
•	 Beck Depression Inventory 
•	 Bipolar Spectrum Diagnostic Scale 
•	 Brief Psychiatric Rating Scale 
•	 Center for Epidemiologic Studies 

Depression Scale
 
•	 Geriatric Depression Scale 
•	 Major Depression Inventory 
•	 Mood Disorders Questionnaire 
•	 Montgomery Asberg Depression Rating 
Scale 
•	 Post-Traumatic Stress Disorder Checklist 
(civilian version) 
•	 Quick Inventory of Depressive Symptoms 
•	 State-Trait Anxiety Inventory 
•	 Young Mania Rating Scale 
•	 Zung Self-Rating Depression Scale 
An important part of the expanded assessment 
is screening for substance use disorders. Tools 
to assess substance use disorders include the 
following: 
•	 Alcohol, Smoking, and Substance 
Involvement Screening Test (ASSIST) 
•	 Alcohol Use Disorders Identification Test 
(AUDIT)
•	 Alcohol Use Disorders Identification 

Test—Consumption (AUDIT-C)
 
•	 CAGE Adapted to Include Drugs 

(CAGE-AID)
 
•	 Drug Abuse Screening Test 
•	 Michigan Alcoholism Screening Test 

(MAST) (MAST-G for older adults)
 
•	 Patient Health Questionnaire (PHQ9) 
Pharmacological approaches (see the section 
on Medications for People Who Have 
Behavioral Health Disorders, below) and 
nonpharmacological approaches (see Chapter 
6) might be beneficial for helping the client 
become ready for treatment of hepatitis. 
effects of Antiviral Treatment for 
chronic hepatitis on Behavioral 
health 
People who never had problems with anxiety,
depression, or irritability might experience 
these as a result of treatment for chronic 
hepatitis, and stable patients with previ­
ous mental health problems might have 
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exacerbations. Some early symptoms of 
treatment-related depression might also 
mimic opioid withdrawal. This can complicate 
clinical management for the large subset of 
patients with chronic hepatitis C who have a 
history of opioid injection drug use (Schaefer 
& Mauss, 2008). 
In a review article by Robaeys and Buntinx 
(2005), neurobehavioral changes leading to 
depression often begin by the eighth week 
of antiviral therapy, which coincides with the
peak time for quitting medication treatment.
Addressing mental health symptoms is
important to antiviral treatment success
because close adherence to and completion 
of multiple-week therapy are required for 
achieving treatment success (Sylvestre & 
Clements, 2007).
Clients with mental illness who decide to 
undergo treatment for chronic hepatitis 
will require regular psychiatric monitoring.
In addition, treatment adherence might be 
enhanced with the following supports:
•	 Psychosocial interventions 
•	 Medication, therapy, or both to manage 
anger, anxiety, irritability, depression, or 
other side effects of interferon treatment 
•	 Support groups to combat social isolation 
and discrimination resulting from a 
hepatitis diagnosis
•	 Support to prevent relapse to substance 
use 
•	 Motivational therapy to inspire changes 
in daily life that support antiviral 
treatment 
•	 Education on how to prevent transmis­
sion of the hepatitis C virus 
For patients with risk factors for depression 
(e.g., personal or family history of depression,
suicide attempts, alcohol abuse, poor sleep 
quality) preemptive treatment with selective 
serotonin reuptake inhibitors (SSRIs) has been 
used as a prevention strategy (Schaefer & 
Mauss, 2008). Concurrent use of interpersonal 
psychotherapy, behavioral psychotherapies,
and psychosocial support might also be ben­
eficial to these clients (American Psychiatric 
Association, 2010; Wilson, Castillo, & Batey,
2010).
Preexisting psychiatric medication regimens 
might need modification during hepatitis 
treatment. For example, a patient with bipolar 
disorder who takes valproic acid might need 
to change to a mood stabilizing medication 
that is less toxic to the liver while on antiviral 
therapy. A patient who was previously stable 
on an SSRI might need an increased dosage or 
a medication change. Psychiatric medications 
and care might need to continue for at least 6 
to 12 weeks after antiviral treatment is com­
pleted because mood disorders, neurocognitive 
changes, and other psychological problems 
might persist (Schaefer & Mauss, 2008).
With pretreatment screening to determine 
need for medication, continuous monitor­
ing, and individualized treatment, patients 
with preexisting or emerging mental health 
problems might be able to mitigate the 
adverse IFN-alpha psychiatric side effects,
complete treatment, and achieve sustained 
viral response. These positive outcomes have 
been reported with collaborative care provided 
by multidisciplinary management teams that 
include healthcare providers, psychologists,
psychiatrists, addiction specialists, and other 
behavioral health workers (Belfiori et al., 2009;
Guadagnino et al., 2007; Schaefer et al., 2003;
Sylvestre & Clements, 2007).
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Appendix F—Mental Health Treatment Considerations for People Who Have Chronic Viral Hepatitis C 
medications for people Who have 
Behavioral health Disorders 
Affective Disorders 
Depression is common among patients who 
require antiviral treatment of chronic hepati­
tis C (Schaefer & Mauss, 2008). Others can 
develop major depression during the course 
of antiviral treatment. The medications most 
commonly prescribed for depression include 
SSRIs (e.g., fluoxetine, citalopram, sertraline,
paroxetine, escitalopram), serotonin and nor-
ephedrine reuptake inhibitors (e.g., duloxetine,
venlafaxine), and the chemically unique bupro­
pion. Older antidepressant medications (e.g.,
monoamine oxidase inhibitors, tricyclics) are 
less often prescribed because they have more 
side effects and drug interactions (National 
Institute of Mental Health [NIMH], 2008).
Depression screening scales that rely on 
patient self-reporting can be used, but the 
Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR) criteria (APA, 2000) 
and clinical evaluation are essential to guide 
treatment decisions.
Bipolar disorder is another affective disorder 
in which patients cycle through alternating 
episodes of depression and mania. Patients 
are treated with mood stabilizers (e.g.,
carbamazepine, lamotrigine, lithium, oxcar­
bazepine, valproic acid). Antidepressants are 
sometimes added to mood stabilizers to treat 
symptoms of depression in bipolar disorder,
but these medications need to be used with 
great care because of the risk of exacerbating 
manic symptoms and/or inducing suicidality 
(NIMH, 2008). Atypical antipsychotics (e.g.,
aripiprazole, clozaril, olanzapine, risperidone,
ziprasidone) are sometimes added to treat 
depression or bipolar disorder.
Anxiety Disorders 
Anxiety disorders include obsessive-com­
pulsive disorder, PTSD, generalized anxiety 
disorder, panic disorder, social phobia, and 
others (APA, 2000). When patients undergo­
ing treatment for chronic hepatitis exhibit 
symptoms related to anxiety disorders, it is 
important to determine whether symptoms are 
related to the psychological demands of cop­
ing with a chronic disease, whether they are 
due to the rigors of treatment, or whether they 
are an exacerbation of a preexisting condition 
so that appropriate pharmacological and non-
pharmacological treatments can be arranged.
Cognitive behavioral therapy is frequently 
used for the treatment of anxiety disorders and 
can improve symptoms significantly within a 
short timeframe. Other nonpharmacological 
treatments include group therapy, systematic 
desensitization, acupuncture, and biofeedback.
Suicidality 
Suicide is the worst outcome of major depres­
sive disorder, and treatment of modifiable risk 
factors (anxiety, insomnia, agitation, psychotic 
symptoms, and substance abuse) are recom­
mended in addition to treating the depressive 
episode (APA, 2010).
Some of the medications that are used to treat 
depression and bipolar disorder might increase 
the risk of suicidal thoughts and behaviors 
(U.S. Food and Drug Administration, 2009).
All clients should be screened for risk of sui­
cide. People at risk for suicide should be close­
ly monitored for new or worsening symptoms 
of depression, suicidal thoughts or behaviors,
or unusual changes in mood or behavior 
(NIMH, 2008). More information can be 
found in TIP 50: Addressing Suicidal Thoughts 
and Behaviors in Substance Abuse Treatment
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(Center for Substance Abuse Treatment,
2009b). Other materials are available at the 
National Suicide Prevention Lifeline (http://
www.suicidepreventionlifeline.org).
Treating patients With hepatitis c
and serious mental Illness 
Adults with a serious mental illness (SMI) 
are people ages 18 and older who, at any time 
during a given year, have a diagnosable mental,
behavioral, or emotional disorder that meets 
the criteria of DSM-IV-TR (APA, 2000) and 
that results in functional impairment which 
substantially interferes with or limits one or 
more major life activities (Substance Abuse 
and Mental Health Services Administration 
[SAMHSA], 1999). 
Whether SMIs such as psychotic disorders 
and major mood disorders should be contra-
indications to undergoing antiviral therapy 
for hepatitis C is controversial. The American 
Psychiatric Association (APA, 2010) states 
that SMIs are not necessarily contraindica­
tions to antiviral treatment. Psychotic symp­
toms (hallucinations and delusions) make 
effective coping with a chronic infectious 
disease difficult, increase patient risk of sui­
cide, and might make adherence with complex 
antiviral regimens impossible. Patients with 
psychotic symptoms frequently need antipsy­
chotic medications (e.g., aripiprazole, chlor­
promazine, clozaril, fluphenazine, haloperidol,
olanzapine, paliperidone, perphenazine, que­
tiapine, risperidone, ziprasidone) alone or in 
combination with other medications (NIMH,
2008). These complex psychiatric medication 
treatment regimens can be difficult to man­
age during antiviral treatment. Patients with 
depression frequently experience increased 
depressive symptoms during antiviral treat­
ment (Ghany et al., 2009). This increase in 
symptoms has not been reported for patients 
with schizophrenia (Huckans, Mitchell, & 
Pavawalla 2010); however, this has not been 
well studied. 
Antiviral therapy can be successful for chronic 
hepatitis C patients with SMIs but often 
requires expert psychiatric management and 
close monitoring by clinical staff. Intensive 
case management by a behavioral health case 
manager might be needed to support treat­
ment adherence, make and monitor treatment 
appointments, and assist with housing, food,
and employment needs. More frequent physi­
cian appointments might be needed for
laboratory monitoring of liver function and 
to detect any dangerous medication interac­
tions. The decision to treat needs to consider 
the social support network and the availabil­
ity of social services, as well as the patient’s 
abilities.
Drug Interactions 
A combined medication regimen consisting 
of pegylated interferon and ribavirin is the 
standard of care for chronic hepatitis C 
(Ghany et al., 2009). Both antiviral drugs 
have side effects and potential toxicities, but 
they have few specific interactions with medi­
cations used to treat behavioral health disor­
ders (see Exhibit F-1). Interferon has no clini­
cally significant interactions with methadone 
used to treat opioid addiction; however, its 
potential interaction with buprenorphine has 
not been adequately studied to identify such 
interactions. Ribavirin’s potential interactions 
with methadone or buprenorphine have also 
not been studied indepth and are unknown 
(McCance-Katz, Sullivan, & Nallani, 2009).
Ribavirin does not interact adversely with any 
medications listed in Exhibit F-1. The patient 
should be monitored closely for any adverse 
effects or drug interactions when receiving 
medications that are metabolized by the liver.
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exhibit F-1 potential Interactions Among medications Used to Treat chronic 
hepatitis and Behavioral health conditions 
prescription 
medication 
Indication potential Interaction With hepatitis 
medications 
Alprazolam Anxiety The use of telaprevir with alprazolam increases 
exposure to alprazolam. Clinical monitoring for dose 
adjustment is recommended. 
The use of boceprevir could result in increased 
sedation or respiratory depression when used with 
alprazolam. A lower dose of alprazolam should be 
considered. 
Buprenorphine Opioid dependence The use of boceprevir could result in an increase 
or decrease in buprenorphine levels. However, 
the combination of buprenorphine and boceprevir 
has not been studied. Clinical monitoring for dose 
adjustment is recommended. 
Bupropion Depression; nicotine 
dependence 
The use of bupropion is associated with an increased 
risk of seizures. Use of interferon and bupropion 
together might increase seizure risk as well. 
Clozapine Schizophrenia; 
psychosis 
Clozapine might cause marrow disorders, neuroleptic 
malignant syndrome, and increased seizure risk. 
When taken with interferon, the risks of these might 
increase. 
Desipramine Depression The use of telaprevir or boceprevir could result in an 
increase in desipramine concentration, which might 
lead to adverse events (e.g., nausea, dizziness). 
The combination of telaprevir or boceprevir and 
desipramine should be used with caution and a lower 
dose of desipramine should be considered. 
Disulfiram Alcohol use disorders Disulfiram might cause or worsen hepatitis. When 
taken with interferon alpha 2a, there is increased risk 
of peripheral neuropathy. 
Escitalopram Depression The use of telaprevir can result in decreased 
escitalopram concentration. Clinical monitoring for 
dose adjustment is recommended. 
Methadone Opioid dependence The use of telaprevir is associated with decreased 
methadone concentration. Clinical monitoring for 
dose adjustment is recommended. 
The use of boceprevir could result in an increase 
or decrease in methadone levels. However, the 
combination of methadone and boceprevir has not 
been studied. Clinical monitoring for dose adjustment 
is recommended. 
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exhibit F-1 potential Interactions Among medications Used to Treat chronic 
hepatitis and Behavioral health conditions (continued) 
prescription 
medication 
Indication potential Interaction With hepatitis 
medications 
Midazolam Anxiety Telaprevir is contraindicated with oral midazolam. 
The interaction could result in increased sedation or 
respiratory depression.
The use of boceprevir could result in increased 
sedation or respiratory depression when used with 
intravenous midazolam. A lower dose of intravenous 
midazolam should be considered. 
Naltrexone Opioid and alcohol 
use disorders 
When taken with interferon alpha 2a, naltrexone 
might exacerbate liver damage. 
Trazodone Depression The use of telaprevir or boceprevir can result in an 
increase in trazodone concentration, which might 
lead to adverse events (e.g., nausea, dizziness). 
The combination of telaprevir or boceprevir and 
trazodone should be used with caution and a lower 
dose of trazodone should be considered. 
Triazolam Insomnia Telaprevir and boceprevir are contraindicated with 
triazolam. The interaction could result in increased 
sedation or respiratory depression. 
Zolpidem Insomnia The use of telaprevir can result in decreased 
zolpidem concentration. Clinical monitoring and dose 
adjustment of zolpidem is recommended to achieve 
the desired response. 
Sources: Physicians’ Desk Reference 2010 (64th ed.), 2009; U.S. Food and Drug Administration, 2011c and 2011d. 
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Appendix G—motivational 
Interviewing and counseling 
resources 
•	 Case Management Adherence Guidelines, Version 2.0 (Case Management 
Society of America, 2006), http://www.cmsa.org/portals/0/pdf/CMAG2.pdf 
•	 Enhancing Motivation for Change in Substance Abuse Treatment (Center for 
Substance Abuse Treatment [CSAT], 1999), http://www.ncbi.nlm.nih.gov/
bookshelf/br.fcgi?book=hssamhsatip&part=A61302 
•	 Enhancing Motivation for Change Inservice Training (CSAT, 2006), http://
www.kap.samhsa.gov/products/manuals/tip35c/index.htm 
•	 Group Treatment for Substance Abuse: A Stages-of-Change Therapy Manual. M. 
Velasquez, G. Maurer, C. Crouch, & C. DiClemente. New York: Guilford 
Press, 2001 
•	 Motivational Groups for Community Substance Abuse Programs. K. Ingersoll,
C. Wagner, & S. Gharib. Kansas City: Addiction Technology Transfer 
Center Network, 2000 
•	 Motivational Interviewing: Preparing People for Change, 2nd ed. W. Miller & 
S. Rollnick. New York: Guilford Press, 2002 
•	 The Motivational Interviewing Web Page, http://www.motivationalinterview.org
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Appendix h—sources for 
Financial Assistance 
•	 A source for identifying government sources of healthcare and support ben­
efit programs by State. (http://www.benefits.gov/) 
•	 Low-income clients might be eligible for Medicaid, but benefits vary sig­
nificantly across States. (http://cms.hhs.gov) 
•	 Federally funded health centers provide medical services to people who are 
uninsured and underinsured. (1-800-ASK-HRSA [1-800-275-4772]). 
•	 The Veterans Healthcare System offers hepatitis C virus screening, treat­
ment, and support services to eligible U.S. veterans.
(http://www.hepatitis.va.gov) 
•	 The Ryan White CARE Act provides medications to eligible low-income 
U.S. residents who have HIV, including those co-infected with hepatitis.
(http://hab.hrsa.gov) 
•	 Needymeds.org is a consumer site providing sources on pharmaceutical,
State, Medicare, and Medicaid financial support for the treatment of serious 
diseases, including hepatitis.
(http://www.needymeds.org/) 
•	 Partnership for Prescription Assistance is a pharmaceutical-company­
sponsored resource that offers low- or no-cost medication to people who 
lack prescription drug coverage.
(http://www.pparx.org) 
•	 National Foundation for Transplants helps individuals find financial sup­
port for transplantation operations.
(http://www.transplants.org) 
•	 National Transplant Assistance Fund raises funds for uninsured medical 
expenses related to transplantation.
(http://www.transplantfund.org) 
•	 Hepatitis clinical trials are available to a limited number of people.
(http://clinicaltrials.gov/ct2/results?term=hepatitis) 
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Appendix I—hepatitis c
Training programs for 
substance Abuse Treatment 
program staff 
Focus on Hepatitis C was developed by the Hepatitis C Association, sponsored 
by the Substance Abuse and Mental Health Services Administration. The 3-hour 
training includes a PowerPoint presentation, a question-and-answer session, and 
a discussion of local resources. Content includes functions of the liver, risk factors,
modes of transmission, diagnostic process and treatment of HCV, natural history 
and progression of HCV and HCV/HIV co-infection, healthful lifestyle choices 
that preserve liver health, counseling guidelines, and issues and challenges in
providing care for clients with hepatitis C in treatment centers. Training provides 
information on locating community resources; Web sites, toll-free support lines,
and venues for medical care; and information on obtaining treatment assistance 
for people who are not insured or are underinsured. Continuing education credits 
can be earned (http://www.hepcfocus.com). 
•	 The Centers for Disease Control and Prevention (CDC) maintains 
numerous trainings and resources (http://www.cdc.gov/ncidod/diseases/
hepatitis/resource/training/counseling.htm). 
•	 HCV Advocate offers training resources and information from the client’s 
perspective (http://www.hcvadvocate.org/hepatitis/training_resources.asp). 
•	 CDC’s Division of Viral Hepatitis provides funding to HCV coordinators 
across the country to offer viral hepatitis counseling, testing, vaccinations,
and other services (http://www.cdc.gov/hepatitis/index.htm).
•	 Pharmaceutical manufacturers of hepatitis medications are often willing to 
conduct free onsite training sessions for counseling staff. Contact manufacturers
directly. 
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Cheryl Anderson
Bureau of Primary Health Care 
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Health Resources and Services 
Administration 
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Prevention Branch, Division of Viral 
Hepatitis
Centers for Disease Control and 
Prevention 
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Director 
Center for Substance Abuse Treatment 
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Services Administration 
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Lead Government Project Officer,
Methamphetamine
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Substance Abuse and Mental Health 
Services Administration 
Rockville, Maryland 
Christina Currier 
Government Project Officer
Center for Substance Abuse Treatment 
Substance Abuse and Mental Health 
Services Administration 
Rockville, Maryland 
David A. Fiellin, M.D., Chair
Professor of Medicine and of Public 
Health and Associate Professor of 
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Yale University School of Medicine
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Services Administration 
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AIDS Coordinator 
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Medical Officer 
Systems Improvement Branch
Center for Substance Abuse Treatment 
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Administration 
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117 
Jack Stein, M.S.W., Ph.D.
Director 
Division of Services Improvement
Center for Substance Abuse Treatment 
Substance Abuse and Mental Health Services 
Administration 
Rockville, Maryland 
Chris Taylor
Viral Hepatitis Program Manager
National Alliance of State and Territorial 
AIDS Directors 
Washington, D.C. 
Thelma King Thiel, RN
Chair and Chief Executive Officer 
Hepatitis Foundation International
Silver Spring, Maryland 
Appendix J—Stakeholders Meeting Participants 
David C. Thompson
HIV/AIDS Team Leader
Center for Substance Abuse Treatment 
Substance Abuse and Mental Health Services 
Administration 
Rockville, Maryland 
Mary R. Vienna
Health Resources and Services Administration 
Rockville, Maryland 

119 
 
 
 
  
 
 
 
 
 
Appendix K—Field reviewers 
Corinna Dan, RN, M.P.H.
Hepatitis Foundation International
Silver Spring, Maryland 
Brenda Davis 
Clinic Manager
Beth Israel Medical Center 
Methadone Maintenance Treatment 
Program
New York, New York 
Leonard Gill 
President, HCV Peer Educator/
Patient Advisory Committee
Albert Einstein College of Medicine
Division of Substance Abuse 
Bronx, New York 
Carol L. Kuprevich, Ed.D.
Director of Community Planning,
Program Development, and 
Training
Delaware Division of Alcohol,
Drug Abuse and Mental Health
New Castle, Delaware 
Shirley Mikell
NAADAC—The Association for 
Addiction Professionals 
Alexandria, Virginia 
Rosa Rodriguez
Substance Abuse Counselor 
Albert Einstein College of Medicine
Peekskill, New York 
Leonard B. Seeff, M.D.
Senior Scientist for Hepatitis 
Research 
National Institute of Diabetes and
Digestive and Kidney Diseases,
Division of Digestive Diseases and 
Nutrition 
National Institutes of Health 
Bethesda, Maryland 
Carol Sholiton 
President and Founder 
Methadone Support Org 
Scottsdale, Arizona 
Dee-Dee Stout, M.A., CADC II,
MINT 
Director 
Responsible Recovery
Emeryville, California 
Lynn E. Sullivan, M.D.
Assistant Professor of Medicine 
Yale University
New Haven, Connecticut 
120 
 
 
Lynn E. Taylor, M.D.
Assistant Professor of Medicine 
The Warren Alpert Medical School of Brown 
University
Providence, Rhode Island 
Thelma King Thiel, RN
Chair and Chief Executive Officer 
Hepatitis Foundation International
Silver Spring, Maryland 
Jeanne Wells 
Social Worker 
Rocky Mountain Health Services
Woodland Park, Colorado 
Kimberly Wright
Medical Services Coordinator 
Missouri RAIN 
Columbia, Missouri 
and 
National Institute of Diabetes and 
Digestive and Kidney Diseases
National Institutes of Health 
Bethesda, Maryland 
121 
  
 
 
 
 
  
  
Appendix l— 
Acknowledgments 
Numerous people contributed to the development of this Treatment 
Improvement Protocol (TIP), including the TIP Consensus Panel (p. xiii),
stakeholders (Appendix J), and field reviewers (Appendix K). 
This publication was written and produced under contract numbers 270-04­
7049 and 270-09-0307, by the Knowledge Application Program (KAP), a Joint 
Venture of JBS International, Inc., and The CDM Group, Inc., for the Center 
for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health 
Services Administration (SAMHSA), U.S. Department of Health and Human 
Services (HHS). 
Lynne MacArthur, M.A., A.M.L.S., served as the JBS KAP Executive Project 
Co-Director, and Barbara Fink, RN, M.P.H., served as the JBS KAP Managing 
Project Co-Director. Other JBS KAP personnel included Candace Baker,
M.S.W., MAC, Deputy Director for Product Development; Deborah Steinbach,
M.A., Senior Writer; Patricia Kassebaum, M.A., Senior Writer; Kris Rusch,
M.A., Senior Writer; Martha J. Horn, Ph.D., Senior Writer; Frances Nebesky,
M.A., Quality Assurance Editor; Wendy Caron, Quality Assurance Manager;
Erin P. Doherty, Copy Editor; Terrie Young, Graphic Designer; and 
Erin Sandor, Graphic Designer. 

 123 
Index 
A 
Acupuncture, 46, 105
Acute hepatitis, 4, 6, 7, 8, 42
Adefovir dipivoxil, 41, 87
Administrators’ guide
education, 65–66
funding comprehensive services, 63
integrating interventions with HIV services, 68
legal and ethical issues, 71
medical evaluation and diagnosis, 62
outreach activities, 66–68
policies and procedures development, 69
prevention and vaccination, 65
program assessment and planning, 61–62
program evaluation, 69
screening for hepatitis, 62
successful implementation, 70–71
support services, 66, 68
treatment guidelines, 62–66
Affective disorders, 105
AIDS. See HIV co-infection 
Alcohol abuse 
hepatitis treatment and, 34
Alternative medicine, 46, 99–100
American Association for the Study of Liver Diseases Guidelines, 33, 64
Anemia 
as treatment side effect, 44
Antibodies, 13, 14, 15, 16, 22, 87, 89
Antigens, 13, 14, 22, 87
Antiviral treatment, 3, 20, 25–29, 31–38, 40–50, 53, 55, 57 
Anxiety disorders, 105 
B 
Behavioral health disorders 
counseling, 37, 47, 67, 101–102, 109
hepatitis treatment and, 49–50 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
Biopsy, liver, 23, 27–29, 45, 63
Boceprevir, 25, 26, 43, 87, 107, 108 
CAM. See Complementary or alternative 
medicine 
Case management, 57–58, 102, 106
CDC. See Centers for Disease Control and 
Prevention 
Center for Substance Abuse Treatment, ii, vii,
xi, 58, 62, 106, 109, 115–117, 121

Centers for Disease Control and Prevention,

5, 6, 8, 14, 15, 62, 64, 91, 113, 115

Chronic hepatitis
genotype test, 25–26
liver biopsy, 27–29
liver panel, 23–24
symptoms of, 4
treatment counseling, 35–36, 42
treatment guidelines, 62–66
viral load tests, 24–25
Cirrhosis, 1, 4, 6, 8, 11, 12, 24, 27, 32, 88
Client counseling. See Counseling approaches 
Client education, 66
Combating the Silent Epidemic of Viral 
Hepatitis: U.S. Department of Health 
and Human Services Action Plan for the 
Prevention, Care and Treatment of Viral 
Hepatitis, 2
Complementary or alternative medicine, 46,
99–100 
Confidentiality issues, 64, 67, 71, 72
Consensus Panel, viii, ix, 7, 16, 65, 121
Counseling approaches
addressing relapse, 55–56, 102
building therapeutic relationship, 52
case management, 57–58
confronting social factors, 54–55
developing prevention plans, 54
ensuring safety, 52
helping clients understand diagnoses, 53
hepatitis B, 42
hepatitis education, 10, 18–19 
liver biopsy decision, 27–28
motivational approaches, 48, 54, 59, 102,
104, 109
providing reliable information, 52, 102 
resources, 109
risky behavior, 16, 18, 19, 46, 54, 67
screening process, 15–21
strategies, 51, 52
substance abuse treatment planning, 53
support systems, 56–57
treatment based on HCV status, 35–36
treatment decisions, 31, 35–37, 42
CSAT. See Center for Substance Abuse 
Treatment 
D 
Deoxyribonucleic acid tests, 24, 88
Depression, 32, 34, 41, 44, 49, 50, 53, 55, 59,
68, 102, 103–105
hepatitis treatment considerations, 34
as treatment side effect, 44
Dietary supplements, 46, 99–100
DNA tests, 24
Drug interactions, 105, 106–108 
E 
Educate-Motivate-Facilitate groups, 68
Education activities, 38, 48, 51, 52, 61, 63,
65–66, 69, 91, 92, 93, 104, 113
End-stage liver disease, 32, 36, 42, 46, 49, 88
Entecavir, 40, 41, 50
Ethical issues, 71
Ethnicity
impact on hepatitis treatment, 35, 37
Eye disorders
as treatment side effect, 44 
F 
Family support, 57, 59
FDA. See U.S. Food and Drug Administration
Fibrosis, 4, 8, 27, 36, 88
Financial assistance sources, 111
Focus on Hepatitis C, 113 
125 
Index
 
 
 
 
 
 
 
 
 
 
 
G 
Genotypes

impact on hepatitis treatment, 34

tests, 23, 25–26

Glossary, 87–90 
H 
HAV. See Hepatitis A

HBV. See Hepatitis B

HCV. See Hepatitis C

HCV Advocate, 113

HDV. See Hepatitis D virus

Health Insurance Portability and Accountability

Act, 71

Hepatitis

causes of, 3

Hepatitis, acute, 4, 42

Hepatitis, chronic

genotype test, 25–26

liver biopsy, 27–29

liver panel, 23–24

symptoms of, 4

treatment counseling, 35–36

treatment guidelines, 62–66

viral load tests, 24–25

Hepatitis, viral. See also Counseling approaches
 
causes of, 3

co-infections, 3–4, 10–11

interagency working group, 1–2

liver damage, 4

medical evaluation, 23–29

program services, 61–72

screening process, 13–22, 62

symptoms, 4

treatment, 39–50, 62–66

treatment decisions, 31–38

types of, 3–4, 10

Hepatitis A

course of disease, 5

disease burden, 5

duration of illness, 4–5

HIV co-infection, 11

modes of transmission, 5

overview, 3–4
 
prevention of infection, 5–6

screening process, 14

substance use and, 5

treatment for, 40

vaccination, 65

Hepatitis B

course of disease, 6–7

disease burden, 6

HIV co-infection, 11

modes of transmission, 6

overview, 3–4

prevention of infection, 7

screening process, 14

substance use and, 7

treatment for, 40–42

vaccination, 65

Hepatitis C Association, 113

Hepatitis C

antiviral treatment, 42–44, 95–97

course of disease, 8–9

disease burden, 8

duration of illness, 7–8

HIV co-infection, 11, 48–49

mental health treatment considerations,

101–108
 
modes of transmission, 8

overview, 3–4

prevention of infection, 9

screening process, 14–15

substance use and, 9

treatment counseling, 35–36

treatment for, 40, 42–49

treatment response classifications, 34

Hepatitis D virus, 10

Hepatitis E virus, 10

Hepatitis F virus, 10

Hepatitis G virus, 10

Herbal treatments, 46, 99–100

HEV. See Hepatitis E virus
 
HFV. See Hepatitis F virus
 
HGV. See Hepatitis G virus
 
HHS. See U.S. Department of Health and 

Human Services 
HIPAA. See Health Insurance Portability and 
Accountability Act 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV co-infection
 
integrating hepatitis interventions with 

existing services, 68

treatment issues, 11, 35, 45, 48–49
 
I
 
IDU. See Injection drug use
Implementing Change in Substance Abuse 
Treatment Programs, 62

Informed consent, 29, 71–72

Injection drug use, 1, 6, 8, 15, 17, 34, 48, 54,

65, 104

Institute of Medicine, 1, 4, 8, 62

Interferon, 25, 32, 41, 43, 89, 96, 104, 106–108

IOM. See Institute of Medicine
 
K 
KAP Keys, 123

Knowledge Application Program, ii, viii, 121,

123
 
L 
Lamivudine, 41, 89

Legal issues, 67, 71

LFTs. See Liver function tests
 
Liver
 
biopsy, 23, 27–29, 45, 63

function of, 3

hepatitis damage, 4, 35

Liver function tests, 23–24

Liver panel, 23–24

Liver transplantation, 36, 42, 45–46
 
M 
Mania 
as treatment side effect, 44

MAT. See Medication-assisted treatment
 
Medication. See Treatment
 
Medication-assisted treatment, 37, 45, 46–47,

58, 62

Medicinal plant treatments, 46, 99–100

Men who have sex with men, 5, 7

Mental health disorders
 
affective disorders, 105

anxiety disorders, 105
 
behavioral health counseling, 101–102

effects of antiviral treatment, 103–104

hepatitis treatment and, 49–50

psychiatric assessment, 103

serious mental illness, 106–108

suicidality, 34, 104, 105–106

treatment readiness, 102–103

Minneapolis Healthy Liver Program, 70

Motivational approaches, 54, 102, 109

MSM. See Men who have sex with men
 
Multidisciplinary teams, 64
 
N 
NASTAD. See National Alliance of State and 

Territorial AIDS Directors
 
National Alliance of State and Territorial 

AIDS Directors, 65

National Institutes of Health Consensus 

Statement, 33

Neutropenia

as treatment side effect, 44

New York State Department of Health 

Guidelines, 33

Nucleic acid tests, 24
 
O 
OASIS. See Organization to Achieve 
Solutions in Substance-Abuse 
Onsite treatment, 63–64
Opioid dependence
hepatitis treatment and, 34, 37, 45, 46–47,

107
 
Opioid treatment programs, 47, 62, 65

Organization to Achieve Solutions in 

Substance-Abuse, 68

OTP. See Opioid treatment program

Outreach activities, 66–68
 
P 
Peer counseling, 56–57, 68

Practice Guidelines of the American 

Association for the Study of Liver 

Diseases, 33, 64

Pregnancy

antiviral treatment considerations, 32, 33,

53
 
127 
Index
 
 
 
 
 
  
 
 
 
  
  
 
 
Prevention activities, 5–7, 9, 54, 65

Privacy issues, 71

Program services

education, 65–66

evaluation of, 69

funding comprehensive services, 63

integrating interventions with HIV 

services, 68

legal and ethical issues, 71

medical evaluation and diagnosis, 62

outreach activities, 66–68

policies and procedures development, 69

prevention and vaccination, 65

screening for hepatitis, 62

successful implementation, 70–71

support services, 33, 61, 66, 68, 70, 94

treatment guidelines, 62–66

Project Samaritan Health Services, 63

Psychiatric assessment, 103

Pulmonary disorders

as treatment side effect, 44
 
Q
Quick Guide, 123
 
R 
Referrals, 19, 38, 47, 57, 64

Resources, 91–94, 109

Ribavirin, 25, 26, 32, 33, 39, 43, 44, 89, 96, 97,

106
 
Ribonucleic acid tests, 15, 24

Risky behavior, 16, 18, 19, 22, 46, 54, 67

RNA tests, 15, 24
 
S 
SAMHSA. See Substance Abuse and Mental 
Health Services Administration 
Screening process

antigens and antibodies, 13

client counseling, 15–21

hepatitis A, 14

hepatitis B, 14

hepatitis C, 14–15

program services, 62

results, 20–21
 
staff training, 69

treatment program’s role, 13

Serious mental illness, 106–108

Services. See Program services
 
SMI. See Serious mental illness
 
Social factors, 54–55

Spleen, 4

Staff education, 66–67, 69, 113

Staff member rights, 71

Substance Abuse and Mental Health Services 

Administration
 
Focus on Hepatitis C, 113

general, ii, vii, viii, xi, 64, 106, 115–117, 121

publications ordering, 123

website, 64

Substance use disorders. See also Program 
services
 
counseling strategies, 51

hepatitis risk, 1, 5, 7, 9

opioid dependence and hepatitis treatment,

34, 46–47

relapses, 47–48, 55–56, 64

treatment planning, 53

SUDs. See Substance use disorders
 
Suicidality, 34, 104, 105–106

Superinfection, 10

Support groups, 56

Support services, 56–57, 66, 68

Sustained virologic response, 34, 42–43

SVR. See Sustained virologic response
 
T 
TAP 31. See Technical Assistance Publication, 31

Technical Assistance Publication, 31, 62

Telaprevir, 25, 26, 43

Telbivudine, 41, 90

Tenofovir, 40, 41, 50, 90

Terminology, 2–3

TIPS. See Treatment Improvement Protocols
 
Training. See Staff education
 
Transplantation, liver, 36, 42, 45–46

Treatment
 
adherence to, 33–34, 35, 36, 44, 47, 49, 53,

58, 64, 65, 67, 68, 103, 104, 106

antiviral, 42–44
 
128 
 
 
 
 
 
 
 
barriers to, 37–38, 49, 52, 67

for behavioral health disorders, 105–106,

101–108
 
behavioral health disorders and, 49–50

complementary or alternative medicine, 46,

99–100
 
contraindications, 32–33

counselor’s role, 31

deferring, 44–45

drug interactions, 106–108

effects of antiviral treatment on behavioral 

health, 103–104

guidelines, 46, 62–66

health problems and, 33, 44

for hepatitis A, 40

for hepatitis B, 40–42

for hepatitis C, 40, 42–49

HIV co-infection and, 48–49, 113

likelihood of success, 34–35

liver transplantation, 36, 42, 45–46

multidisciplinary teams, 64

onsite, 63–64

opioid dependence and, 34, 37, 45, 46–47

options, 2, 31–32, 36, 39, 42, 48

pregnancy and, 32, 33, 53

readiness for, 102–103

recommendations, 39–40

referral to hepatitis treatment providers, 64

response classifications, 34

side effects, 27, 28, 36, 37, 39, 40, 43–44,

46, 47, 95–97
 
supporting decisions, 36–37

timing of, 32

Treatment Improvement Protocols

audience for, 2

development process, viii

format, vii–viii

purpose of, 2, 123

terminology, 2–3

website, vii

Twinrix, 7, 65
 
U 
U.S. Department of Health and Human Services
interagency working group on viral 

hepatitis, 1–2

U.S. Department of Veterans Affairs, 56, 64

U.S. Food and Drug Administration, 15, 25,

65, 87, 89, 90, 105, 108
 
V
 
Vaccination, 1, 5, 6, 7, 10, 12, 16, 20, 21, 35,

36, 40, 54, 61, 62, 65, 67, 70, 71, 113 

Viral hepatitis. See Hepatitis, viral

Viral Hepatitis Action Plan, 2

Viral load
 
impact on hepatitis treatment, 34

tests, 24–25

Virologic relapses, 34
 
129 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
csAT TIps and publications Based on TIps 
What Is a TIp? 
Treatment Improvement Protocols (TIPs) are the products of a systematic and innovative process that 
brings together clinicians, researchers, program managers, policymakers, and other Federal and non-Fed­
eral experts to reach consensus on state-of-the-art treatment practices. TIPs are developed under CSAT’s 
Knowledge Application Program to improve the treatment capabilities of the Nation’s alcohol and drug 
abuse treatment service system. 
What Is a Quick Guide? 
A Quick Guide clearly and concisely presents the primary information from a TIP in a pocket-sized 
booklet. Each Quick Guide is divided into sections to help readers quickly locate relevant material. Some 
contain glossaries of terms or lists of resources. Page numbers from the original TIP are referenced so 
providers can refer back to the source document for more information. 
What Are KAp Keys? 
Also based on TIPs, KAP Keys are handy, durable tools. Keys may include assessment or screening 
instruments, checklists, and summaries of treatment phases. Printed on coated paper, each KAP Keys set 
is fastened together with a key ring and can be kept within a treatment provider’s reach and consulted 
frequently. The Keys allow you—the busy clinician or program administrator—to locate information 
easily and to use this information to enhance treatment services. 
ordering Information 
Publications may be ordered for free at http://store.samhsa.gov. To order over the phone, please call 
1-877-SAMHSA-7 (1-877-726-4727) (English and Español). Most publications can also be down­
loaded at http://www.kap.samhsa.gov. 
TIP 1 	 State Methadone Treatment Guidelines— TIP 9 Assessment and Treatment of Patients With 
Replaced by TIP 43 Coexisting Mental Illness and Alcohol and 
TIP 2* 	 Pregnant, Substance-Using Women— Other Drug Abuse—Replaced by TIP 42
BKD107 TIP 10 Assessment and Treatment of Cocaine-
TIP 3 	 Screening and Assessment of Alcohol- and Abusing Methadone-Maintained Patients— 
Other Drug-Abusing Adolescents—Replaced Replaced by TIP 43 
by TIP 31 TIP 11* Simple Screening Instruments for Outreach 
TIP 4 	 Guidelines for the Treatment of Alcohol- for Alcohol and Other Drug Abuse and 
and Other Drug-Abusing Adolescents— Infectious Diseases—BKD143 
Replaced by TIP 32 Quick Guide for Clinicians QGCT11 
TIP 5 Improving Treatment for Drug-Exposed KAP Keys for Clinicians KAPT11 
Infants—BKD110 TIP 12 Combining Substance Abuse Treatment 
TIP 6* Screening for Infectious Diseases Among With Intermediate Sanctions for Adults in 
Substance Abusers—BKD131 the Criminal Justice System—Replaced by TIP 
Quick Guide for Clinicians QGCT06 44 
KAP Keys for Clinicians KAPT06 TIP 13 Role and Current Status of Patient 
TIP 7 	 Screening and Assessment for Alcohol and Placement Criteria in the Treatment of 
Other Drug Abuse Among Adults in the Substance Use Disorders—BKD161 
Criminal Justice System—Replaced by TIP 44 Quick Guide for Clinicians QGCT13 
TIP 8	 Intensive Outpatient Treatment for Alcohol Quick Guide for Administrators QGAT13 
and Other Drug Abuse—Replaced by TIPs 46 KAP Keys for Clinicians KAPT13 
and 47 
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TIP 14 Developing State Outcomes Monitoring 
Systems for Alcohol and Other Drug Abuse
Treatment—BKD162 
TIP 15 Treatment for HIV-Infected Alcohol and 
Other Drug Abusers—Replaced by TIP 37 
TIP 16 Alcohol and Other Drug Screening of 
Hospitalized Trauma Patients—BKD164 
Quick Guide for Clinicians QGCT16 
KAP Keys for Clinicians KAPT16 
TIP 17 Planning for Alcohol and Other Drug Abuse 
Treatment for Adults in the Criminal Justice 
System—Replaced by TIP 44 
TIP 18 The Tuberculosis Epidemic: Legal and 
Ethical Issues for Alcohol and Other Drug
Abuse Treatment Providers—BKD173 
Quick Guide for Clinicians QGCT18 
KAP Keys for Clinicians KAPT18 
TIP 19 Detoxification From Alcohol and Other 
Drugs—Replaced by TIP 45 
TIP 20 Matching Treatment to Patient Needs in 
Opioid Substitution Therapy—Replaced by 
TIP 43 
TIP 21 Combining Alcohol and Other Drug Abuse 
Treatment With Diversion for Juveniles in 
the Justice System—(SMA) 08-4073
Quick Guide for Clinicians and 
Administrators QGCA21 
TIP 22 LAAM in the Treatment of Opiate 
Addiction—Replaced by TIP 43 
TIP 23 Treatment Drug Courts: Integrating 
Substance Abuse Treatment With Legal
Case Processing—(SMA) 08-3917
Quick Guide for Administrators QGAT23 
TIP 24 A Guide to Substance Abuse Services for 
Primary Care Clinicians—(SMA) 08-4075
Concise Desk Reference Guide BKD123 
Quick Guide for Clinicians QGCT24 
KAP Keys for Clinicians KAPT24 
TIP 25 Substance Abuse Treatment and Domestic 
Violence—(SMA) 08-4076
Linking Substance Abuse Treatment and 
Domestic Violence Services: A Guide for 
Treatment Providers MS668 
Linking Substance Abuse Treatment and 
Domestic Violence Services: A Guide for 
Administrators MS667 
Quick Guide for Clinicians QGCT25 
KAP Keys for Clinicians KAPT25 
TIP 26 Substance Abuse Among Older Adults— 
(SMA) 08-3918
Substance Abuse Among Older Adults: A 
Guide for Treatment Providers MS669 
Substance Abuse Among Older Adults: A 
Guide for Social Service Providers MS670 
Substance Abuse Among Older Adults:
Physician’s Guide MS671 
Quick Guide for Clinicians QGCT26 
KAP Keys for Clinicians KAPT26 
TIP 27 Comprehensive Case Management for 
Substance Abuse Treatment—(SMA)
08-4215 
Case Management for Substance Abuse 
Treatment: A Guide for Treatment Providers 
MS673 
Case Management for Substance Abuse 
Treatment: A Guide for Administrators 
MS672 
Quick Guide for Clinicians QGCT27 
Quick Guide for Administrators QGAT27 
TIP 28* Naltrexone and Alcoholism Treatment— 
Replaced by TIP 49 
TIP 29 Substance Use Disorder Treatment for 
People With Physical and Cognitive
Disabilities—(SMA) 08-4078
Quick Guide for Clinicians QGCT29 
Quick Guide for Administrators (SMA) 
08-3592 
KAP Keys for Clinicians KAPT29 
TIP 30 Continuity of Offender Treatment for 
Substance Use Disorders From Institution to 
Community—(SMA) 08-3920
Quick Guide for Clinicians QGCT30 
KAP Keys for Clinicians KAPT30 
TIP 31 Screening and Assessing Adolescents for 
Substance Use Disorders—(SMA) 08-4079
See companion products for TIP 32.
TIP 32 Treatment of Adolescents With Substance 
Use Disorders—(SMA) 08-4080
Quick Guide for Clinicians QGC312 
KAP Keys for Clinicians KAP312 
TIP 33 Treatment for Stimulant Use Disorders— 
(SMA) 06-4209
Quick Guide for Clinicians QGCT33 
KAP Keys for Clinicians KAPT33 
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TIP 34 Brief Interventions and Brief Therapies for 

Substance Abuse—(SMA) 07-3952

Quick Guide for Clinicians QGCT34 

KAP Keys for Clinicians KAPT34
 
TIP 35 Enhancing Motivation for Change in 

Substance Abuse Treatment—(SMA)

08-4212 

Quick Guide for Clinicians QGCT35 
KAP Keys for Clinicians KAPT35 
TIP 36 Substance Abuse Treatment for Persons 

With Child Abuse and Neglect Issues—
 
(SMA) 08-3923

Quick Guide for Clinicians QGCT36 
KAP Keys for Clinicians KAPT36 
Helping Yourself Heal: A Recovering Woman’s 
Guide to Coping With Childhood Abuse 

Issues (SMA) 08-4132

Available in Spanish: PHD981S 

Helping Yourself Heal: A Recovering Man’s 

Guide to Coping With the Effects of 

Childhood Abuse (SMA) 08-4134

Available in Spanish: PHD1059S 
TIP 37 Substance Abuse Treatment for Persons 

With HIV/AIDS—(SMA) 08-4137

Quick Guide for Clinicians MS678 

KAP Keys for Clinicians KAPT37 

Drugs, Alcohol, and HIV/AIDS: A Consumer 

Guide (SMA) 08-4127 

Drugs, Alcohol, and HIV/AIDS: A Consumer 

Guide for African Americans (SMA) 07-4248
 
TIP 38 Integrating Substance Abuse Treatment and 

Vocational Services—(SMA) 06-4216

Quick Guide for Clinicians QGCT38
 
Quick Guide for Administrators QGAT38 

KAP Keys for Clinicians KAPT38
 
TIP 39 Substance Abuse Treatment and Family 

Therapy—(SMA) 08-4219

Quick Guide for Clinicians QGCT39
 
Quick Guide for Administrators QGAT39
 
TIP 40 Clinical Guidelines for the Use of 

Buprenorphine in the Treatment of Opioid

Addiction—(SMA) 07-3939

Quick Guide for Physicians QGPT40
KAP Keys for Physicians KAPT40 
TIP 41 Substance Abuse Treatment: Group 

Therapy—(SMA) 05-3991

Quick Guide for Clinicians QGCT41
 
TIP 42 Substance Abuse Treatment for Persons 

With Co-Occurring Disorders—(SMA)

08-3992
 
Quick Guide for Clinicians (SMA) 07-4034

Quick Guide for Administrators QGAT42
 
KAP Keys for Clinicians (SMA) 08-4036 

TIP 43 	 Medication-Assisted Treatment for Opioid

Addiction in Opioid Treatment Programs—
 
(SMA) 08-4214

Quick Guide for Clinicians QGCT43 

KAP Keys for Clinicians (SMA) 07-4108 

TIP 44 Substance Abuse Treatment for Adults in the 

Criminal Justice System—(SMA) 05-4056

Quick Guide for Clinicians QGCT44
 
KAP Keys for Clinicians (SMA) 07-4150 

TIP 45 Detoxification and Substance Abuse 

Treatment—(SMA) 08-4131

Quick Guide for Clinicians (SMA) 06-4225

KAP Keys for Clinicians (SMA) 06-4224 

Quick Guide for Administrators (SMA) 

06-4226 

TIP 46 Substance Abuse: Administrative Issues in 
Outpatient Treatment—(SMA) 06-4157

Quick Guide for Administrators (SMA) 

07-4232 

TIP 47 Substance Abuse: Clinical Issues in 

Outpatient Treatment—(SMA) 06-4182

Quick Guide for Clinicians (SMA) 07-4233

KAP Keys for Clinicians (SMA) 07-4251
 
TIP 48 Managing Depressive Symptoms in 

Substance Abuse Clients During Early

Recovery—(SMA) 08-4353 

TIP 49 Incorporating Alcohol Pharmacotherapies 

Into Medical Practice—(SMA) 09-4380

Quick Guide for Counselors (SMA) 10-4542

KAP Keys for Clinicians (SMA) 10-4544

Quick Guide for Physicians (SMA) 10-4543
 
TIP 50 Addressing Suicidal Thoughts and Behaviors 

in Substance Abuse Treatment—(SMA)

09-4381
 
TIP 51 Substance Abuse Treatment: Addressing the 

Specific Needs of Women—(SMA) 09-4426
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 TIP 52  Clinical Supervision and Professional 
Development of the Substance Abuse 
Counselor—(SMA) 09-4435 
TIP 53  Addressing Viral Hepatitis in People With 
Substance Use Disorders—(SMA) 11-4656 
TIP 54 Managing Chronic Pain in Adults With or in 
Recovery From Substance Use Disorders— 
(SMA) 12-4671 
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